Rip1 modulators, preparations, and uses thereof

Abstract

This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e. g., including those mediated by receptor-interacting protein 1 (RIP1) signaling.

Description

Cross Reference to Related Application This application claims priority to International Application No. PCT / CN2022 / 078424, filed on February 28, 2022, the content of which is incorporated by reference in its entirety. Field of the Disclosure The present disclosure relates to compounds that modulate the receptor-interacting protein 1 (RIP1), compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds to treat various diseases or conditions, e.g., those mediated by RIP1. Background of the Disclosure Necroptosis, an important form of programmed cell death (PCD), is a highly regulated caspase-independent type of cell death that plays a critical role in many necrotic cell diseases, manifested in various pathological forms of cell death, including ischemic brain injury, neurodegenerative diseases, viral infections, and peripheral autoimmune diseases. (Dunai, et al., Dec 2011, Pathol. Oncol. Res.: POR 17 (4): 791-800. J. Med. Chem. 2020, 63, 4, 1490-1510. Nature Reviews Drug Discovery, 19, 553-571(2020)). Tumor necrosis factor alpha (TNF-a)-induced NF-kB activation plays a central role in the immune system and inflammatory responses. Receptor-interacting protein 1 (RIP1) is a multi-functional signal transducer involved in mediating nuclear factor kB (NF-kB) activation, apoptosis, and necroptosis. The kinase activity of RIP1 is critically involved in mediating necroptosis, a caspase-independent pathway of necrotic cell death. (Holler et al. Nat Immunol 2000; 1: 489-495; Degterev et al. Nat Chem Biol 2008; 4: 313-321). RIP1 can contribute to PD-1 immunotherapy resistance (e.g., Manguso et al., 2017 Nature 547, 413-418) and can act as a checkpoint kinase governing tumor immunity (e.g., Wang et al, Cancer Cell 34, 757-774, Nov 12, 2018). RIP1 has emerged as a promising therapeutic target for the treatment of a wide range of human neurodegenerative, autoimmune, and inflammatory diseases, such as psoriasis, rheumatoid arthritis, and ulcerative colitis (Pharmacol. Res. Perspect. 2017, 5, e00365, PNAS May 14, 2019 116 (20) 9714-9722), as well for CNS indications such as ALS and - 1 - 2023224057   06 Oct 2026 Alzheimer’s disease. (Nat. Rev. Neurosci. 2019, 20, 19-33). Certain compounds for modulating necrosis or necroptosis are disclosed in U.S. Patent No. 9,974,762, U.S. Patent No. 10,092,529, U.S. Patent No. 6,756,394, U.S. Patent No. 8,278,344, U.S. Patent Publication No. 20120122889, U.S. Patent Publication No. 5 20090099242, U.S. Patent Publication No. 20100317701, U.S. Patent Publication No. 20110144169, U.S. Patent Publication No. 20030083386, U.S. Patent Publication No. 201200309795, WO2009023272, WO2010075290, WO2010075561, WO2012125544, WO 2020 / 103884, WO-2021233397, WO-2021233396, WO-2021233394, WO-2020103884, and WO-2020103859. 10 Summary of the Disclosure One aspect of this disclosure provides a compound selected from compounds of the Formulae disclosed herein (e.g., Formulae I, IIa, IIb, IIc, IId, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IVa, IVb, Va, Vb, Vc, Vd, VIa, VIb, VIc, VId, VIe, VIf, VIIa, VIIb, VIIc, VIIIa, VIIIb, 15 VIIIc, VIIId, VIIIe, VIIIf, and Compounds 1 to 702) disclosed herein, a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, which can be employed in the treatment of various diseases or conditions, such as diseases or conditions caused by axonal degeneration. In a first aspect of the invention, there is provided a compound of the following 20 structural Formula I: Ring A a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein: 25 X1is N; X2is N; X3is absent; X4 is C; Ring A is phenyl, 5- to 9-membered heteroaryl, 5- to 6-membered cycloalkyl, or 5- to 9membered heterocyclyl; 2023224057   06 Oct 2026 Ring B is phenyl, 5- to 9-membered heteroaryl, 4- to 6-membered cycloalkyl, or 4- to 8membered heterocyclyl; Ring C is phenyl, 5- to 6-membered heteroaryl, 5- to 6-membered cycloalkyl, or 5- to 6membered heterocyclyl; 5 the bond between X2 and X4 is a double bond; Ra, for each occurrence, is independently selected from halogen, cyano, =O, NO2, C1 to C6 alkyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 10 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; C2 to C6 alkenyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 15 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; C2 to C6 alkynyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, 20 -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; 25        3 to 10-membered cycloalkyl optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq; 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq; 30        -C(=O)Rs; -C(=O)ORs; -C(=O)(C=O)ORs; 2023224057   06 Oct 2026 -C(=O)NRpNRpRq; -C(=O)NRpORs; -C(=O)NRpRq; -NRpRq; -NRpC(=O)Rs, wherein Rp and Rs are defined below in this first aspect or the Rp and Rs of NRpC(=O)Rs join and form a 5 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S; -NRp2C(=O)ORs2, wherein Rp2 and Rs2 are defined below in this first aspect or the Rp2 and Rs2 of -NRp2C(=O)ORs2 join and form a 5 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S; -ORs: wherein: Rp and Rq, for each occurrence, are independently selected from hydrogen and C1-C6 alkyl, wherein: the C1-C6 alkyl of any one of Rp and Rq is optionally substituted with 1 to 3 groups selected from halogen, -NRp1C(=O)ORs1, cyano, -ORs1, -O(C1 to C3 alkyl)ORs1, 3 to 10-membered cycloalkyl, 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and phenyl; wherein the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of any one of Rp and Rq, and the 3 to 10-membered cycloalkyl and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of the C1-C4 alkyl of any one of Rp and Rq, are each optionally substituted with 1 to 3 groups selected from halogen, CN, =O, NRp1Rq1, ORs1, -NRp1C(=O)Rs1, -NRp1C(=O)ORs1, 3 to 10-membered cycloalkyl, and C1 to C3 alkyl optionally substituted with C3-C4 cycloalkyl; Rs, for each occurrence, is independently selected from hydrogen, C1-C6 alkyl, phenyl, 5 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, 3 to 10membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the C1-C6 alkyl, phenyl, 5 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of Rs are each optionally substituted with 1 to 3 groups selected from halogen, NRp1Rq1, -NRp1C(=O)ORs1, cyano, -OH, -O(C1 to C3 alkyl), - 4 - 2023224057   06 Oct 2026 -O(C1 to C3 alkyl)OH, -O(C1 to C3 alkyl)O(C1 to C3 alkyl), 3 to 10-membered cycloalkyl, 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and phenyl; Rp1 and Rq1, for each occurrence, are each independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; 5        Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rp2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rs2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl 10 optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rb, for each occurrence, is independently selected from halogen, CN, =O, and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen; Rc, for each occurrence, is independently selected from halogen, CN, C1-C6 alkyl, ORs1, and -C(=O)ORs1; 15   R1 is H, R2 is selected from H, halogen, CN, ORs1, -NRp1Rq1, and C1 to C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, or R1 and R2 join to form a 5- to 6-membered heterocycle optionally substituted by 1 to 3 groups selected from halogen and C1 to C3 alkyl optionally substituted by 1 to 3 groups selected from halogen; 20  R3 is absent; R4 is H; L is selected from -NRx-, -(CH2)uO(CH2)u-, -(CH2)uS(=O)w-(CH2)u-, -C(=O)-, and C1-C3 alkylene, wherein the C1-C3 alkylene of L is optionally substituted by 1 to 2 groups selected from OH and C1-C3 alkyl,; wherein 25  Rp1 and Rq1, for each occurrence, are each independently selected from hydrogen and C1-C4 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, and OH; Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, and OH; and Rx is selected from H and C1-C4 alkyl; 30 m and p are each an integer independently selected from 0, 1, 2, 3, and 4; n is an integer selected from 0, 1, and 2; w, for each occurrence, is an integer independently selected from 0, 1, and 2; 2023224057   06 Oct 2026 u, for each occurrence, is an integer independently selected from 0, 1, and 2; provided that the compounds is not: , wherein P1 is N. In a second aspect of the invention, there is provided a compound of the following 5 structural Formula Vie: Formula VIe a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein: 10        Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1, Z2, and Z3, are each independently selected from S, C, and N, Z4 is selected from C and N, V1 and V2 are each independently selected from C and N, 15 L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, wherein Rx is selected from H and C1-C4 alkyl 2023224057   06 Oct 2026 Ra, for each occurrence, is independently selected from absent, H, C1-C3 alkyl, Rb, for each occurrence, is independently selected from H, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, -OCH3, CH3, and CN, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, Rp2 and Rq2 are each independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and optionally substituted 3 to 10-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, p is 0, 1, or 2, q is 0, 1, or 2, provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N. In a third aspect of the invention, there is provided the compounds of the Formulae disclosed according to the first aspect or the second aspect, the compounds selected from Compounds 1 to 702 shown below, a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing. In a fourth aspect of the invention, there is provided a pharmaceutical compositions comprising a compound of the Formulae according to the first, second or third aspect, a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, and at least one pharmaceutically acceptable carrier. These compositions may further comprise an additional active pharmaceutical agent. In fifth aspect of the invention, there is provided a method of treating a disease or condition mediated by receptor-interacting protein 1 (RIP1) signaling, comprising administering to a subject, a therapeutically effective amount of a compound of the Formulae according to the first, second or third aspect , a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition according to the fourth aspect, wherein the disease or condition mediated by RIP1 signaling is selected from an inflammatory disease, an immune disease (e.g., an autoimmune disease), a necrotic cell disease, a neurodegenerative disease, a central nervous system (CNS) disease, an ischemic brain injury, an ocular disease, a viral infection disease, and a malignancy. In a sixth aspect of the invention, there is provided a method of treating a disease or condition mediated by receptor-interacting protein 1 (RIP1) signaling, comprising administering - 7 - 2023224057   06 Oct 2026 to a subject, a therapeutically effective amount of a compound of the Formulae according to the first, second or third aspect, a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition according to the fourth aspect. 5 In some embodiments, the methods of treatment comprise administering to a subject in need thereof, a compound selected from Compounds 1 to 702 shown below, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition comprising any of the foregoing. In some embodiments, the methods of treatment comprise administration of an additional 10 active pharmaceutical agent to the subject in need thereof, either in the same pharmaceutical composition as a compound of the Formulae disclosed herein, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or in a separate composition. In some embodiments, the methods of treatment comprise administering a compound selected from Compounds 1 to 702 shown below, a 15 tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing with an additional active pharmaceutical agent either in the same pharmaceutical composition or in a separate composition. When administered as a separate dosage form, the additional therapeutic agent may be administered prior to, at the same time as, or following administration of the compound, tautomer, hydrate, stereoisomer, or 20 a pharmaceutically acceptable salt disclosed herein. In a seventh aspect of the invention, there is provided a method of inhibiting receptorinteracting protein 1 (RIP1), comprising contacting the RIP1 protein or a fragment thereof with a compound of the Formulae or a compound selected from Compounds 1 to 702 according to the first, second or third aspect, a tautomer thereof, a stereoisomer of the 25 compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition according to the fourth aspect. Detailed Description of the Disclosure I. Definitions The term “a” or “an” when referring to a noun as used herein encompasses the 30 expression “at least one” and therefore encompasses both singular and plural units of the noun. For example, “an additional pharmaceutical agent” means a single or two or more additional pharmaceutical agents. 2023224057   06 Oct 2026 The term "alkyl" refers to a hydrocarbon group selected from linear and branched saturated hydrocarbon groups, containing 1-20, e.g., 1-18, 1-12, 1-10, 1-8, 1-6, 1-4, or 1-3, carbon atoms. Examples of the alkyl group include methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), and 1,1-dimethylethyl or t-butyl ("t-Bu"). Other examples of an alkyl group include 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl groups. Lower alkyl contains 1-8, preferably 1-6, more preferably 1-4 carbon atoms, and more preferably 1-3 carbon atoms. The term "alkenyl" refers to a hydrocarbon group selected from linear and branched hydrocarbon groups, comprising at least one C=C double bond and 2-20, e.g., 2-18, 2-12, 2-10, 2-8, 2-6, or 2-4, carbon atoms. Examples of the alkenyl group include ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1,3-dienyl groups. Lower alkenyl contains 2-8, preferably 2-6, and more preferably 2-4 carbon atoms. The term "alkynyl" refers to a hydrocarbon group selected from linear and branched hydrocarbon groups, comprising at least one C=C triple bond and 2-20, e.g., 2-18, 2-12, 2-10, 28, 2-6, or 2-4, carbon atoms. Examples of the alkynyl group include ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups. Lower alkynyl contains 2-8, preferably 2-6, and more preferably 2-4 carbon atoms. The term “heteroalkyl” refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by a heteroatom, e.g., nitrogen, oxygen, or sulfur, e.g., CH3CH2OH, CH3CH2OC2H5, CH3CH2SH, CH3CH2SC2H5, CH3CH2NH2, CH3CH2NHC2H5, etc. In some embodiments, in addition to the replacement of one or more of the constituent carbon atoms by nitrogen, oxygen, or sulfur, a heteroalkyl group is further optionally substituted as defined herein. The term “ring” or “ring system” refers to a monocyclic and a polycyclic (e.g., bicyclic and tricyclic) group. A ring can be a carbon cycle or heterocycle, aromatic or non-aromatic. For example, a bicyclic ring can be a fused, bridged, or spiro cyclic system. The term "cycloalkyl" refers to a hydrocarbon group selected from saturated and partially unsaturated cyclic hydrocarbon groups, e.g., monocyclic and polycyclic (e.g., bicyclic and - 9 - 2023224057   06 Oct 2026 tricyclic) groups. For example, the cycloalkyl group may be of 3-12, 3-10, 3-8, 3-6, 3-4, or 5-6 carbon atoms. Even further for example, the cycloalkyl group may be a monocyclic group of 312, 3-8, 3-6, 3-4, or 5-6 carbon atoms. Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. Examples of the bicyclic cycloalkyl groups include those having 7-12 ring atoms arranged as a bicycle ring selected from [4,4], [4,5], [5,5], [5,6], and [6,6] ring systems, or as a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. The ring may be saturated or have at least one double bond (i.e., partially unsaturated), but is not fully conjugated, and is not an aromatic ring, as “aromatic ring” is defined herein. The term "heterocyclic" or "heterocycle" or "heterocyclyl" refers to a ring selected from 3- to 12-membered, e.g., 3- to 6-membered, 3- to 5-membered, 4- to 5-membered, or 5- to 6membered, monocyclic, bicyclic, and tricyclic, saturated and partially unsaturated rings comprising at least one carbon atom in addition to 1, 2, 3, or 4 heteroatoms, selected from, e.g., oxygen, sulfur, nitrogen, and silicon. “Heterocycle” also refers to a 5- to 7-membered heterocyclic ring comprising at least one heteroatom selected from N, O, and S fused with 5-, 6-, and / or 7-membered cycloalkyl, carbocyclic aromatic, or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring when the heterocyclic ring is fused with a carbocyclic aromatic or a heteroaromatic ring, and that the point of attachment can be at the cycloalkyl or heterocyclic ring when the heterocyclic ring is fused with cycloalkyl. “Heterocycle” also refers to an aliphatic spirocyclic ring comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring. The rings may be saturated or have at least one double bond (i.e., partially unsaturated). A heterocycle may be substituted with oxo. The point of the attachment may be carbon or heteroatom in the heterocyclic ring. A heterocycle is not a heteroaryl as defined herein. Examples of heterocycles include, but are not limited to, (as numbered from the linkage position assigned priority 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2,5-piperazinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, 1,4-oxathianyl, - 10 - 2023224057   06 Oct 2026 1,4-dioxepanyl, 1,4-oxathiepanyl, 1,4-oxaazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl, 1,4-diazepanyl, 1,4-dithianyl, 1,4-azathianyl, oxazepinyl, diazepinyl, thiazepinyl, dihydrothienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-5 pyranyl, 1,4-dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinylimidazolinyl, pyrimidinonyl, 1,1-dioxo-thiomorpholinyl, 3-azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl and azabicyclo[2.2.2]hexanyl. Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl, and 1, 1-dioxo-1-10 thiomorpholinyl. The term "fused ring" herein refers to a polycyclic ring system, e.g., a bicyclic or tricyclic ring system, in which two rings share only two ring atoms and one bond in common. Examples of fused rings may comprise a fused bicyclic cycloalkyl ring such as those having from 7 to 12 ring atoms arranged as a bicyclic ring selected from [4,4], [4,5], [5,5], [5,6], and [6,6] ring 15 systems as mentioned above; a fused bicyclic aryl ring such as 7- to 12-membered bicyclic aryl ring systems as mentioned above, a fused tricyclic aryl ring such as 10- to 15-membered tricyclic aryl ring systems mentioned above; a fused bicyclic heteroaryl ring such as 8- to 12-membered bicyclic heteroaryl rings as mentioned above, a fused tricyclic heteroaryl ring such as 11- to 14membered tricyclic heteroaryl rings as mentioned above; and a fused bicyclic or tricyclic 20 heterocyclyl ring as mentioned above. The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, and silicon, including, any oxidized form of nitrogen or sulfur; the quaternized form of any basic nitrogen or a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (wherein R is, e.g., an optionally 25 substituted alkyl group) (as in N-substituted pyrrolidinyl). The term “unsaturated”, as used herein, means that a moiety has one or more units or degrees of unsaturation. Unsaturation is the state in which not all of the available valence bonds in a compound are satisfied by substituents and thus the compound contains one or more double or triple bonds. A double bond may be depicted as         (two solid lines). 30 The depiction of------ (a solid line and a dashed line), as used herein, denotes a bond that may be a double bond or a single bond. The term “alkoxy” as used herein, refers to an alkyl group, as defined above, wherein 2023224057   06 Oct 2026 one carbon of the alkyl group is replaced by an oxygen atom, provided that the oxygen atom is linked between two carbon atoms. The term “halogen” includes F, Cl, Br, and I, i.e., fluoro, chloro, bromo, and iodo, respectively. 5 As used herein, a “CN,” “cyano” or “nitrile” group refers to -C=N. As used herein, an “aromatic ring” refers to a carbocyclic or heterocyclic ring that contains conjugated, planar ring systems with delocalized pi electron orbitals comprised of [4n+2] p orbital electrons, wherein n is an integer of 0 to 6. A “non-aromatic” ring refers to a carbocyclic or heterocyclic that does not meet the requirements set forth above for an 10 aromatic ring, and can be either completely or partially saturated. Non-limiting examples of aromatic rings include aryl and heteroaryl rings that are further defined as follows. An CJ “aromatic ring” may be depicted as a cycle with conjugated double bonds, such as         , n ZZZ^, or as a cycle with an inside circle, such as            . The term “aryl” herein refers to a group selected from: monocyclic carbocyclic aromatic 15 rings, for example, phenyl; bicyclic ring systems such as 7-12 membered, e.g., 9-10 membered, bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, selected, for example, from naphthalene, indane, and 1,2,3,4-tetrahydroquinoline; and tricyclic ring systems such as 10-15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene. 20        For example, the aryl group may be a 6-membered carbocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl or heterocyclic ring optionally comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the carbocyclic aromatic ring when the carbocyclic aromatic ring is fused with a heterocyclic ring, and the point of attachment can be at the carbocyclic aromatic ring or at the cycloalkyl group when the 25 carbocyclic aromatic ring is fused with a cycloalkyl group. Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in "-yl" by removal of one hydrogen atom from the carbon atom with 2023224057   06 Oct 2026 the free valence are named by adding "-idene" to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. The term "heteroaryl" refers to a group selected from: 5- to 7-membered, e.g., 5- to 6membered, aromatic, monocyclic rings comprising 1, 2, 3, or 4 heteroatoms selected from N, O, 5 and S, with the remaining ring atoms being carbon; 8- to 12-membered bicyclic rings comprising 1, 2, 3, or 4 heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and 11- to 14-membered tricyclic rings comprising 1, 2, 3, or 4 heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic 10 and at least one heteroatom is present in an aromatic ring. For example, the heteroaryl group may be a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring. For such fused, bicyclic heteroaryl ring systems wherein only one of the rings comprises at least one heteroatom, the point of attachment may be at the heteroaromatic ring or at the cycloalkyl ring. 15 When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of the heteroaryl group include, but are not limited to, (as numbered from the 20 linkage position assigned priority 1) pyridyl (such as 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furyl, benzofuryl, benzoimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolinyl, pyrazolyl, pyrrolopyridinyl 25 (such as 1H-pyrrolo[2,3-b]pyridin-5-yl), pyrazolopyridinyl (such as 1H-pyrazolo[3,4-b]pyridin-5-yl), benzoxazolyl (such as benzo[d]oxazol-6-yl), pteridinyl, purinyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, 30 benzothiazolyl (such as benzo[d]thiazol-6-yl), indazolyl (such as 1H-indazol-5-yl) and 5,6,7,8-tetrahydroisoquinolinyl. The term “acyl” refers to a substituent group where a point of attachment in the substituent 2023224057   06 Oct 2026 group is a carbonyl. Exemplary acyl groups include, but are not limited to, -C(=O)R’, -C(=O)NR’R’’, or -C(=O)OR’, wherein R’ and R’’ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, any of which may be further substituted by one or more substituents. Some of the compounds may exist with different points of attachment of hydrogen, referred to as “tautomers.” For example, compounds including carbonyl -CH2C(O)- groups (keto forms) may undergo tautomerism to form hydroxyl -CH=C(OH)- groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are also intended to be included where applicable. The compounds, tautomers, solvates, or pharmaceutically acceptable salts of the disclosure may contain an asymmetric center and may thus exist as enantiomers. For example, where the compounds possess two or more asymmetric centers, they may additionally exist as diastereoisomers. Enantiomers and diastereoisomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereoisomers are intended to be included in this disclosure. All stereoisomers of the compounds, tautomers, solvates, and pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included. Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of a chiral HPLC column. A single stereoisomer, e.g., a substantially pure enantiomer, may be obtained by resolution of the racemic mixture using a method such as formation of diastereoisomers using optically active resolving agents. Racemic mixtures of chiral compounds of the disclosure can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) - 14 - 2023224057   06 Oct 2026 formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereoisomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. In the present disclosure, certain single stereoisomers, e.g., substantially pure enantiomers, are separated from one another, e.g., by a chiral separation. However, the absolute configuration of certain separated single stereoisomers are not presently known. Such unknown chiral centers are denoted with a * in the structural formulae and the corresponding compounds are denoted as “single unknown stereoisomer.” For instance, Compounds 3 and 4 (Examples 3 and 4) were synthesized and separated by chiral separation and the chemical structures of Compounds 3 and 4 each bear a star to indicate the unknown absolute configuration, and indicated as “single unknown stereoisomer.” The term “substantially pure” in the context of stereoisomers means that the target stereoisomer contains no more than 35%, such as no more than 30%, further such as no more than 25%, even further such as no more than 20%, by weight of any other stereoisomer(s). In some embodiments, the term “substantially pure” means that the target stereoisomer contains no more than 10%, for example, no more than 5%, such as no more than 1%, by weight of any other stereoisomer(s). Unless otherwise indicated, structures depicted herein are meant to include all isomeric forms of the structure, e.g., racemic mixtures, cis / trans isomers, geometric (or conformational) isomers, such as (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, geometric and conformational mixtures of the compounds disclosed herein are within the scope of the disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure. The disclosure provides pharmaceutically acceptable salts of the disclosed compounds, tautomers, solvates, and stereoisomers. A salt of a compound is formed between an acid and a basic group of the compound, such as an amino functional group, or a base and an acidic group of the compound, such as a carboxyl functional group. The term “pharmaceutically acceptable,” as used herein, refers to a component that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. A “pharmaceutically - 15 - 2023224057   06 Oct 2026 acceptable salt” means any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this disclosure. “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, selected, for example, from hydrochlorates, phosphates, diphosphates, hydrobromates, 5 sulfates, sulfinates, and nitrates; as well as salts with organic acids, selected, for example, from malates, maleates, fumarates, tartrates, succinates, citrates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, alkanoates such as acetate, and salts with HOOC-(CH2)n-COOH, wherein n is selected from 0 to 4. Similarly, examples of pharmaceutically acceptable cations include, but are not limited to, sodium, 10 potassium, calcium, magnesium, aluminum, lithium, and ammonium. Suitable pharmaceutically acceptable salts are, for example, those disclosed in S. M. Berge, et al. J. Pharmaceutical Sciences, 1977, 66, pp. 1 to 19. Acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, 15 hydroiodic acid, sulfuric acid, and phosphoric acid, as well as organic acids such as paratoluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, benzenesulfonic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, 20 and acetic acid. Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate (i.e., caprate), caprylate, acrylate, formate, isobutyrate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-l,6-25 dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylene sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, P-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and other salts. In some embodiments, pharmaceutically acceptable acid 30 addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, 2023224057   06 Oct 2026 alkaline earth metal, ammonium, and N+(C1-4 alkyl)4 salts. This disclosure also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Suitable non-limiting examples of alkali and alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium salts. Further non-limiting examples 5 of pharmaceutically acceptable salts include salts of ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate. Other suitable, non-limiting examples of pharmaceutically acceptable salts include besylate and glucosamine salts. If a compound is obtained as an acid addition salt, the free base can be obtained by 10 basifying a solution of the acid addition salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used without undue 15 experimentation to prepare non-toxic pharmaceutically acceptable addition salts. The compounds, tautomers, solvates, stereoisomers, and pharmaceutically acceptable salts of the disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, -CD3, -CD2H or -CDH2 contains one or more deuteriums in place of hydrogen. For example, the compounds may be radiolabeled with 20 radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds of the disclosure, whether radioactive or not, are intended to be encompassed within the scope of the disclosure. As used herein, “optionally substituted” is interchangeable with the phrase “substituted or unsubstituted.” In general, the term “substituted,” refers to the replacement 25 of a hydrogen radical in a given structure with the radical of a specified substituent. Unless otherwise indicated, an “optionally substituted” group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent chosen from a specified group, the substituent may be either the same or different at every position. 30 Combinations of chemical components, e.g., substituents, ring structures, linkers (L), and / or heteroatoms, envisioned by this disclosure are those that result in the formation of stable or chemically feasible compounds. 2023224057   06 Oct 2026 In some embodiments, substituents are independently selected from optionally substituted heteroatom and optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbyl, particularly wherein the optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbyl is optionally-substituted, optionally hetero-, optionally cyclic alkyl, alkenyl or alkynyl, or optionally-substituted, optionally hetero-, aryl; and / or the optionally substituted heteroatom is halogen, optionally substituted hydroxyl (such as alkoxy, aryloxy), optionally substituted acyl (such as formyl, alkanoyl, carbamoyl, carboxyl, amido), optionally substituted amino (such as amino, alkylamino, dialkylamino, amido, sulfamidyl), optionally substituted thiol (such as mercapto, alkylthiol, aryl thiol), optionally substituted sulfinyl or sulfonyl (such as alkylsulfinyl, arylsulfinyl, alkyl sulfonyl, arylsulfonyl), nitro, or cyano. In some embodiments, substituents are independently selected from: halogen, -R', -OR', =O, =NR', =N-OR', -NR'R", -SR', -SiR'R"R'", -OC(=O)R', -C(=O)R', -CO2R', -C(=O)NR'R", -OC(=O)NR'R", -NR"C(=O)R', -NR'-C(=O)NR"R'", -NR'-SO2NR"R'", -NR"CO2R', -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', -SO2R', -SO2NR'R", -NR"SO2R, -CN, -NO2, -N3, -CH(Ph)2, perfluoro(C1-C4)alkoxy, and perfluoro(C1-C4)alkyl, in a number ranging from zero to three, with those groups having zero, one, or two substituents being particularly preferred. R', R", and R'" each independently refer to hydrogen, unsubstituted C1-C8 alkyl and heteroalkyl, C1-C8 alkyl and heteroalkyl substituted with one to three halogens, unsubstituted aryl, aryl substituted with one to three halogens, unsubstituted alkyl, alkoxy, or thioalkoxy groups, or aryl-(C1-C4) alkyl groups. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6- or 7-membered ring. Hence, -NR'R" includes 1-pyrrolidinyl and 4-morpholinyl. When the aryl group is 1,2,3,4-tetrahydronaphthalenyl, it may be substituted with a substituted or unsubstituted C3-C7 spirocycloalkyl group. The C3-C7 spirocycloalkyl group may be substituted in the same manner as defined herein for "cycloalkyl." In some embodiments, substituents are selected from: halogen, -R', -OR', =O, -NR'R", -SR', -SiR'R"R'", -OC(=O)R', -C(=O)R', -CO2R', -C(=O)NR'R", -OC(=O)NR'R", -NR"C(=O)R', -NR"CO2R', -NR'-SO2NR"R'", -S(=O)R', -SO2R', -SO2NR'R", -NR"SO2R, -CN, -NO2, perfluoro C1-C4 alkoxy and perfluoro C1-C4 alkyl, where R' and R" are as defined above. In some embodiments, substituents are independently selected from substituted or unsubstituted heteroatom, substituted or unsubstituted, 0-3 heteroatom-containing C1-C6 alkyl (e.g., C1-C3 alkyl or C1-C2 alkyl), substituted or unsubstituted, 0-3 heteroatom-containing C2-C6 - 18 - 2023224057   06 Oct 2026 alkenyl (e.g., C2-C4 alkenyl), substituted or unsubstituted, 0-3 heteroatom-containing C2-C6 alkynyl (e.g., C2-C4 alkynyl), or substituted or unsubstituted, 0-3 heteroatom-containing C6-C14 aryl (e.g., C5-C6 aryl), wherein each heteroatom is independently oxygen, phosphorus, sulfur, or nitrogen. 5 In some embodiments, substituents are independently selected from aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkyloxy, alkyl, alkenyl, alkynyl, amine, azo, halogen, carbamoyl, carbonyl, carboxamido, carboxyl, cyanyl, ester, haloformyl, hydroperoxyl, hydroxyl, imine, isocyanide, isocyante, N-tert-butoxycarbonyl, nitrate, nitrile, nitrite, nitro, nitroso, phosphate, phosphono, sulfide, sulfonyl, sulfo, sulfhydryl, thiol, thiocyanyl, trifluoromethyl, and 10 trifluromethyl ether (OCF3) groups. In some embodiments, substituents are structurally depicted herein. For example, a ring substituted by R at any chemically feasible position can be depicted as *        , wherein the symbol “*” denotes a point of connection to another component of a molecule. In another example, a bicyclic group substituted by R at any chemically feasible position 15 can be depicted as          R , wherein the symbol “*” denotes a point of connection to another component of a molecule and R can be substituted at any chemically feasible position on the 4-membered ring or the 5-membered ring of the bicyclic group. Preferred substituents are disclosed herein and exemplified in the tables, structures, examples, and claims, and may be applied across different compounds of this disclosure. For 20  example, substituents of a given compound may be combinatorically used with other compounds. It may be advantageous to separate reaction products from one another and / or from starting materials. The desired products of each step or series of steps are separated and / or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or 25 solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example, reverse-phase and normal phase; size exclusion; ion exchange; high, medium, and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed ("SMB") and preparative thin or thick layer 2023224057   06 Oct 2026 chromatography, as well as techniques of small scale thin layer and flash chromatography. One skilled in the art may apply such techniques to achieve a desired separation. Non-limiting examples of suitable solvents that may be used in this disclosure include water, methanol (MeOH), ethanol (EtOH), dichloromethane or methylene chloride (CH2Cl2), toluene, acetonitrile (MeCN), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methyl acetate (MeOAc), ethyl acetate (EtOAc), heptanes, isopropyl acetate (IPAc), tert-butyl acetate (t-BuOAc), isopropyl alcohol (IPA), tetrahydrofuran (THF), 2-methyl tetrahydrofuran (2-Me THF), methyl ethyl ketone (MEK), tert-butanol, diethyl ether (Et2O), methyl-tert-butyl ether (MTBE), 1,4-dioxane, and N-methyl pyrrolidone (NMP). Non-limiting examples of suitable bases that may be used in this disclosure include 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), potassium tert-butoxide (KOtBu), potassium carbonate (K2CO3), N-methylmorpholine (NMM), triethylamine (Et3N; TEA), diisopropylethyl amine (i-Pr2EtN; DIPEA), pyridine, potassium hydroxide (KOH), sodium hydroxide (NaOH), lithium hydroxide (LiOH), and sodium methoxide (NaOMe; NaOCH3). The term “subject” refers to an animal including a human. The term “therapeutically effective amount” refers to the amount of a compound that produces a desired effect for which it is administered (e.g., improvement in a disease or condition, lessening the severity of a disease or condition, and / or reducing progression of a disease or condition, e.g., ALS, Parkinson’s disease, multiple sclerosis, traumatic brain injury, diabetic neuropathy, and CIPN. The disease or condition may be caused by axonal degeneration. The exact amount of a therapeutically effective amount will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lloyd (1999), The Art, Science and Technology of Pharmaceutical Compounding). As used herein, the term “treatment” and its cognates refer to slowing or stopping disease progression. “Treatment” and its cognates as used herein include, but are not limited to the following: complete or partial remission, curing a disease or condition or a symptom thereof, lower risk of a disease or condition, e.g., ALS, Parkinson’s disease, multiple sclerosis, traumatic brain injury, diabetic neuropathy, and CIPN. The disease or condition may be caused by axonal degeneration. Improvements in or lessening the severity of any of these symptoms can be assessed according to methods and techniques known in - 20 - 2023224057   06 Oct 2026 the art. The terms “about” and “approximately,” when used in connection with a number such as a percentage include the number as specified, and a range of the number (e.g., a range of percentages, for example, a range of ±10% with respect to a specific point value) that 5 is recognized by one of ordinary skill in the art. II. Compounds and Compositions In a first embodiment, there is provided a compound of the following structural Formula I: 10                                   Formula I a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein: X1 is N; X2 is N; X3 is absent; X4 is C; Ring A is phenyl, 5- to 9-membered heteroaryl, 5- to 6-membered cycloalkyl, or 5- to 915 membered heterocyclyl; Ring B is phenyl, 5- to 9-membered heteroaryl, 4- to 6-membered cycloalkyl, or 4- to 8membered heterocyclyl; Ring C is phenyl, 5- to 6-membered heteroaryl, 5- to 6-membered cycloalkyl, or 5- to 6membered heterocyclyl; 20 the bond between X2 and X4 is a double bond; Ra, for each occurrence, is independently selected from halogen, cyano, =O, NO2, C1 to C6 alkyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 25 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected 2023224057   06 Oct 2026 from C1 to C6 alkyl, halogen, and ORs; C2 to C6 alkenyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 5 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; C2 to C6 alkynyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; 3 to 10-membered cycloalkyl optionally substituted by 1 to 4 groups selected from halogen, 15 CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq; 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq; -C(=O)Rs; 20 -C(=O)ORs; -C(=O)(C=O)ORs; -C(=O)NRpNRpRq; -C(=O)NRpORs; -C(=O)NRpRq; 25        -NRpRq; -NRpC(=O)Rs, wherein Rp and Rs are defined below in this claim or the Rp and Rs of NRpC(=O)Rs join and form a 5 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S; -NRp2C(=O)ORs2, wherein Rp2 and Rs2 are defined below in this claim or the Rp2 and Rs2 30 of -NRp2C(=O)ORs2 join and form a 5 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S; -ORs: 2023224057   06 Oct 2026 wherein: Rp and Rq, for each occurrence, are independently selected from hydrogen and C1-C6 alkyl, wherein: the C1-C6 alkyl of any one of Rp and Rq is optionally substituted with 1 to 3 groups selected 5 from halogen, -NRp1C(=O)ORs1, cyano, -ORs1, -O(C1 to C3 alkyl)ORs1, 3 to 10-membered cycloalkyl, 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and phenyl; wherein the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of any one of Rp and Rq, and the 3 to 10-membered cycloalkyl and 3 to 10-membered 10 heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of the C1-C4 alkyl of any one of Rp and Rq, are each optionally substituted with 1 to 3 groups selected from halogen, CN, =O, NRp1Rq1, ORs1, -NRp1C(=O)Rs1, -NRp1C(=O)ORs1, 3 to 10-membered cycloalkyl, and C1 to C3 alkyl optionally substituted with C3-C4 cycloalkyl; Rs, for each occurrence, is independently selected from hydrogen, C1-C6 alkyl, phenyl, 5 15 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, 3 to 10membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the C1-C6 alkyl, phenyl, 5 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl 20 comprising 1-3 heteroatoms selected from N, O, and S of Rs are each optionally substituted with 1 to 3 groups selected from halogen, NRp1Rq1, -NRp1C(=O)ORs1, cyano, -OH, -O(C1 to C3 alkyl), -O(C1 to C3 alkyl)OH, -O(C1 to C3 alkyl)O(C1 to C3 alkyl), 3 to 10-membered cycloalkyl, 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and phenyl; Rp1 and Rq1, for each occurrence, are each independently selected from hydrogen and 25 C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rp2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; 30        Rs2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rb, for each occurrence, is independently selected from halogen, CN, =O, and C1-C4 alkyl 2023224057   06 Oct 2026 optionally substituted by 1 to 3 groups of halogen; Rc, for each occurrence, is independently selected from halogen, CN, C1-C6 alkyl, ORs1, and -C(=O)ORs1; R1 is H, 5   R2 is selected from H, halogen, CN, ORs1, -NRp1Rq1, and C1 to C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, or R1 and R2 join to form a 5- to 6-membered heterocycle optionally substituted by 1 to 3 groups selected from halogen and C1 to C3 alkyl optionally substituted by 1 to 3 groups selected from halogen; R3 is absent; 10  R4 is H; L is selected from -NRx-, -(CH2)uO(CH2)u-, -(CH2)uS(=O)w-(CH2)u-, -C(=O)-, and C1-C3 alkylene, wherein the C1-C3 alkylene of L is optionally substituted by 1 to 2 groups selected from OH and C1-C3 alkyl,; wherein Rp1 and Rq1, for each occurrence, are each independently selected from hydrogen and C1-C4 15 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, and OH; Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, and OH; and Rx is selected from H and C1-C4 alkyl; m and p are each an integer independently selected from 0, 1, 2, 3, and 4; 20 n is an integer selected from 0, 1, and 2; w, for each occurrence, is an integer independently selected from 0, 1, and 2; u, for each occurrence, is an integer independently selected from 0, 1, and 2; 2023224057   06 Oct 2026 Combinations of substituents or other variations (e.g., optional presence of heteroatoms in a ring) as disclosed herein are those that result in the formation of stable or chemically feasible compounds. For abbreviation or according to common practice, certain 5 hydrogen atoms attached to a certain atom (e.g., a carbon atom C or a nitrogen atom N) are not specifically spelled out in a chemical structure, formula, or notation; hydrogen atoms are deemed to be present to the extent the valences of the certain atom (e.g., C or N) are completed. In a second embodiment, in a compound, the tautomer thereof, the stereoisomer of the 10 compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring A is a phenyl, pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, pyrazolyl, imidazolyl, pyrrolyl, pyridazinyl, piperazinyl, oxazolyl, isoxazolyl, triazolyl, cyclopentyl, cyclohexanyl, tetrahydro-furanyl, or tetrahydro-pyranyl group; and all other variables not specifically defined herein are defined in the preceding embodiment. 15 In a third embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring B is a phenyl, pyridinyl, thiazolyl, cyclopentenyl, cyclobutanyl, cyclohexanyl, piperidyl, or pyrrolidinyl group, or a 5- to 8-membered bicyclic group optionally containing one or two N atoms; and all other variables not specifically defined herein are defined in any one of the 20 preceding embodiments. In a fourth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring C is phenyl, pyridinyl, thiazolyl, isothiazolyl, oxazolyl, cyclopentyl, cyclopentenyl, cyclohexanyl, cyclohexenyl, isoxazolyl, tetrahydro-pyranyl, or dihydro-pyranyl group; and all 25 other variables not specifically defined herein are defined in any one of the preceding embodiments. 2023224057   06 Oct 2026 In a fifth embodiment, a compound of the disclosure is one of the following structural formula IIa: Ring C Formula IIa 5 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein R1 and R2 do not join to form a 5- to 6-membered heterocycle; and all other variables not specifically defined herein are as defined in any one of the preceding embodiments. In a sixth embodiment, a compound of the disclosure is one of the following structural 10 formula IIb: Formula IIb the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein V1, V2, and V3 are each independently 15 selected from C, O, and N, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, and q is selected from 0, 1, and 2; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 2023224057   06 Oct 2026 In a seventh embodiment, a compound of the disclosure is one of the following structural formula IIc: Ring C 5                                      Formula IIc the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein V1 and V2 are each independently selected from C, O, and N, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, and q is selected from 0, 1, and 2; and all other variables not specifically defined 10 herein are as defined in any of the appropriate preceding embodiments. Also disclosed herein is a compound of the following structural formula IId: a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a 15 pharmaceutically acceptable salt of the foregoing; wherein R1 and R2 do not join to form a 5- to 6-membered carbocycle or heterocycle; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 2023224057   06 Oct 2026 In a ninth embodiment, a compound of the disclosure is one of the following structural formula IIIa: Formula IIIa 5 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing; wherein Y1 and Y2 are each independently selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a tenth embodiment, a compound of the disclosure is one of the following structural 10 formula IIIb: the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing; wherein Y1, is selected from S, C, O, and N, 15 Y2 and Y3 are each independently selected from S, C, O and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. As disclosed herein, combinations of heteroatoms are those that result in the formation of stable or chemically feasible compounds. For example, with respect to Formula IIIb, the clause “Y2 and Y3 are each independently selected from S, C, O and N” refer 20 to those combinations of heteroatoms that result in the formation of stable or chemically feasible compounds. For instance, when Y2 and Y3 of Formula IIIb are both O, such 2023224057   06 Oct 2026 combination of Y2 and Y3 would result in unstable or chemically infeasible compounds. Such unstable or chemically infeasible compounds are not intended to be covered by the compounds of this disclosure. In an eleventh embodiment, a compound of the disclosure is one of the following structural 5 formula IIIc: Ring A Formula IIIc the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the 10 pharmaceutically acceptable salt of the foregoing, Y1 is selected from C and N, Y2 and Y3 are each independently C or absent; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a twelfth embodiment, a compound of the disclosure is one of the following structural formula IIId: 15 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Y1 is selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding 20 embodiments. 2023224057   06 Oct 2026 In a thirteenth embodiment, a compound of the disclosure is one of the following structural formula IIIe: Formula IIIe 5 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fourteenth embodiment, a compound of the disclosure is one of the following structural formula IIIf: 10 RingC Formula IIIf the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Y1 is selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding 15 embodiments. Also disclosed herein is a compound of the following structural formula IVa: RingC Formula IVa 2023224057   06 Oct 2026 a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein Z1, Z2, Z3 and Z4 are each independently selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. Also disclosed herein is a compound of the following structural formula IVb: 10 RingC Formula IVb a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein Z1, Z2, and Z3, are each independently selected from S, O, C, and N, and Z4 is selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a seventeenth embodiment, a compound of the disclosure is one of the following structural formula Va: 15 20 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In an eighteenth embodiment, a compound of the disclosure is one of the following 2023224057   06 Oct 2026 structural formula Vb: the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, Q3, and Q4 are each independently selected from C, N, S, and O; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a nineteenth embodiment, a compound of the disclosure is one of the following structural formula Vc: 10 15 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1 is C, O, or absent; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 2023224057   06 Oct 2026 In a twentieth embodiment, a compound of the disclosure is one of the following structural formula Vd: Formula Vd 5 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1 is C or absent; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a twenty-first embodiment, a compound of the disclosure is one of the following 10 structural formula VIa: RingC Formula VIa the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently 15 selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1, Z2, and Z3, are each independently selected from S, O, C, and N, Z4 is selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 2023224057   06 Oct 2026 In a twenty-second embodiment, a compound of the disclosure is one of the following structural formula VIb: Formula VIb 5 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ra, for each occurrence, is independently selected from halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), -OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, Ra1 is selected from optionally 10 substituted C1-C3 alkyl, optionally substituted 3- to 6-membered cycloalkyl, optionally substituted 3- to 6-membered heterocyclyl, -NHC(=O)Rp2, and -NRp2Rq2; wherein Rp2 and Rq2, for each occurrence, are each independently selected from hydrogen and optionally substituted C1-C6 alkyl, or Rp2 and Rq2 join and form an optionally substituted 3 to 10-membered heterocyclyl; and all other variables not specifically defined herein are as defined in any of the 15 appropriate preceding embodiments. In a twenty-third embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ra, for each occurrence, is independently selected fromCH3, CHF2, F, Cl, CN, NH2, NHCH3, OH, -CH2OH, -COOMe, -COOEt, -CONH2, -C(=O)H, -CH2CN, -CH2NH2 , CF3, and NO2, and 20 Ra1          is          selected          from          COOMe,          COOEt, and -NRp2Rq2, wherein Rp2 and Rq2 join and form a 3 to 10-membered heterocyclyl optionally substituted by 1 to 2 groups selected from halogen, OH, CN, -O(C1-C3 alkyl), NH2, NHBoc, NH(C1-C3 alkyl), and C1-C3 alkyl optionally substituted with 1 to 3 groups selected from halogen, 2023224057   06 Oct 2026 CN, NH2, NHBoc, and OH; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a twenty-fourth embodiment, a compound of the disclosure is one of the following structural formula VIc: the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ra, for each occurrence, is independently selected from halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), OH, -O(C1-C3 alkyl), -10 C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10-membered heteroaryl; and all other variables not specifically defined herein are as defined 15 in any of the appropriate preceding embodiments. In a twenty-fifth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ra, for each occurrence, is independently selected from CH3, CHF2, F, Cl, CN, NH2, NHCH3, and OH; and all other variables not specifically defined herein are as defined in any of the 20 appropriate preceding embodiments. 2023224057   06 Oct 2026 In a twenty-sixth embodiment, a compound of the disclosure is one of the following structural formula VId: Formula VId the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, Ra, for each occurrence, is independently selected from H and C1-C3 alkyl, Rb, for each occurrence, is independently selected from absent, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, CH3, -OCH3, and CN, p is 0, 1, or 2, and Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10-membered heteroaryl; provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a twenty-seventh embodiment, a compound of the disclosure is one of the following structural formula VIe: 2023224057   06 Oct 2026 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein V1 and V2 are each independently selected from C, N, and O, L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, Ra, 5 for each occurrence, is independently selected from H and C1-C3 alkyl, Rb, for each occurrence, is independently selected from absent, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, -OCH3, CH3, and CN, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, p is 0, 1, or 2, q is 0, 1, or 2, and Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, 10 optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10 membered heteroaryl; provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a twenty-eighth embodiment, a compound of the disclosure is one of the following 15 structural formula VIf: Formula VIf the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein V1, V2 , and V3 are each 20 independently selected from C, N, and O, L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, Ra, for each occurrence, is independently selected from H and C1-C3 alkyl, Rb, for each occurrence, is independently selected from absent, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, CH3, -OCH3, and CN, Rf, for each occurrence, is independently selected from C1-C3 25 alkyl and halogen, p is 0, 1, or 2, q is 0, 1, or 2, and Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered 2023224057   06 Oct 2026 cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10-membered heteroaryl; provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene optionally substituted by C3-C4 cycloalkyl, Z4 is C or N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a twenty-ninth embodiment, a compound of the disclosure is one of the following structural formula VIIa: the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a thirtieth embodiment, a compound of the disclosure is one of the following structural formula VIIb: Formula VIIb the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1 is selected - 38 - 2023224057   06 Oct 2026 from C and N, Ra, for each occurrence, is independently selected from absent, halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), -OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, Ra1 is selected from optionally substituted C1-C3 alkyl, optionally substituted 5 3- to 6-membered cycloalkyl, optionally substituted 3- to 6-membered heterocyclyl, -NHC(=O)Rp2, and -NRp2Rq2, wherein Rp2 and Rq2, for each occurrence, are each independently selected from hydrogen and optionally substituted C1-C6 alkyl, or Rp2 and Rq2 join and form an optionally substituted 3 to 10-membered heterocyclyl; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 10 In a thirty-first embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ra, for each occurrence, is independently selected from CH3, CHF2, F, Cl, CN, NH2, NHCH3, OH, -CH2OH, -COOMe, -COOEt, -CONH2, -C(=O)H, -CH2CN, -CH2NH2 , CF3, and NO2, and Ra1 is selected from COOMe, COOEt, nh2 cn oh nh2 15 o , and - NRp2Rq2, wherein Rp2 and Rq2 join and form a 3 to 10-membered heterocyclyl optionally substituted by 1 to 2 groups selected from halogen, OH, CN, -O(C1-C3 alkyl), NH2, NHBoc, NH(C1-C3 alkyl), and C1-C3 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, NH2, NHBoc, and OH; and all other variables not specifically defined herein are as defined 20 in any of the appropriate preceding embodiments. In a thirty-second embodiment, a compound of the disclosure is one of the following structural formula VIIc: Formula VIIc 25 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the 2023224057   06 Oct 2026 pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1 is selected from C and N, Ra, for each occurrence is independently selected from halogen, CN, NO2, NH2, -NH(C1-C3alkyl), -OH, -O(C1-C3alkyl), -C(=O)H, -C(=O)O(C1-C3alkyl), -C(=O)NH2, and C1-5 C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, RP2 and Rq2, are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10-membered heteroaryl; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 10 In a thirty-third embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ra, for each occurrence, is independently selected from CH3, CHF2, F, Cl, CN, NH2, NHCH3, OH, -CH2OH, -COOMe, -COOEt, -CONH2, -C(=O)H, -CH2CN, -CH2NH2 , CF3, and NO2, and wherein the 3 to 10-membered cycloalkyl, 3 to 10-membered heterocyclyl, and 3 to 10 15 membered heteroaryl of RP2 and Rq2 are optionally substituted with 1 to 2 groups selected from halogen, OH, CN, -O(C1-C3 alkyl), NH2, NHBoc, NH(C1-C3 alkyl), and C1-C3 alkyl optionally substituted with halogen, CN, NH2, NHBoc, and OH; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a thirty-fourth embodiment, a compound of the disclosure is one of the following 20 structural VIIIa, VIIIb, or VIIIc: Formula VIIIa 2023224057   06 Oct 2026 5 the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z’ is selected from C and N, Z1, Z2, and Z3, are each independently selected from S, O, C, and N, Z4 is selected from C and N, Ra, for each occurrence is independently selected from halogen, CN, NO2, NH2, 10 -NH(C1-C3alkyl), -OH, -O(C1-C3alkyl), -C(=O)H, -C(=O)O(C1-C3alkyl), -C(=O)NH2, and C1- C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, Ring D is 3 to 10-membered heterocyclyl, Rg, for each occurrence, is independently selected from halogen, OH, CN, -O(C1-C3 alkyl), NH2, NHBoc, NH(C1-C3 alkyl), and C1-C3 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, NH2, NHBoc, and OH, s is an integer 15 selected from 0, 1, and 2; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a thirty-fifth embodiment, a compound of the disclosure is one of the following structural formula VIIId, VIIIe, or VIIIf: 2023224057   06 Oct 2026 Formula VIIIe the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z’ is selected 10 from C and N, Z1, Z2 and Z3 are each independently selected from S, O, C and N, Z4 is selected from C and N, Ra, for each occurrence is independently selected from halogen, CN, NO2, NH2, NH(C1-C3alkyl), OH, -O(C1-C3alkyl), -C(=O)H, -C(=O)O(C1-C3alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, Rh, for each occurrence, is independently selected from H, C1-C3 alkyl optionally substituted with 1-3 15 groups selected from halogen and 3 to 4- membered cycloalkyl, 3-6 membered cycloalkyl optionally substituted by 1 to 3 groups selected from halogen and C1-C3 alkyl, and 3-6 membered heterocyclyl optionally substituted by 1 to 3 groups selected from halogen and C1-C3 alkyl; and - 42 - 2023224057   06 Oct 2026 all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a thirty-sixth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, i 0 5 10 ;C, X4^ b<X2 of Formula I is selected from: ; Ring C substituted with p groups of Rc is selected from: and ; Ring B substituted with n groups of Rb is selected from: and L is selected from: *-S and 0 'V* O ; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 2023224057   06 Oct 2026 In a thirty-seventh embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring A substituted with m groups of Ra is selected from: * and wherein Ra’, for each occurrence, is independently selected from F, Cl, -OCH3, CH3, NH2, and CN; L is -O-; the position denoted by the * on the left side of the above structures is connected to L, and the position denoted by the * on the right side of the above structures is connected to 10 an Ra; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a thirty-eighth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, 15 Ring A substituted by m groups of Ra is selected from: and L is - SO2-; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a thirty-ninth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, 20 of Formula I is: 2023224057   06 Oct 2026 10 0 , wherein, R2 is selected from H, halogen, CN, -NH2, OH, OCH3, and Ci to C3 alkyl optionally substituted by 1 to 3 groups selected from halogen; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fortieth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, r3 of Formula I is selected from: ; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-first embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, of Formula I is selected from: 2023224057   06 Oct 2026 wherein Rf, for each occurrence, is independently selected from C1-C2 alkyl and halogen, and q is selected from 0, 1, and 2; wherein R is selected from halogen and C1 to C3 alkyl; and all other variables not specifically defined herein are as defined in any of the appropriate preceding 5 embodiments. In a forty-second embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, 0 । a J X4<^ ^*2 *3 of Formula I is selected from: ; and all 10 other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-third embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring A is selected from: 2023224057   06 Oct 2026 * / N            Q O , and •"V'N, wherein Ring A is substituted with m groups of Ra; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-fourth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, 10 Ring A substituted by m groups of Ra is selected from: 2023224057   06 Oct 2026 and wherein Rk is selected from -C(=O)NH2, -C(=O)NHCH3, -C(=O)N(CH3)2, and, wherein Rj, for each occurrence, is independently selected from F, Cl, CH3, and CN; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-fifth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring B is selected from: 10 , wherein Ring B is substituted with n groups of Rb; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-sixth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring B substituted by n groups of Rb is selected from: 15 and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-seventh embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring C is selected from: 2023224057   06 Oct 2026 10 N=\ i \ * * and , wherein Ring C is substituted with p groups of Rc; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a forty-eighth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ring C substituted by p groups of Rc is selected from: F F NC Cl * * * ; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. Also described herein is a compound, tautomer, a solvate or stereoisomer of the compound 2023224057   06 Oct 2026 or the tautomer, or pharmaceutically acceptable salt of this disclosure, Ra, for each occurrence, is independently selected from absent; halogen; cyano; =O; NO2; C1 to C6 alkyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 5 10-membered heterocyclyl, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; C2 to C6 alkenyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10 10-membered heterocyclyl, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; C2 to C6 alkynyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 15 10-membered heterocyclyl, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs; 3 to 10-membered cycloalkyl optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq; 20 3 to 10-membered heterocyclyl optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq; -C(=O)Rs; -C(=O)ORs; -C(=O)(C=O)ORs; 25 -C(=O)NRpRqNRpRq; -C(=O)NRpRqORs; -C(=O)NRpRq; -NRpRq; -NRpC(=O)Rs, wherein Rp and Rs are defined below or the Rp and Rs of NRpC(=O)Rs 30 join and form a 5 to 10-membered heterocyclyl; -NRp2C(=O)ORs2, wherein Rp2 and Rs2 are defined below or the Rp2 and Rs2 of - NRp2C(=O)ORs2 join and form a 5 to 10-membered heterocyclyl; 2023224057   06 Oct 2026 -ORs: wherein: Rp and Rq, for each occurrence, are independently selected from hydrogen and C1-C6 alkyl, or Rp and Rq join and form a 3 to 10-membered heterocyclyl, wherein: the C1-C4 alkyl of any one of Rp and Rq is optionally substituted with 1 to 3 groups selected from halogen, -NRp1C(=O)ORs1, cyano, -OH, -ORs1, -O(C1 to C3 alkyl)ORs1, 3 to 10membered cycloalkyl, 3 to 10-membered heterocyclyl, and phenyl; wherein the 3 to 10-membered heterocyclyl of any one of Rp and Rq, and the 3 to 10-membered cycloalkyl and 3 to 10-membered heterocyclyl of the C1-C4 alkyl of any one of Rp and Rq, are each optionally substituted with 1 to 3 groups selected from halogen, CN, =O, NRp1Rq1, ORs1, -NRp1C(=O)Rs1, -NRp1C(=O)ORs1, 3 to 10-membered cycloalkyl, and C1 to C3 alkyl optionally substituted with C3-C4 cycloalkyl; Rs, for each occurrence, is independently selected from hydrogen, C1-C6 alkyl, phenyl, 5 to 6membered heteroaryl, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl, wherein the C1-C6 alkyl, phenyl, 5 to 6-membered heteroaryl, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl of Rs are each optionally substituted with 1 to 3 groups selected from halogen, NRp1Rq1, -NRp1C(=O)ORs1, cyano, -OH, -O(C1 to C3 alkyl), -O(C1 to C3 alkyl)OH, -O(C1 to C3 alkyl)O(C1 to C3 alkyl), 3 to 10membered cycloalkyl, 3 to 10-membered heterocyclyl, and phenyl; Rp1 and Rq1, for each occurrence, are each independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rp2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; Rs2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fiftieth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ra is selected from NH2, NO2, =O, cyano, I, F, Cl, Br, -CH3, -CH(CH3)2, -CH2CN, -CF3, -CH2OH, - 51 - 2023224057   06 Oct 2026 -CH2CH2OH, -C(CH3)2OH, -CH2C(CH3)2OH, -CHF2, -CHCH3OH, -CH2CONH2, -CH2COOH, -CHCH3NH2, -CH2OH, -CH2CH2OH, -CH2N3, -CH2NH2, -CH2OCH3, (PMB), OH LA 2023224057   06 Oct 2026 2023224057   06 Oct 2026 HN , 2023224057   06 Oct 2026 5 2023224057   06 Oct 2026 5 2023224057   06 Oct 2026 O—* o ।                p / 7 ‘"nA Y H         (-NHBoc),     '— / , and            ; and all other 10 variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-first embodiment, in a compound, the tautomer thereof, the stereoisomer of 2023224057   06 Oct 2026 the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Ra, for each occurrence, is independently selected from CH3, CHF2, F, Cl, CN, NH2, NHCH3,   OH, OH -COOMe, -COOEt, -CONH2,   -C(=O)H,   - CF3, NO2, OH 5 all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-second embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Rb, for each occurrence, is independently selected from halogen, =O, and C1-C2 10 alkyl; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-third embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Rb, for each occurrence, is independently selected from -CH3, =O, F, and Cl; and all 15 other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-fourth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, Rc, for each occurrence, is independently selected from C1-C3 alkyl, CN, halogen, 20 -ORs1, and -C(=O)ORs1, wherein Rs1 is H or C1-C4 alkyl; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-fifth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, 25 Rc, for each occurrence, is independently selected from CH3, CN, F, Cl, -OCH3, and -C(=O)OC(CH3)3; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-sixth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the 30 foregoing, R2 is selected from H, halogen, CN, ORs1, -NRp1Rq1, and C1 to C2 alkyl optionally 2023224057   06 Oct 2026 substituted by 1 to 3 groups selected from halogen, wherein Rs1, Rp1, and Rq1 are independently selected from H and CH3; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-seventh embodiment, in a compound, the tautomer thereof, the stereoisomer 5 of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, R2 is selected from H, CH3, CF3, CN, F, Cl, Br, OH, OCH3, and NH2; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a fifty-eighth embodiment, in a compound, the tautomer thereof, the stereoisomer 10 of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, R1 and R2 join to form a 5- to 6-membered ring optionally substituted by 1 to 2 groups selected from halogen and C1 to C2 alkyl optionally substituted by 1 to 2 groups selected from halogen; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 15 In a fifty-ninth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, R1 and R2 join to form a 5- to 6-membered ring optionally substituted by 1 to 2 groups selected from F and CH3; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. 20 In a sixtieth embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, L is selected from -N(Rx)-, -(CH2)uO(CH2)u-, -(CH2)uS(=O)w-(CH2)u-, -C(=O)-, and C1-C3 alkylene, wherein the C1-C3 alkylene of L is optionally substituted by 1 to 2 groups selected from OH and C1-C3 alkyl, wherein Rx is selected from H and C1-C2 alkyl, u, for each 25 occurrence, is independently 0 or 1; and all other variables not specifically defined herein are as defined in in any of the appropriate preceding embodiments. In a sixty-first embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, L is selected from 2023224057   06 Oct 2026 ; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In a sixty-second embodiment, in a compound, the tautomer thereof, the stereoisomer 5 of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the .        /        0 o               / *-s    „ V* *-s            and *"Vi foregoing, L is selected from                                         0   ; and all other variables not specifically defined herein are as defined in any of the appropriate preceding embodiments. In an embodiment, a compound of the disclosure is one of the following structural Formula 10 VIe: Formula VIe the tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein: 15        Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1, Z2, and Z3, are each independently selected from S, C, and N, Z4 is selected from C and N, 2023224057   06 Oct 2026 V1 and V2 are each independently selected from C and N, L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, wherein Rx is selected from H and C1-C4 alkyl, 5        Ra, for each occurrence, is independently selected from absent, H, C1-C3 alkyl, Rb, for each occurrence, is independently selected from H, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, -OCH3, CH3, and CN, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, Rp2 and Rq2 are each independently selected from H, optionally substituted C1 to C6 alkyl, 10 optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and optionally substituted 3 to 10-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, p is 0, 1, or 2, q is 0, 1, or 2, 15 provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N. In another embodiment, in a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein: 20         Z1 is S, Z2is C, Z3is N, Z4is C, V1 and V2 are each independently selected from C and N, 25        L is selected from -O-, -CH2-, -S(=O)-, and -S(=O)2-, Ra, when attached to Z2, is selected from H and C1-C3 alkyl, Ra, when attached to Z1, is absent, Rb, for each occurrence, is independently selected from H, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, -OCH3, CH3, and CN, 30        Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, Rp2 and Rq2 are each independently selected from H and C1 to C6 alkyl, p is 0 or 1, and 2023224057   06 Oct 2026 q is 0 or 1. In certain embodiments, a compound of the disclosure is selected from Compounds 1 to 702, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing. In an embodiment, a compound, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing of the disclosure is selected from Compounds 13, 14, 31, 75, 284 and 494. Another embodiment of the disclosure provides a pharmaceutical composition comprising a compound of the Formulae according to the first, second or third aspect, a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, and at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier is selected from pharmaceutically acceptable vehicles and pharmaceutically acceptable adjuvants. In some embodiments, the pharmaceutically acceptable carrier is chosen from pharmaceutically acceptable fillers, disintegrants, surfactants, binders, and lubricants. It will also be appreciated that a pharmaceutical composition of this disclosure can be employed in combination therapies; that is, the pharmaceutical compositions described herein can further include an additional active pharmaceutical agent. Alternatively, a pharmaceutical composition comprising a compound selected from a compound of the Formulae disclosed herein (e.g., Compounds 1 to 702) disclosed herein, a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing can be administered as a separate composition concurrently with, prior to, or subsequent to, a composition comprising an additional active pharmaceutical agent. In some embodiments, the pharmaceutically acceptable carrier may be chosen from adjuvants and vehicles. The pharmaceutically acceptable carrier, as used herein, can be chosen, for example, from any and all solvents, diluents, other liquid vehicles, dispersion aids, suspension aids, surface active agents, isotonic agents, thickening agents, emulsifying agents, preservatives, solid binders, and lubricants, which are suited to the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of - 62 - 2023224057   06 Oct 2026 Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988 to 1999, Marcel Dekker, New York discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier is incompatible with the compounds of this disclosure, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this disclosure. Non-limiting examples of suitable pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates, glycine, sorbic acid, and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts, and electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars (such as lactose, glucose and sucrose), starches (such as corn starch and potato starch), cellulose and its derivatives (such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate), powdered tragacanth, malt, gelatin, talc, excipients (such as cocoa butter and suppository waxes), oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil), glycols (such as propylene glycol and polyethylene glycol), esters (such as ethyl oleate and ethyl laurate), agar, buffering agents (such as magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffer solutions, non-toxic compatible lubricants (such as sodium lauryl sulfate and magnesium stearate), coloring agents, releasing agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservatives, and antioxidants. A compound selected from a compound of the Formulae disclosed herein (e.g., Compounds 1 to 702) disclosed herein, a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition disclosed herein can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions. The compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein can also be administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other - 63 - 2023224057   06 Oct 2026 dosages forms that can also be used to administer the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, e.g., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration. Gelatin capsules containing a compound, a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing disclosed herein and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like, can also be used. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can further comprise at least one agent selected from coloring and flavoring agents to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols can be examples of suitable carriers for parenteral solutions. Solutions for parenteral administration may comprise a water-soluble salt of the at least one compound describe herein, at least one suitable stabilizing agent, and if necessary, at least one buffer substance. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, can be examples of suitable stabilizing agents. Citric acid and its salts and sodium EDTA can also be used as examples of suitable stabilizing agents. In addition, parenteral solutions can further comprise at least one preservative, selected, for example, from benzalkonium chloride, methyl- and propylparaben, and chlorobutanol. A pharmaceutically acceptable carrier is, for example, selected from carriers that are compatible with active ingredients of the composition (and in some embodiments, capable of stabilizing the active ingredients) and not deleterious to the subject to be treated. For example, solubilizing agents, such as cyclodextrins (which can form specific, more soluble complexes with the at least one compound and / or at least one pharmaceutically acceptable salt disclosed herein), can be utilized as pharmaceutical excipients for delivery of the active ingredients. 2023224057   06 Oct 2026 Examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow # 10. Suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences, A. Osol. For administration by inhalation, the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein may also be delivered as powders, which may be formulated, and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. One exemplary delivery system for inhalation can be metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein in at least one suitable propellant, selected, for example, from fluorocarbons and hydrocarbons. For ocular administration, an ophthalmic preparation may be formulated with an appropriate weight percentage of a solution or suspension of the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein in an appropriate ophthalmic vehicle, such that the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye. Useful pharmaceutical dosage-forms for administration of the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions. In some embodiments, the pharmaceutical compositions disclosed herein may be in the form of controlled release or sustained release compositions as known in the art. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules, lozenges or the like in the case of solid compositions. In such compositions, the active material is usually a component ranging from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight with - 65 - 2023224057   06 Oct 2026 the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form. Unit dosage formulations are preferably about of 5, 10, 25, 50, 100, 250, 500, or 1,000 mg per unit. In a particular embodiment, unit dosage forms are packaged in a multipack adapted for sequential use, such as blisterpack comprising sheets of at least 6, 9 or 12 unit dosage forms. In some embodiments, unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with, for example, 100 milligrams of the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein in powder, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. In some embodiments, a mixture of the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein and a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried. In some embodiments, tablets can be prepared by conventional procedures so that the dosage unit comprises, for example, 100 milligrams of the compound, stereoisomers thereof, or pharmaceutically acceptable salts thereof, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. In some embodiments, a parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of the compound and / or at least an enantiomer, a diastereoisomer, or pharmaceutically acceptable salt thereof disclosed herein in 10% by volume propylene glycol. The solution is made to the expected volume with water for injection and sterilized. In some embodiment, an aqueous suspension can be prepared for oral administration. For example, each 5 milliliters of an aqueous suspension comprising 100 milligrams of finely divided compound, stereoisomers thereof, or pharmaceutically acceptable salts thereof, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin can be used. The same dosage forms can generally be used when the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein is administered stepwise or - 66 - 2023224057   06 Oct 2026 in conjunction with at least one other therapeutic agent. When drugs are administered in physical combination, the dosage form and administration route should be selected depending on the compatibility of the combined drugs. Thus, the term coadministration is understood to include the administration of at least two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the at least two active components. The compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt disclosed herein can be administered as the sole active ingredient or in combination with at least one second active ingredient. The compound, tautomer, solvate, or stereoisomer described herein may be used in the aforementioned form or in the form of their pharmaceutically acceptable salts, such as hydrochlorides, hydrobromides, acetates, sulfates, citrates, carbonates, trifluoroacetates and the like. When the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein contain relatively acidic functionalities, salts can be obtained by addition of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or the like. When the compound, tautomer, solvate, or stereoisomer described herein contain relatively basic functionalities, salts can be obtained by addition of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic,benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, for example, Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 1977, 66, 1-19). Neutral forms of the pharmaceutically acceptable salt described herein may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional manner. This disclosure provides prodrugs. Prodrugs of the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt described herein that readily undergo - 67 - 2023224057   06 Oct 2026 chemical changes under physiological conditions to provide the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt of the present disclosure. Additionally, prodrugs can be converted to the compound, tautomer, solvate, stereoisomer, or a pharmaceutically acceptable salt of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be more bioavailable by oral administration than the parent drug. The prodrug may also have improved solubility in pharmacological compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound of the present disclosure which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, i.e., the active entity. Certain compound, tautomer, stereoisomer, or pharmaceutically acceptable salt of the disclosure can exist in unsolvated forms as well as solvated forms, including hydrate forms. Certain compound, tautomer, solvate, stereoisomer, or pharmaceutically acceptable salt of the disclosure may exist in multiple crystalline or amorphous forms. Certain compound, tautomer, solvate, or pharmaceutically acceptable salt in this disclosure possesses asymmetric carbon atoms (optical centers) or double bonds; the racemates, enantiomers, diastereoisomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present disclosure. III. Methods of Treatment and Uses In an embodiment, there is provided a method of treating a disease or condition mediated by receptor-interacting protein 1 (RIP1) signaling, comprising administering to a subject, a therapeutically effective amount of a compound according to any one of claims 1 to 62, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, or the pharmaceutical composition according to claim 63; wherein the disease or condition mediated by RIP1 signaling is selected from the group consisting of an inflammatory disease, an immune disease, an allergic disease, transplant rejection, a necrotic cell disease, a neurodegenerative disease, a central nervous system (CNS) disease, ischemic brain injury, an ocular disease, an infectious disease, a viral infection disease, - 68 - 2023224057   06 Oct 2026 and a malignancy. In another embodiment, there is provided a method of treating a disease or condition mediated by receptor-interacting protein 1 (RIP1) signaling, comprising administering to a subject a compound, tautomer, hydrate, stereoisomer, or pharmaceutically acceptable salt as 5 described herein, including a compound of the Formulae of the first, second or third aspect, a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition according to the fourth aspect. In an embodiment, the disease or condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, 10 and a viral infection. In other embodiments, there is provided a method of inhibiting receptor-interacting protein 1 (RIP1), comprising contacting the RIP1 protein or a fragment thereof with a compound of the Formulae according to the first, second or third aspect, a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, or 15 a pharmaceutical composition according to the fourth aspect. Also described herein, a compound, tautomer, hydrate, stereoisomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical 20 composition thereof, is for use in treating a disease or condition selected from an inflammatory disease, an immune disease (e.g., an autoimmune disease), an allergic disease, transplant rejection, a necrotic cell disease, a neurodegenerative disease, a central nervous system (CNS) disease, ischemic brain injury, an ocular disease, an infectious disease, and a malignancy. In some embodiments, the disease or condition is mediated by receptor-interacting protein 1 (RIP1) 25 signaling. In some embodiments, the disease or condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and a viral infection. In another aspect, disclosed herein is a compound, tautomer, hydrate, stereoisomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae 30 disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof, for use as a medicament. 2023224057   06 Oct 2026 In another aspect, disclosed herein is use of a compound, tautomer, hydrate, stereoisomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof, for the manufacture of a medicament for treating a disease or condition selected from an inflammatory disease, an immune disease (e.g., an autoimmune disease), an allergic disease, transplant rejection, a necrotic cell disease, a neurodegenerative disease, a central nervous system (CNS) disease, ischemic brain injury, an ocular disease, an infectious disease, and a malignancy. In some embodiments, the disease or condition is mediated by RIP1 signaling. In some embodiments, the disease or condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and a viral infection. In yet another aspect, disclosed herein is a method of treating a disease or condition selected from an inflammatory disease, an immune disease (e.g., an autoimmune disease), an allergic disease, transplant rejection, a necrotic cell disease, a neurodegenerative disease, a central nervous system (CNS) disease, ischemic brain injury, an ocular disease, an infectious disease, and a malignancy in a subject, comprising administering a therapeutically effective amount of a compound, tautomer, a hydrate or stereoisomer of the compound or the tautomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof. In some embodiments, the disease or condition is mediated by RIP1 signaling. In some embodiments, the disease or condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, ALS, Alzheimer’s disease, and a viral infection. In a further aspect of this disclosure, a compound, tautomer, hydrate, stereoisomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof, is for use in treating a disease or condition mediated by RIP1 signaling. In some embodiments, the disease or condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and a viral infection. In another aspect, disclosed herein is use of a - 70 - 2023224057   06 Oct 2026 compound, tautomer, a hydrate or stereoisomer of the compound or the tautomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702 a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a 5 pharmaceutical composition thereof, for the manufacture of a medicament for treating a disease or condition mediated by RIP1 signaling. In some embodiments, the disease or condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, ALS, Alzheimer’s disease, and a viral infection. In yet another aspect, disclosed herein is a method of treating a disease or condition mediated by RIP1 signaling in a subject, comprising administering 10 a therapeutically effective amount of a compound, tautomer, a hydrate or stereoisomer of the compound or the tautomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof. In some embodiments, the disease or 15 condition is selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, ALS, Alzheimer’s disease, and a viral infection. In another aspect of this disclosure, a compound, tautomer, a hydrate or stereoisomer of the compound or the tautomer, or pharmaceutically acceptable salt as described herein, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a 20 hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof, is for use in mediating, e.g., inhibiting, RIP1 by contacting the RIP1 protein or a fragment thereof (e.g., kinase domain, intermediate domain, and / or death domain) with the compound, tautomer, a hydrate or stereoisomer of the compound or the tautomer, pharmaceutically acceptable salt, or pharmaceutical composition. In 25 yet another aspect, disclosed herein is a method of inhibiting RIP1, comprising contacting the RIP1 protein or a fragment thereof (e.g., kinase domain, intermediate domain, and / or death domain) with a compound, tautomer, a hydrate or stereoisomer of the compound or the tautomer, or pharmaceutically acceptable salt as described herein to a subject, including a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or 30 stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof. A compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, 2023224057   06 Oct 2026 a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof may be administered once daily, twice daily, or three times daily, for example, for the treatment of a disease or condition as described above, e.g., a disease or condition selected from an inflammatory disease, an immune disease (e.g., an autoimmune disease), an allergic disease, transplant rejection, a necrotic cell disease, a neurodegenerative disease, CNS disease, ischemic brain injury, an ocular disease, an infectious disease, and a malignancy, including those mediated by RIP1 signaling; a disease or condition selected from ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, ALS, Alzheimer’s disease, and a viral infection, including those mediated by RIP1 signaling; a disease or condition mediated by RIP1 signaling. In some embodiments, 2 mg to 1500 mg or 5 mg to 1000 mg of a compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof are administered once daily, twice daily, or three times daily. A compound of the Formulae disclosed herein, Compounds 1 to 702, a tautomer thereof, a hydrate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition thereof may be administered, for example, various manners, such as orally, topically, rectally, parenterally, by inhalation spray, or via an implanted reservoir, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The term “parenteral” as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. The compositions disclosed herein may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art. Parenteral administration can be by continuous infusion over a selected period of time. Other forms of administration contemplated in this disclosure are as described in International Patent Application Nos. WO 2013 / 075083, WO 2013 / 075084, WO 2013 / 078320, WO 2013 / 120104, WO 2014 / 124418, WO 2014 / 151142, and WO 2015 / 023915. The contacting is generally effected by administering to the subject an effective amount of one or more compounds, tautomers, hydrates, stereoisomers, and pharmaceutically acceptable salt disclosed herein. Generally, administration is adjusted to achieve a therapeutic dosage of about 0.1 to 50, preferably 0.5 to 10, more preferably 1 to 10 mg / kg, though optimal dosages are - 72 - 2023224057   06 Oct 2026 compound specific, and generally empirically determined for each compound. The dosage administered will be dependent on factors, such as the age, health and weight of the recipient, the extent of disease, type of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. In general, a daily dosage of the active ingredient can vary, 5 for example, from 0.1 to 2000 milligrams per day. For example, 10-500 milligrams once or multiple times per day may be effective to obtain the desired results. The subject compositions may also be coformulated and / or coadministered with a different compound to treat applicable indications, or to treat programmed cell death. In some embodiments, applicable indications include brain injury, neurodegenerative diseases, viral 10 infections, immune tolerance, and cancer, e.g., to promote tumor immunity in pancreatic cancer and melanoma. Examples In order that the disclosure described herein may be more fully understood, the 15 following examples are disclosed herein. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this disclosure in any way. Example 1. Synthesis of Exemplary Compounds The compounds of the disclosure, selected from a compound of the Formulae 20 depicted herein, a tautomer thereof, a solvate or stereoisomer of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, can be made according to standard chemical practices or as illustrated herein, including the following synthetic schemes for compounds 1 to 702 as representative examples of Formula I. The intermediates 5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one, methyl 25 5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxylate and 2-(3-fluoro-4-hydroxyphenyl)-5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one were purified by chiral HPLC to give two stereoisomers. They were used as starting materials to synthesize the corresponding target compounds. 30 2023224057   06 Oct 2026 Example 1: Method 1 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4- dihydro-3H-1,2,4-triazol-3-one K2CO3,DMF,0°C-r.t,16h Step 1 Cul,K2CO3 120°C,DMF,2h Step 2 5 Step 1: 4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 2,4-dihydro-3H-1,2,4-triazol-3-one (41.06 g, 0.483 mol) was dissolved in 300 mL DMF. K2CO3 (138 g, 1 mol) was added. 2-(bromomethyl)-1,3-difluorobenzene (100 g, 0.483 mol) in 200 mL DMF was added dropwise to the solution at 0oC. The reaction mixture was stirred at room temperature for 16h. The solvent was evaporated to dryness to obtain a residue. Water was added 10 to the residue and extracted with EA (2 L X 3). The organic layers were combined and evaporated to dryness to give a crude product. It was triturated with tert-Butyl methyl ether to give 59 g white solid. Yield: 57.9%. LC-MS (m / z): 212.2 [M+H]+. Step 2: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 15 4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (20 g, 0.094 mol), and 4-bromo-2-fluorophenol (17.8 g, 0.094 mol) were mixed in 400 mL 1,4-dioxane. K2CO3 (39.0 g, 0.28 mol), CuI (2.66 g, 0.014 mol) and DMDACH ((1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine ) (4 g, 0.028 mol) were added. The reaction mixture was refluxed for 16 h under N2. It was cooled and filtered. The solid was washed with DCM. The organic layers were combined and evaporated 20 to dryness to obtain a residue. The residue was purified by column chromatography (PE / EA = 9 / 1 to 4 / 1) to give 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one as beige solid (10 g, yield: 33.1%). LC-MS (m / z): 322.3 [M+H]+. Step 3 : 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 25 To a solution of 5-bromo-4-methylthiazole (4.96 g, 0.0279 mol) in NMP (50 mL) was added 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (6.87 g, 2023224057   06 Oct 2026 0.0214 mol) and potassium carbonate (5.92 g, 0.0429 mol) under Ar. The reaction mixture was stirred at 150 oC for 2 h. Water was added and the reaction solution was extracted with EtOAc (300 mL X 3). The organic layers were combined and washed with water (150 mL) and brine. The organic layer was dried with MgSO4, filtered and evaporated to dryness to obtain a residue. 5 The residue was purified by column chromatography (PE / EA = 9 / 1 to 4 / 1) to give 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H -1,2,4-triazol-3-one was obtained as a light-yellow solid (5.9 g, yield: 66.0%). LC-MS (m / z): 419.1 [M+H]+. Step 4: 10 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-hydroxyphenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one (2 g, 4.78 mmol) in MeCN (50 mL) was added 1-bromopyrrolidine-2,5-dione (1.70 g, 9.56 mmol). The reaction was stirred at 90 oC for 2 h. The reaction progress was monitored 15 by LCMS. When the starting material was consumed, the reaction solution was concentrated to dryness and the residue was extracted with EtOAc (100 mL X 3). The organic layers were combined and washed with water (50 mL) and brine. The organic layer was dried with MgSO4, filtered and evaporated to dryness to obtain a residue. The residue was purified by column chromatography (PE / EA = 9 / 1 to 1 / 1) to give 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3- 20 fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one as light-yellow solid(1.82 g, yield: 76.56%). LC-MS (m / z): 497.1, 499.1. [M+H]+. 1H NMR (400 MHz, DMSO-d6) 8 8.35 (s, 1H), 7.88 (dd, J = 12.4, 2.4 Hz, 1H), 7.71 - 7.64 (m, 1H), 7.48 (tt, J = 8.4, 6.8 Hz, 1H), 7.33 (t, J = 9.2 Hz, 1H), 7.21 - 7.10 (m, 2H), 4.98 (s, 2H), 2.21 (s, 3H). Examples (Compounds) 2-9 were synthesized using a similar method to that used in Example 1. 25 2023224057   06 Oct 2026 Example (Compound) No. Method Activity Structure and Name Appearan ce and Yield 1H NMR Data MS(m / z) [M+H]+ Example 1 Method 1 ++++ N^Br 1          11 2-(4-((2-bromo-4-methylthiazol-5- yl)oxy)-3-fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one lightyellow solid, yield: 76.6% 1H NMR (400 MHz, DMSO-d6) 5 8.35 (s, 1H), 7.88 (dd, J = 12.4, 2.4 Hz, 1H), 7.71 - 7.64 (m, 1H), 7.48 (tt, J = 8.4, 6.8 Hz, 1H), 7.33 (t, J= 9.2 Hz, 1H), 7.21 - 7.10 (m, 2H), 4.98 (s, 2H), 2.21 (s, 3H). 497.1, 499.1 Example 2 Method 1 ++++ F       0 F N   F O 4-(2,6-difluorobenzyl)-2-(3-fluoro- 4-((4-methylthiazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one brown solid, yield: 70% 1H NMR (400 MHz, CDCl3) 5 8.44 (s, 1H), 7.91 (dd, J = 12.0, 2.4 Hz, 1H), 7.73 (ddd, J = 9.2, 2.4, 1.6 Hz, 1H), 7.58 (s, 1H), 7.41-7.33 (m, 1H), 7.03 - 6.94 (m, 3H), 4.97 (s, 2H), 2.37 (s, 3H). 419.4 Example 3 Method 1 Single unknown stereoisomer ++++ Q i - s^n (S)-2-(3-fluoro-4-((4- methylthiazol-5-yl)oxy)phenyl)-5- phenyl-2,5,6,7-tetrahydro-3H- pyrrolo [2,1-c][1,2,4]triazol-3 -one white solid, yield: 37.6 % 1H NMR (400 MHz, Chloroform-d) 5 8.40 (s, 1H), 7.88 (dd, J = 12.4, 2.4 Hz, 1H), 7.69 (dt, J = 9.2, 2.0 Hz, 1H), 7.43 - 7.31 (m, 3H), 7.26 - 7.23 (m, 2H), 6.98 (t, J = 8.8 Hz, 1H), 5.28 (dd, J = 7.6, 4.0 Hz, 1H), 3.12 - 2.97 (m, 2H), 2.97 - 2.85 (m, 1H), 2.60 - 2.46 (m, 1H), 2.36 (s, 3H). 409.2 Example 4 Method 1 ++++ 0      F Zn4 / =< < u ,N% >°\ / S^N (R)-2-(3-fluoro-4-((4- white solid, yield: 1H NMR (400 MHz, Chloroform-d) 5 8.42 (s, 1H), 7.88 (dd, J = 12.4, 2.4 Hz, 1H), 7.69 (dt, J = 9.2, 2.0 Hz, 1H), 409.2 2023224057   06 Oct 2026 Single unknown stereoisomer methylthiazol-5-yl)oxy)phenyl)-5- phenyl-2,5,6,7-tetrahydro-3H- pyrrolo [2,1-c][1,2,4]triazol-3 -one 39.1 % 7.44 - 7.31 (m, 3H), 7.26 - 7.23 (m, 2H), 6.98 (t, J = 8.8 Hz, 1H), 5.28 (dd, J = 7.6, 4.0 Hz, 1H), 3.13 - 2.98 (m, 2H), 2.98 - 2.86 (m, 1H), 2.61 - 2.44 (m, 1H), 2.36 (s, 3H). Example 5 Method 1 ++++ F          0     ___ / Cl 2-(3-chloro-4-((4-methylthiazol-5- yl)oxy)phenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one Red solid, yield: 31.5% 1H NMR (400 MHz, DMSO-d6) 5 8.75 (s, 1H), 8.34 (s, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 9.2, 2.8 Hz, 1H), 7.48 (tt, J = 8.4, 6.8 Hz, 1H), 7.20 -7.10 (m, 3H), 4.98 (s, 2H), 2.24 (s, 3H). 435.2 Example 6 Method 1 +++ N I 0 .- / N^Br 2-((1-(4-((2-bromo-4- methylthiazol-5-yl)oxy)-3- fluorophenyl)- 5 -oxo-1,5 -dihydro- 4H-1,2,4-triazoM- yl)methyl)benzonitrile Yellow solid, yield: 18.8% 1H NMR (400 MHz, DMSO-d6) 5 8.38 (s, 1H), 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.74 (ddd, J = 9.2, 2.4, 1.2 Hz, 1H), 7.55 - 7.45 (m, 3H), 7.16 (t, J = 8.0 Hz, 2H), 4.98 (s, 2H), 2.35 (s, 3H). 485.4, 487.4 Example 7 Method 1 ++++ N 11       0 J jr v Br 2-((1-(4-((2-bromo-4- methylthiazol-5-yl)oxy)-3-fluorophenyl)- 5 -oxo-1,5 -dihydro-4H-1,2,4-triazol-4-yl)methyl)-3 -fluorobenzonitrile Yellow solid, yield: 19.4% 1H NMR (400 MHz, DMSO-d6) 5 8.40 (s, 1H), 7.91 (dd, J = 12.4, 2.4 Hz, 1H), 7.72 (ddd, J = 9.2, 2.4, 1.2 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.16 (t, J = 8.0 Hz, 2H), 4.98 (s, 2H), 2.35 (s, 3H). 503.9, 505.9 Example 8 Method 1 ++++ ^X-F ^n' f s^N 2-(3 -fluoro-4-((4-methylthiazol- 5 - yl)oxy)phenyl)-4-(2-fluorobenzyl)- light yellow solid, yield: 1H NMR (400 MHz, DMSO-d6) 5 8.73 (s, 1H), 8.36 (s, 1H), 7.90 (dd, J = 12.6, 2.5 Hz, 1H), 7.71 (ddd, J = 9.0, 2.6, 1.5 Hz, 1H), 7.40 (ddt, J = 11.8, 401.1 2023224057   06 Oct 2026 2,4-dihydro-3 H-1,2,4-triazol-3 -one 42.0 % 6.3, 3.7 Hz, 2H), 7.31-7.16 (m, 3H), 4.96 (s, 2H), 2.26 (s, 3H). Example 9 Method 1 +++ O'v^-Z Cl N ° fy y> \ K AA s-^ V N N N 4-((4-chloropyridin-2-yl)methyl)-2-(3 -fluoro-4-((4-methylthiazol-5 -yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one yellow solid, yield: 37.6% 1H NMR (400 MHz, DMSO-d6) 5 8.73 (s, 1H), 8.51 (d, J = 5.4 Hz, 1H), 8.37 (s, 1H), 7.91 (dd, J = 12.6, 2.5 Hz, 1H), 7.72 (ddd, J = 9.1, 2.6, 1.4 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.50 (dd, J = 5.4, 2.0 Hz, 1H), 7.25 (t, J = 9.1 Hz, 1H), 5.04 (s, 2H), 2.26 (s, 3H). 418.1 Example 10: Method 2 methyl 5-(4-(4-((4-chloropyridin-2-yl)methyl)-5-oxo-4,5-dihydro-1H-1,2,4- triazol-1-yl)-2-fluorophenoxy)-4-methylthiazole-2-carboxylate 10 Step 1: 4-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a solution of 2,4-dihydro-3H-1,2,4-triazol-3-one (85 g, 1 mol, 1.0 eq.), and K2CO3 (207 g, 1.5 mol, 1.5 eq.) in DMF (800 mL), a solution of PMBCl (172 g, 1.1 mol, 1.1 eq.) in DMF (200 mL) was added dropwise slowly at 0oC. The resulted solution was stirred at 28 oC overnight. It was filtered and the filtrate was concentrated under vacuo and diluted with EA (500 mL), washed with brine (50 mL x 2), dried over Na2SO4, concentrated to 200 mL, added PE (400 mL) and filtered to obtain a solid . 4-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one was obtained as a white solid (90 g, yield: 90 %). LC-MS (m / z): 206.1 [M+H]+. 2023224057   06 Oct 2026 Step 2: 5-(4-bromo-2-fluorophenoxy)-4-methylthiazole A solution of 4-bromo-2-fluorophenol (54 g, 281 mmol), 5-bromo-4-methyl-1,3-thiazole (50 g, 281 mmol), K2CO3 (78 g, 562 mmol) in DMF (800 mL) was stirred at 150°C for 2 h. The resulted solution was filtered and the filtrate was diluted with EA (1.5 L), washed with water (500 mL x 2) and brine (1 L), dried over Na2SO4, concentrated and purified by silica gel column ( EA: PE = 0:1 ~ 1:1) to obtain 5-(4-bromo-2-fluorophenoxy)-4-methylthiazole as an off-white solid (77 g, yield: 85%). LC-MS (m / z): 287.9 [M+H]+. Step 3: 2-(3-fluoro-4-((4-methylthiazol-5-yl)oxy)phenyl)-4-(4-methoxybenzyl)-2,4-dihydro -3H-1,2,4-triazol-3-one A solution of 4-(2-methoxy-5-methylphenyl)-2H-1,2,4-triazol-3-one (55 g, 267 mmol), 5-(4-bromo-2-fluorophenoxy)-4-methyl-1,3-thiazole (77 g, 267 mmol), (1R,2R)-1-N,2-N-dimethylcyclohexane-1,2-diamine (11.4 g, 80 mmol), CuI (15 g, 80 mmol), Cs2CO3 (174 g, 534 mmol) in DMF (1 L) was stirred at 100C for 16h. The resulted solution was filtered and the filtrate concentrated, purified by silica gel column ( EA : PE = 0:1 ~ 2:1) to obtain 2-(3-fluoro-4-((4-methylthiazol-5-yl)oxy)phenyl)-4-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one as a colorless oil (65 g, yield: 78%). LC-MS (m / z): 413.1 [M+H]+. Step 4 : 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(4-methoxybenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one To a solution of 2-{3-fluoro-4-[(4-methyl-1,3-thiazol-5-yl)oxy]phenyl}-4- (2-methoxy-5-methylphenyl)-1,2,4-triazol-3-one (60 g, 146 mmol) in ACN (800 mL), a solution of NBS (31 g, 175 mmol) in ACN (200 mL) was added slowly at 0°C, the reaction was stirred at r.t. for 10 min. The resulted solution was filtered, and the filtrate was concentrated and purified by silica gel column with EA: PE = 0:1 ~ 2:1 to obtain 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one as a yellow solid (60 g, yield : 75%). LC-MS (m / z): 491.0 [M+H]+. 1H NMR (400 MHz, CDCi3) 8 7.92 (dd, J = 12.2, 2.5 Hz, 1H), 7.79 - 7.72 (m, 1H), 7.41 (s, 1H), 7.29 (d, J = 2.9 Hz, 1H), 7.27 (s, 1H), 7.04 (t, J = 8.9 Hz, 1H), 6.94 - 6.89 (m, 2H), 4.79 (s, 2H), 3.81 (s, 3H), 2.30 (s, 3H). Step 5: methyl 5-(2-fluoro-4-(4-(4-methoxybenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) phenoxy)-4-methylthiazole-2-carboxylate A solution of 2-{4-[(2-bromo-4-methyl-1,3-thiazol-5-yl)oxy]-3-fluorophenyl} -4-(2-methoxy-5-methylphenyl)-1,2,4-triazol-3-one (1.2 g, 2.4 mmol), Pd(OAc)2 (110 mg, 0.4 mmol), Xant-Phos (280 mg, 0.4 mmol), TEA (1.2 g, 12 mmol) in MeOH (30 mL) was stirred under an - 79 - 2023224057   06 Oct 2026 atmosphere of CO at 75C for 16h. The resulted solution was concentrated and purified by Combi-Flash ( EA : PE = 0:1 ~ 2:1) to obtain methyl 5-(2-fluoro-4-(4-(4-methoxybenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole-2-carboxylate as an off-white solid (600 mg, yield : 48%). LC-MS (m / z) : 471.0 [M+H]+. 5 Step 6: methyl 5-(2-fluoro-4-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole-2-carboxylate A solution of methyl 5-{2-fluoro-4-[4-(2-methoxy-5-methylphenyl)-5-oxo-1,2,4-triazol-1-yl] phenoxy}-4-methyl-1,3-thiazole-2-carboxylate (600 mg, 1.3 mmol), TfOH (574 mg, 3.8 mmol) in TFA (3 mL) was stirred at 80°C for 16h. The resulted solution was diluted with EA (30 mL), 10 washed with water (30 mL), brine (30 mL), dried over Na2SO4, concentrated and purified by Combi-Flash ( EA : PE = 0:1 ~ 2:1) to obtain methyl 5-(2-fluoro-4-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole-2-carboxylate (350 mg, yield: 70%) as a green solid. LC-MS (m / z): 413.0 [M+H]+. Step 7:     methyl 5-(4-(4-((4-chloropyridin-2-yl)methyl)-5-oxo-4,5-dihydro-1H-1,2,4- 15 triazol-1-yl)-2-fluorophenoxy)-4-methylthiazole-2-carboxylate: To a solution of 4-chloro-2-(chloromethyl)pyridine (30 mg, 0.185 mmol) in DMF (5 mL) was added methyl 5-[2-fluoro-4-(5-oxo-4H-1,2,4-triazol-1-yl)phenoxy]-4-methyl-thiazole-2-carboxylate (32 mg, 0.0926 mmol) and potassium carbonate (38 mg, 0.278 mmol). The reaction mixture was stirred at 25 oC for 2 h. The reaction was taken up in EtOAc 20  (100 mL) and the organic layers were combined and washed with water (2 x 50 mL) then brine (50 mL). The reaction mixture was dried with MgSO4 and evaporated to dryness. The crude product was then purified by Pre-TLC (PE:EA=2:3) to give methyl 5-[4-[4-[(4-chloro-2-pyridyl)methyl]-5-oxo-1,2,4-triazol-1-yl]-2-fluoro-phenoxy]-4-methyl-thiazole-2-carboxylate as white solid(25 mg, yield: 28.4%). MS (m / z): 476.1 [M+H]+.1H NMR (400 MHz, DMSO) 8 25 8.51 (d, J = 5.4 Hz, 1H), 8.40 (s, 1H), 7.96 (dd, J = 12.5, 2.5 Hz, 1H), 7.78 (ddd, J = 9.1, 2.5, 1.4 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.54 - 7.42 (m, 2H), 5.05 (s, 2H), 3.87 (s, 3H), 2.35 (s, 3H). Examples (Compounds) 11-12 were synthesized using a similar method to that used in Example 10. 30 2023224057   06 Oct 2026 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 10 Method 2 ++ pi- / \                  .'O. .-i ?> [TY —(  K       s-Y methyl              5-(4-(4-((4- chloropyridin-2-yl)methyl)-5- oxo-4,5-dihydro-1H-1,2,4- triazol-1-yl)-2-fluorophenoxy)- 4-methylthiazole-2-carboxylate white solid, yield: 28.4% 1H NMR (400 MHz, DMSO-d6) 8 8.51 (d, J = 5.4 Hz, 1H), 8.40 (s, 1H), 7.96 (dd, J = 12.5, 2.5 Hz, 1H), 7.78 (ddd, J = 9.1, 2.5, 1.4 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.54 - 7.42 (m, 2H), 5.05 (s, 2H), 3.87 (s, 3H), 2.35 (s, 3H). 476.1 Example 11 Method 2 + F        0 \ Yx / ^.Y Yn Y~n i%vY\Y 4-(2,6-difluorobenzyl)-2-(4- methyl-2-(pyridin-4- yloxy)thiazol-5-yl)-2,4-dihydro- 3H-1,2,4-triazol-3-one white solid, yield: 7.1 % 1H NMR (400 MHz, Chloroform-d) 8 8.07 (d, J = 7.6 Hz, 2H), 7.62 (s, 1H), 7.46 - 7.34 (m, 1H), 7.01 (t, J = 8.0 Hz, 2H), 6.56 (d, J = 7.2 Hz, 2H), 4.98 (s, 2H), 2.41 (s, 3H). 402.2 Example 12 Method 2 ++++ O F 2-(4-((2-chloro-5-fluoropyridin- 4-yl)oxy)-3 -fluorophenyl)- 5 - phenyl-2,5,6,7-tetrahydro-3H- pyrrolo[2,1-c][1,2,4]triazol-3-one grey solid, yield: 54.2 % 1H NMR (400 MHz, Chloroform-d) 8 8.24 (d, J = 2.4 Hz, 1H), 8.04 - 7.96 (m, 1H), 7.87 (ddd, J = 9.2, 2.4, 1.6 Hz, 1H), 7.44 - 7.33 (m, 3H), 7.28 - 7.21 (m, 3H), 6.65 (dd, J = 6.0, 1.2 Hz, 1H), 5.30 (dd, J = 7.6, 4.0 Hz, 1H), 3.16 - 3.00 (m, 2H), 3.00 - 2.89 (m, 1H), 2.64 -2.48 (m, 1H). 441.2 2023224057   06 Oct 2026 Example 13: Method 3 h2nny0’—' 0 EtOH, 90°C, 48 h Step 9 Step 7 DMF. 130°C,16h Step 8 Step 10 StepH Step 1: 5-(4-bromo-2-fluoro-phenoxy)-4-methyl-thiazole To a solution of 4-Bromo-2-fluorophenol (1.00 eq, 20.0 g, 105 mmol) in NMP (200 mL), was 5 added 5-Bromo-4-methylthiazole (1.10 eq, 20.5 g, 115 mmol) and CsF (3.00 eq, 49.9 g, 314 mmol), the mixture was stirred for 3 h at 150 oC under nitrogen atmosphere. The reaction was diluted with EtOAc (1000 mL) and the organics washed with water (500 mL x 2), then saturated brine (500 mL). The organics were then separated and dried (with MgSO4) before concentration to dryness. The residue was purified by silica gel chromatography eluted with 50% EtOAc in 10 petroleum ether to give 5-(4-bromo-2-fluoro-phenoxy)-4-methyl-thiazole (18 g, 56.2 mmol, 53.7 % yield) as a yellow oil. MS (m / z): 288.2, 290.2 [M+H]+. Step 2: 5-(4-bromo-2-fluoro-phenoxy)-2-iodo-4-methyl-thiazole To a solution of 5-(4-bromo-2-fluoro-phenoxy)-4-methyl-thiazole (1.00 eq, 14 g, 48.6 mmol) in MeCN (300 mL), was added NIS (2.20 eq, 18.6 g, 106.8 mmol), AcOH (30.0 mL), the mixture 15 was stirred for 16 h at 80 oC under nitrogen atmosphere. The reaction was quenched with saturated solution of Na2S2O4. The mixture was diluted with EtOAc (500 mL) and the organics washed with water (200 mL x 2), then saturated brine (200 mL). The organics were then separated and dried (MgSO4) before concentration to dryness. The residue was purified by silica gel chromatography eluted with 30% EtOAc in petroleum ether to give 5-(4-bromo-2-fluoro-20 phenoxy)-2-iodo-4-methyl-thiazole (12g, 29.0 mmol, 59.6 % yield) as a yellow solid. MS (m / z): 414.2, 416.2 [M+H]+. Step 3: methyl 5-(4-bromo-2-fluoro-phenoxy)-4-methyl-thiazole-2-carboxylate To a 2023224057   06 Oct 2026 solution of 5-(4-bromo-2-fluoro-phenoxy)-2-iodo-4-methyl-thiazole (1.00 eq, 10 g, 24.2 mmol) in methanol (300 mL), was added Pd(OAc)2 (0.30 eq, 1.62 g, 7.24 mmol), Xantphos (0.60 eq, 8.42 g, 14.50 mmol) and TEA (5.0 mL), the mixture was stirred for 16 h at 50 oC under CO balloon. The reaction was taken up in EtOAc (500mL) and the organics washed with water (300 mL x 2) and saturated brine (200 mL). The organics were then separated and dried (MgSO4) before concentration to dryness. The crude was then purified by flash column chromatography eluted with 30% EtOAc in petroleum ether. The desired fractions were concentrated to dryness in vacuo to afford methyl 5-(4-bromo-2-fluoro-phenoxy)-4-methyl-thiazole-2-carboxylate (5.8 g, 15.1 mmol, 62.43 % yield) as a brown oil. MS (m / z): 346.2, 348.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) 5 7.38 (ddd, J = 10.0, 2.4, 0.8 Hz, 1H), 7.27 - 7.23 (m, 1H), 6.94 (t, J = 8.4 Hz, 1H), 3.98 (d, J = 0.8 Hz, 3H), 2.41 (d, J = 0.8 Hz, 3H). Step 4: 5-phenylpyrrolidin-2-one A solution of benzene (242 g, 3.10 mol, 2.0 eq) in Eaton's reagent (500 mL) was added into a suspension of (S)-5-oxopyrrolidine-2-carboxylic acid (200 g, 1.55 mol, 1.0 eq) in Eaton's reagent (1500 mL). The reaction was heated to 60 oC for 72 h under nitrogen atmosphere. The mixture reaction was poured into ice water and adjusted to pH > 7 by a NaOH aqueous solution. The aqueous layer was extracted with EtOAc, washed with water and brine, dried over Na2SO4, filtered, and concentrated to give 5-phenylpyrrolidin-2-one (130 g, 52% yield) as a white solid. MS (m / z): 162.2 [M+H]+. Step 5: 5-phenylpyrrolidine-2-thione To a solution of 5-phenylpyrrolidin-2-one (130 g, 0.80mol, 1.0 eq) in toluene (1200 mL) was added Lawession reagent (640.3 g, 1.59 mol, 2.0 eq). The mixture was stirred at 80 oC for 4 h under nitrogen atmosphere. Then cooled to 20 oC and concentrated, purified by chromatography (EtOAc / petroleum ether = 1 / 6 to 1:1) to give 5-phenylpyrrolidine-2-thione (128 g, 91% yield) as a white solid. MS (m / z): 178.0 [M+H]+. Step 6: 5-(methylthio)-2-phenyl-3,4-dihydro-2H-pyrrole To a solution of 5-phenylpyrrolidine-2-thione (128 g, 0.72 mol, 1.0 eq) in Me2CO (1750 mL) was added MeI (122.5 g ,0.86 mol, 1.2 eq) and K2CO3 (249.7 g, 1.80mol, 2.5 eq). The reaction mixture was stirred at 25 oC for 16 h under nitrogen atmosphere. The mixture reaction was extracted with EtOAc, and the organic layer was washed with water and brine, then dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography (EtOAc / petroleum ether =2 / 1) to give 5-(methylthio)-2-phenyl-3,4-dihydro-2H-pyrrole (77g, 55.7 % - 83 - 2023224057   06 Oct 2026 yield) as a white oil. MS (m / z): 192.1 [M+H]+. Step 7 : ethyl 2-(2-phenyl-3,4-dihydro-2H-pyrrol-5-yl)hydrazine-1-carboxylate To a solution of 5-(methylthio)-2-phenyl-3,4-dihydro-2H-pyrrole (77 g, 0.40 mol, 1.0 eq) in EtOH (500 mL) was added ethyl hydrazinecarboxylate (41.9 g, 0.40 mol, 1.0 eq), the mixture reaction was heated to 90 oC for 48 h under nitrogen atmosphere. The reaction mixture was concentrated and the residue was washed with EtOAc / petroleum ether (5 / 1). The solid was collected to give ethyl 2-(2-phenyl-3,4-dihydro-2H-pyrrol-5-yl)hydrazine-1-carboxylate (80 g, 80.0% yield) as a white solid. MS (m / z): 248.2 [M+H]+. Step 8 :5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one Ethyl 2-(2-phenyl-3,4-dihydro-2H-pyrrol-5-yl)hydrazine-1-carboxylate (40 g, 0.16 mol) in DMF (200 mL) was stirred at 130 oC for 16 h. DMF was evaporated in vacuum. The residue was purified by chromatography (MeOH / DCM = 2% to 10%) to provide 5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one (16 g, 49.0% yield) as a white solid. MS (m / z): 202.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) 5 9.35 (brs, 1H), 7.41 - 7.29 (m, 3H), 7.20 (d, J = 7.2 Hz, 2H), 5.22 (dd, J = 8.0, 4.0 Hz, 1H), 3.08 - 2.98 (m, 1H), 2.97 - 2.86 (m, 1H), 2.86 - 2.75 (m, 1H), 2.51 - 2.39 (m, 1H). Step 9 : methyl 5-[2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4] triazol-2-yl)phenoxy]-4-methyl-thiazole-2-carboxylate To a solution of 5-phenyl-2,5,6,7-tetrahydropyrrolo[2,1-c][1,2,4]triazol-3-one (1.00 eq, 2906 mg, 14.4 mmol) in DMF (250mL), was added Cui (0.50 eq, 1379 mg, 7.22 mmol), K2CO3 (2.00 eq, 3986 mg, 28.9 mmol), methyl 5-(4-bromo-2-fluoro-phenoxy) -4-methyl-thiazole-2-carboxylate (1.00 eq, 5000 mg, 14.4 mmol), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (1.00 eq, 2051 mg, 14.4 mmol). The reaction mixture was stirred for 1 h at 100 oC under nitrogen. The reaction was concentrated to dryness and the residue was taken up in EtOAc (1000 mL) and the organics washed with water (300 mL x 2) and saturated brine (300 mL). The organics were then separated and dried (with MgSO4) before concentration to dryness. The crude was then purified by flash column chromatography eluted with 50% EtOAc in petroleum ether. The desired fractions were concentrated to dryness in vacuo to afford methyl 5-[2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-yl)phenoxy]-4-methyl-thiazole-2-carboxylate (5 g, 10.2 mmol, 70.5 % yield) as a yellow oil. MS (m / z): 467.2 [M+H]+. methyl 5-[2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-yl) phenoxy]-4-methyl-thiazole-2-carboxylate (10.0 g) was purified by chiral separation by SFC - 84 - 2023224057   06 Oct 2026 under condition (column : Lux Cellulose-4 ; column Size: 5cm x 25cm, 5um ; Mobile Phase A: CO2 / Mobile Phase B: MeOH:CAN; Wave Length: UV 220 nm; 25 oC). methyl (R)-5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4] triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxylate 4.545 g white solid, the first peak (Peak-1: ee% = 99.86%, chemical purity = 96.97%, retention time: 1.356 min), MS (m / z): 467.2 [M+H]+. H NMR (400 MHz, Chloroform-d) 1H NMR (400 MHz, Chloroform-d) 8 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.76 (dt, J = 9.2, 2.0 Hz, 1H), 7.44 - 7.32 (m, 3H), 7.27 - 7.23 (m, 2H), 7.11 (t, J = 8.8 Hz, 1H), 5.32 - 5.25 (m, 1H), 3.96 (s, 3H), 3.13 -2.99 (m, 2H), 2.99 - 2.87 (m, 1H), 2.59 - 2.45 (m, 1H), 2.43 (s, 3H). methyl (S)-5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4] triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxylate 4.575 g white solid, the second peak (Peak-2: ee% = 99.92%, chemical purity = 99.50%, retention time: 1.766 min) , MS (m / z): 467.2 [M+H]+. 8 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.76 (dt, J = 9.2, 2.0 Hz, 1H), 7.44 - 7.32 (m, 3H), 7.26 - 7.22 (m, 2H), 7.11 (t, J = 8.8 Hz, 1H), 5.28 (dd, J = 7.6, 4.0 Hz, 1H), 3.96 (s, 3H), 3.18 - 2.99 (m, 2H), 2.97 - 2.91 (m, 1H), 2.59 - 2.47 (m, 1H), 2.43 (s, 3H). Step 10: 5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxamide To a solution of methyl 5-[2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-5H-pyrrolo [2,1-c][1,2,4]triazol-2-yl)phenoxy]-4-methyl-thiazole-2-carboxylate (1.00 eq, 5 g, 10.7 mmol) in methanol (5 mL), was added NH3 (7M in MeOH) (30 mL). The reaction mixture was stirred for 1 h at 100 oC under nitrogen. The reaction mixture was concentrated to dryness, then triturated with MeOH to give 5-(2-fluoro-4-(3-oxo-5-phenyl -6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxamide (4 g, 8.8 mmol, 68.2 % yield) as an off-white solid . MS (m / z): 452.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) 5 8.09 (brs, 1H), 7.88 (dd, J = 12.8, 2.4 Hz, 1H), 7.79 (brs, 1H), 7.70 (dt, J = 9.2, 2.0 Hz, 1H), 7.42-7.37 (m, 3H), 7.367.30 (m, 3H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 3.07 - 2.97 (m, 2H), 2.97 - 2.85 (m, 1H), 2.38 -2.32 (m, 1H), 2.31 (s, 3H). Step 11: 5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxamide(1.0 g) was separated by chiral separation by SFC under basic condition [column : Lux Cellulose-4 ; column Size : 5cm x 25cm, 5um ; Mobile Phase A: CO2 / - 85 - 2023224057   06 Oct 2026 Mobile Phase B: MeOH:CAN(0.5% 2mM NH3-MeOH); Wave Length: UV 220 nm; 25 oC)] to give two compounds. (R)-5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxamide 5 0.403 g white solid, yield: 40.3%, the first peak (peak-1: ee% = 97.50%, chemical purity = 99.41%, retention time: 1.940 min), MS (m / z): 452.2 [M+H]+.1H NMR (400 MHz, Chloroform-d) 5 7.92 (dd, J = 12.4, 2.4 Hz, 1H), 7.74 (dt, J = 9.2, 2.0 Hz, 1H), 7.43-7.37 (m, 2H), 7.36-7.31 (m, 1H), 7.27 - 7.23 (m, 1H), 7.15 - 7.04 (m, 2H), 5.50 (brs, 1H), 5.28 (dd, J = 7.6, 4.0 Hz, 1H), 3.13 - 2.98 (m, 2H), 2.98 - 2.86 (m, 1H), 2.61 - 2.46 (m, 1H), 2.37 (s, 3H). 10 (S)-5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo[2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxamide 0.374 g white solid, yield: 37.4%, the second peak (peak-2: ee% = 98.50%, chemical purity = 98.91%, retention time: 2.198 min) , MS (m / z): 452.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) 5 8.09 (brs, 1H), 7.88 (dd, J = 12.8, 2.4 Hz, 1H), 7.79 (brs, 1H), 7.73 - 7.66 (m, 1H), 7.43 - 7.37 15 (m, 3H), 7.36-7.30 (m, 3H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 3.09 - 2.96 (m, 2H), 2.96 - 2.87 (m, 1H), 2.39 - 2.28 (m, 4H). Examples (Compounds) 14-36, 685-702 were synthesized using a similar method to that used in Example 13 Compound No. Method Activity Structure and Name Appearanc e and Yield 1H NMR Data MS(m / z) [M+H]+ Example 13 Method 3 ++++ 0 V A          N^AnH2 N F 5-(2-fluoro-4-(3-oxo-5-phenyl- 6,7-dihydro-3 H-pyrrolo [2,1- c][1,2,4]triazol-2(5H)- yl)phenoxy)-4-methylthiazole-2- carboxamide off-white solid, yield: 68.2 % 1HNMR (400 MHz, DMSO-d6) 5 8.09 (brs, 1H), 7.88 (dd, J = 12.8, 2.4 Hz, 1H), 7.79 (brs, 1H), 7.70 (dt, J = 9.2, 2.0 Hz, 1H), 7.42-7.37 (m, 3H), 7.367.30 (m, 3H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 3.07 - 2.97 (m, 2H), 2.97 - 2.85 (m, 1H), 2.38 - 2.32 (m, 1H), 2.31 (s, 3H). 452.2 2023224057   06 Oct 2026 Example 14 Method 3 Single     unknown stereoisomer ++++ 0 ( 3        N^NH, 0    —i xNX _ / =\ r F (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylthiazole-2-carboxamide white solid, yield: 43.5% 1HNMR (400 MHz, DMSO-d6) 6 8.09 (brs, 1H), 7.88 (dd, J = 12.8, 2.4 Hz, 1H), 7.79 (brs, 1H), 7.73 - 7.66 (m, 1H), 7.43 - 7.37 (m, 3H), 7.36-7.30 (m, 3H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 3.09 - 2.96 (m, 2H), 2.96 - 2.87 (m, 1H), 2.39 - 2.28 (m, 4H). 452.3 Example 15 Method 3 Single     unknown stereoisomer +++ o C                       NH2 O       ---(. 1 xNx / =0^ (   1   N-<\ / >-O F (R)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylthiazole-2-carboxamide white solid, yield: 45.9% 1H NMR (400 MHz, Chloroform-d) 5 7.92 (dd, J = 12.4, 2.4 Hz, 1H), 7.74 (dt, J = 9.2, 2.0 Hz, 1H), 7.43-7.37 (m, 2H), 7.36-7.31 (m, 1H), 7.27 - 7.23 (m, 1H), 7.15 - 7.04 (m, 2H), 5.50 (brs, 1H), 5.28 (dd, J = 7.6, 4.0 Hz, 1H), 3.13 - 2.98 (m, 2H), 2.98 - 2.86 (m, 1H), 2.61 - 2.46 (m, 1H), 2.37 (s, 3H). 452.2 Example 16 Method 3 Single     unknown stereoisomer ++++ M / V Cl (S)-5-(2-chloro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylthiazole-2-carboxamide white solid, yield: 9.8 % 1H NMR (400 MHz, Chloroform-d) 5 8.15 (d, J = 2.4 Hz, 1H), 7.87 (dd, J = 9.2, 2.4 Hz, 1H), 7.37 (dq, J = 14.4, 7.2 Hz, 3H), 7.27 - 7.23 (m, 2H), 7.06 - 6.94 (m, 2H), 5.54 (s, 1H), 5.28 (dd, J = 7.6, 4.4 Hz, 1H), 3.05 (dt, J = 14.0, 8.0 Hz, 2H), 3.00 - 2.86 (m, 1H), 2.54 (td, J = 11.2, 10.0, 5.2 Hz, 1H), 2.34 (s, 3H). 468.2 Example 17 Method 3 Single     unknown stereoisomer ++++ / =\ Wl / V S^N ° nh2 (S)- 4-methyl-5-(4-(3-oxo-5-phenyl- 6,7-dihydro-3 H-pyrrolo [2,1- light yellow solid, yield: 11.7 % 1H NMR (400 MHz, Chloroform-d) 5 7.94 (d, J = 8.8 Hz, 2H), 7.43 - 7.29 (m, 3H), 7.27 - 7.23 (m, 2H), 7.11 -7.03 (m, 3H), 5.49 (brs, 1H), 5.29 (dd, J = 7.6, 4.0 Hz, 1H), 3.11 - 2.98 (m, 2H), 2.98 - 2.86 (m, 1H), 2.57 - 2.48 (m, 1H), 2.31 (s, 3H). 434.2 2023224057   06 Oct 2026 c][1,2,4]triazol-2(5H)-yl)phenoxy)thiazole-2-carboxamide Example 18 Method 3 Single     unknown stereoisomer ++++ o O     F S.^N i rQ o^N''^z H 5-(2-fluoro-4-((S)-3-oxo-5- phenyl-6,7-dih.ydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5 H)-yl)phenoxy)-4-methyl-N- ((S)-tetrahydrofuran-3- yl)thiazole-2-carboxamide white solid, yield: 41.1 % 1H NMR (400 MHz, DMSO-d6) 5 8.87 (d, J = 7.2 Hz, 1H), 7.88 (dd, J = 12.4, 2.4 Hz, 1H), 7.69 (d, J = 9.6 Hz, 1H), 7.43 - 7.29 (m, 6H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 4.46 - 4.37 (m, 1H), 3.89 - 3.78 (m, 2H), 3.70 (q, J = 7.6 Hz, 1H), 3.58 (dd, J = 8.8, 5.2 Hz, 1H), 3.09 - 2.98 (m, 2H), 2.96 - 2.86 (m, 1H), 2.38 - 2.28 (m, 4H), 2.18 - 2.05 (m, 1H), 2.05 - 1.93 (m, 1H). 522.2 Example 19 Method 3 Single     unknown stereoisomer ++++ r° ■■■■■■ m H 5-(2-fluoro-4-((S)-3-oxo-5- phenyl-6,7-dih.ydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5 H)-yl)phenoxy)-4-methyl-N- ((S)-tetrahydrofuran-3- yl)thiazole-2-carboxamide white solid, yield: 39.5 % 1H NMR (400 MHz, DMSO-d6) 5 8.88 (d, J = 6.4 Hz, 1H), 7.88 (dd, J = 12.8, 2.4 Hz, 1H), 7.70 (d, J = 9.2 Hz, 1H), 7.44 - 7.29 (m, 6H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 4.46 - 4.37 (m, 1H), 3.89 - 3.78 (m, 2H), 3.70 (q, J = 7.6 Hz, 1H), 3.58 (dd, J = 8.8, 4.8 Hz, 1H), 3.09 - 2.97 (m, 2H), 2.96 - 2.82 (m, 1H), 2.42 - 2.25 (m, 4H), 2.18 - 2.04 (m, 1H), 2.05 - 1.93 (m, 1H). 522.2 Example 20 Method 3 Single     unknown stereoisomer ++++ 0      F (S)-2-(4-((2-((2S,6R)-2,6- dimethylmorpholine-4-carbonyl)- 4-methylthiazol-5-yl)oxy)-3- fluorophenyl)- 5 -phenyl-2,5,6,7- white solid, yield: 31.6 % 1H NMR (400 MHz, DMSO-d6) 8 7.88 (d, J = 13.2 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.45 - 7.36 (m, 3H), 7.36 -7.29 (m, 3H), 5.34 - 5.30 (m, 2H), 4.35 - 4.18 (m, 1H), 3.70 - 3.48 (m, 3H), 3.10 - 2.83 (m, 3H), 2.40 - 2.25 (m, 5H), 1.12 (d, J = 6.2 Hz, 6H). 550.2 2023224057   06 Oct 2026 tetrahydro-3H-pyrrolo [2,1- c][1,2,4]triazol-3-one Example 21 Method 3 Single     unknown stereoisomer ++++ (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo[2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4-methyl-N- (oxetan-3 -yl)thiazole-2- carboxamide white solid, yield: 29.6 % 1H NMR (400 MHz, DMSO-d6) 8 9.54 (brs, 1H), 7.88 (dd, J = 12.8, 2.4 Hz, 1H), 7.73 - 7.66 (m, 1H), 7.44 - 7.29 (m, 6H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 4.97 (p, J = 7.2 Hz, 1H), 4.73 - 4.62 (m, 4H), 3.09 - 2.85 (m, 3H), 2.38 -2.29 (m, 4H). 508.2 Example 22 Method 3 ++++ F        0      ,F I JI      \= / >s f \ N \\ 0 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((4-methyl-2- (morpholine-4-carbonyl)thiazol- 5 -yl)oxy)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3 -one white solid, yield: 22.0 % 1H NMR (400 MHz, DMSO-d6) 8 8.36 (s, 1H), 7.90 (dd, J = 12.8, 2.4 Hz, 1H), 7.72 (dd, J = 9.2, 2.4 Hz, 1H), 7.46 (dq, J = 32.4, 9.2, 8.4 Hz, 2H), 7.16 (t, J = 8.0 Hz, 2H), 4.98 (s, 2H), 3.69 - 3.59 (m, 4H), 2.52 - 2.33 (m, 4H) 2.30 (s, 3H). 532.1 Example 23 Method 3 ++++ 0 0 F / "N-J An o^nh2 5-(2-fluoro-4-(3-oxo-5-phenyl-6,7 -dihydro-3 H-pyrrolo [2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-1,4-dimethyl- 1H-pyrazole-3-carboxamide white solid, yield: 18.2 % 1H NMR (400 MHz, Chloroform-d) 8 7.91 (dd, J = 12.4, 2.4 Hz, 1H), 7.65 (dt, J = 9.2, 2.0 Hz, 1H), 7.37 (dq, J = 14.0, 7.2 Hz, 3H), 7.25 - 7.15 (m, 2H), 6.84 - 6.75 (m, 2H), 5.31 - 5.24 (m, 2H), 3.71 (s, 3H), 3.13 - 3.01 (m, 2H), 2.98 - 2.84 (m, 1H), 2.53 (tt, J = 9.6, 5.6 Hz, 1H), 2.09 (s, 3H). 449.2 Example 24 Method 3 ++++ F         0       ,F cX—o H 5-(4-(4-(2,6-difluorobenzyl)-5 - white solid, yield: 53.8 % 1H NMR (400 MHz, Chloroform-d) 8 7.93 (dd, J = 12.0, 2.4 Hz, 1H), 7.75 (dt, J = 9.2, 2.0 Hz, 1H), 7.58 (s, 1H), 7.47 (brs, 1H), 7.43 - 7.31 (m, 1H), 575.2 2023224057   06 Oct 2026 oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methyl-N-(2-morpholinoethyl)thiazole-2-carboxamide 7.06 (t, J = 8.8 Hz, 1H), 6.98 (t, J = 8.0 Hz, 2H), 4.97 (s, 2H), 3.79 - 3.72 (m, 4H), 3.60 - 3.51 (m, 2H), 2.71 - 2.46 (m, 6H), 2.35 (s, 3H). Example 25 Method 3 ++++ 0 A OTiJO-w OIN^C H 5-(2-fluoro-4-(4-(2-fluorobenzyl)- 5-oxo-4,5-dihydro-1H-1,2,4- triazol-1 -yl)phenoxy)-4-methyl- N-(2-morpholinoethyl)thiazole-2-carboxamide white solid, yield: 29.9 % 1H NMR (400 MHz, Chloroform-d) 5 7.92 (dd, J = 12.0, 2.4 Hz, 1H), 7.75 (dt, J = 9.2, 2.0 Hz, 1H), 7.58 (s, 1H), 7.52 - 7.47 (m, 1H), 7.44 (td, J = 7.6, 1.6 Hz, 1H), 7.40 - 7.32 (m, 1H), 7.21 - 7.03 (m, 3H), 4.91 (d, J = 1.2 Hz, 2H), 3.75 (t, J = 4.8 Hz, 4H), 3.55 (q, J = 6.0 Hz, 2H), 2.61 (t, J = 6.0 Hz, 2H), 2.57 - 2.50 (m, 4H), 2.35 (s, 3H). 557.2 Example 26 Method 3 +++ 0 J sX o^nh2 5-(2-fluoro-4-(4-((3- methylpyridin-2-yl)methyl)-5- oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazole-2-carboxamide yellow solid, yield: 43.5 % 1H NMR (400 MHz, DMSO-d6) 5 8.33 - 8.28 (m, 2H), 8.10 (brs, 1H), 7.96 (dd, J = 12.8, 2.4 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 9.2 Hz, 1H), 7.24 (dd, J = 7.6, 4.8 Hz, 1H), 5.03 (s, 2H), 2.38 (s, 3H), 2.31 (s, 3H). 441.2 Example 27 Method 3 ++++ o OPXXd °>= / oAm^,nh2 N-(2-aminoethyl)-5-(2-fluoro-4-(4-(2-fluorobenzyl)-5-oxo-4,5-dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazole-2-carboxamide white solid, yield: 66.3 % 1H NMR (400 MHz, DMSO-d6) 8 8.68 (brs, 1H), 8.37 (s, 1H), 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.73 (dt, J = 9.2, 1.6 Hz, 1H), 7.39 (td, J = 9.2, 8.4, 3.2 Hz, 3H), 7.25 - 7.18 (m, 2H), 4.96 (s, 2H), 3.27 - 3.20 (m, 2H), 2.68 (t, J = 6.4 Hz, 2H), 2.31 (s, 3H), 1.23 (brs, 1H). 487.3 Example 28 Method 3 ++++ X rzv X, X z white solid, yield:37.2 % 1H NMR (400 MHz, DMSO-d6) 8 8.36 (s, 1H), 7.87 (dd, J = 12.4, 2.4 Hz, 1H), 7.75 - 7.60 (m, 2H), 7.52 - 7.42 445.0 2023224057   06 Oct 2026 2-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4-triazol- 1 -yl)-2-fluorophenoxy)-1 -methyl- 1 H-imidazole-4-carboxamide (m, 2H), 7.16 (t, J = 8.1 Hz, 2H), 6.95 (s, 1H), 4.99 (s, 2H), 3.59 (s, 3H). Example 29 Method 3 ++++ O nNH NH2 F 5-(2-fluoro-4-(3-oxo-5-phenyl- 6,7-dihydro-3 H-pyrrolo [2,1- c][1,2,4]triazol-2(5H)- yl)phenoxy)-1 -methyl-1H-pyrazole-3 -carboxamide white solid, yield:56.4 % 1H NMR (400 MHz, CDCl3) 5 7.96 -7.88 (m, 1H), 7.77 (d, J = 1.2 Hz, 1H), 7.44-7.33 (m , 3H), 7.27 (s, 1H), 7.25 (d, J = 2.8 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 6.06 (s, 1H), 5.31-5.28 (m, 1H), 3.83 (s, 3H), 3.13 - 2.85 (m, 3H), 2.58- 2.45 (m, 1H). 435.4 Example 30 Method 3 Single     unknown stereoisomer ++++ Ry F (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-1 -methyl-1H- pyrazole-3 -carboxamide white solid, yield:74.6 % 1H NMR (400 MHz, DMSO-d6) 5 7.96 - 7.88 (m, 1H), 7.77 (d, J = 1.2 Hz, 1H), 7.44-7.33 (m , 3H), 7.26 (s, 1H), 7.24 (d, J = 2.8 Hz, 1H), 7.20 (d, J = 8.8 Hz, 1H), 6.05 (s, 1H), 5.36 -5.28 (m, 1H), 3.78 (s, 3H), 3.12 - 2.86 (m, 3H), 2.58- 2.45 (m, 1H). 435.1 Example 31 Method 3 ++++ a     o f N       N 0 5-(4-(4-((4-chloropyridin-3 -yl)methyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1-yl)-2- fluorophenoxy)-4-methylthiazole- 2-carboxamide white solid, yield: 16.7% 1H NMR (400 MHz, DMSO-d6) 5 8.63 (s, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.38 (s, 1H), 8.09 (s, 1H), 7.92 (dd, J = 12.4, 2.4 Hz, 1H), 7.80 (s, 1H), 7.73 (dt, J = 8.8, 2.0 Hz, 1H), 7.62 (d, J = 5.2 Hz, 1H), 7.39 (t, J = 9.2 Hz, 1H), 5.04 (s, 2H), 2.30 (s, 3H). 461.9 Example 32 Method 3 +++ J 2             V N K A A s-? N= /  \=N W~F methyl      5-(2-fluoro-4-(4-((3- light yellow solid, yield: 71.9% 1H NMR (400 MHz, DMSO-d6) 5 8.39 (s, 2H), 7.95 (dd, J = 12.6, 2.5 Hz, 1H), 7.86-7.70 (m, 2H), 7.48 (ddd, J = 9.1, 6.9, 2.7 Hz, 2H), 5.14 (d, J = 1.8 460.1 2023224057   06 Oct 2026 fluoropyridin-2-yl)methyl)-5-oxo- 4,5-dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4- methylthiazole-2-carboxylate Hz, 2H), 3.87 (s, 3H), 2.35 (s, 3H). Example 33 Method 3 +++ / 0. J W ii i methyl 5-(4-(4-((3-cyanopyridin- 2-yl)methyl)-5-oxo^-,5-dihydro- 1H-1,2,4- triazol-1 -yl)-2-fluorophenoxy)-4- methylthiazole-2-carboxylate light yellow solid, yield: 73.7% 1H NMR (400 MHz, DMSO-d6) 5 8.79 (dd, J = 5.0, 1.7 Hz, 1H), 8.458.34 (m, 2H), 7.95 (dd, J = 12.5, 2.5 Hz, 1H), 7.78 (dt, J = 9.1, 1.8 Hz, 1H), 7.58 (dd, J = 7.9, 4.9 Hz, 1H), 7.48 (t, J = 9.1 Hz, 1H), 5.29 (s, 2H), 3.87 (s, 3H), 2.35 (s, 3H). 467.1 Example 34 Method 3 +++ 0 V J k a V^N F methyl 5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylthiazole-2-carboxylate yellow oil, yield: 70.5 % NA 467.2 Example 35 Method 3 Single     unknown stereoisomer ++ 0 O / N<^o / -   0     “A s / / i=\ r F methyl (R)-5-(2-fluoro-4-(3-oxo- 5-phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylthiazole-2-carboxylate white solid, yield: 21.0 % 1H NMR (400 MHz, Chloroform-d) 5 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.76 (dt, J = 9.2, 2.0 Hz, 1H), 7.44 - 7.32 (m, 3H), 7.27 - 7.23 (m, 2H), 7.11 (t, J = 8.8 Hz, 1H), 5.32 - 5.25 (m, 1H), 3.96 (s, 3H), 3.13 - 2.99 (m, 2H), 2.99 - 2.87 (m, 1H), 2.59 - 2.45 (m, 1H), 2.43 (s, 3H). 467.2 2023224057   06 Oct 2026 Example 36 Method 3 Single     unknown stereoisomer ++++ 0 F methyl (S)-5-(2-fluoro-4-(3-oxo-5-phenyl-6,7-dihydro-3H-pyrrolo [2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-4-methylthiazole-2-carboxylate white solid, yield: 20.0 % 1H NMR (400 MHz, Chloroform-d) 5 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.76 (dt, J = 9.2, 2.0 Hz, 1H), 7.44 - 7.32 (m, 3H), 7.26 - 7.22 (m, 2H), 7.11 (t, J = 8.8 Hz, 1H), 5.28 (dd, J = 7.6, 4.0 Hz, 1H), 3.96 (s, 3H), 3.18 - 2.99 (m, 2H), 2.97 - 2.91 (m, 1H), 2.59 - 2.47 (m, 1H), 2.43 (s, 3H). 467.2 Example 685 Method 3 Single     unknown stereoisomer +++ Q O           7 NH? / =\ An F (S)-2-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-1 -methyl-1H- imidazole-4-carboxamide white solid, yield: 14.09% 1H NMR (400 MHz, Chloroform-d) 5 7.90 (dd, J = 12.0, 2.8 Hz, 1H), 7.82 -7.75 (m, 1H), 7.48 - 7.29 (m, 6H), 7.26 - 7.23 (m, 1H), 6.63 (brs, 1H), 5.36 - 5.24 (m, 2H), 3.63 (s, 3H), 3.11 - 3.00 (m, 2H), 2.97 - 2.84 (m, 1H), 2.59 - 2.48 (m, 1H). 435.4 Example 686 Method 3 Single     unknown stereoisomer ++++ F (S)-4-ethyl-3-(2-fluoro-4-(3-oxo- 5-phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)isothiazole-5-carboxamide white solid, yield: 5.99% 1H NMR (400 MHz, DMSO-d6) 5 7.85 (dd, J = 12.4, 2.4 Hz, 1H), 7.76 - 7.69 (m, 2H), 7.68 - 7.64 (m, 1H), 7.52 (t, J = 8.8 Hz, 1H), 7.43 - 7.36 (m, 2H), 7.37 - 7.30 (m, 3H), 5.33 (dd, J = 8.0, 4.8 Hz, 1H), 4.26 - 4.18 (m, 2H), 3.09 - 2.98 (m, 2H), 2.97 - 2.90 (m, 1H), 2.39 - 2.30 (m, 1H), 0.91 (t, J = 7.2 Hz, 3H). 466.4 Example 687 Method 3 Single     unknown stereoisomer ++++ Q o AA-o-v ^N'     Z1^NH2 0 (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-1,3,4- white solid, yield: 6.62% 1H NMR (400 MHz, DMSO-d6) 5 8.49 (brs, 1H), 8.13 (brs, 1H), 7.94 (dd, J = 12.4, 2.4 Hz, 1H), 7.85 - 7.78 (m, 1H), 7.78 - 7.71 (m, 1H), 7.43 - 7.31 (m, 5H), 5.33 (dd, J = 7.6, 4.8 Hz, 1H), 3.09 - 2.99 (m, 2H), 2.98 - 2.88 (m, 1H), 2.39 - 2.31 (m, 1H). 439.2 2023224057   06 Oct 2026 thiadiazole-2-carboxamide Example 688 Method 3 Single     unknown stereoisomer +++ Qo y F (S)-2-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)oxazole^- carboxamide white solid, yield: 9.57% 1H NMR (400 MHz, DMSO-d6) 5 8.30 (brs, 1H), 7.94 - 7.86 (m, 1H), 7.84 -7.74 (m, 2H), 7.49 - 7.44 (m, 2H), 7.43 - 7.37 (m, 2H), 7.36 - 7.31 (m, 3H), 5.33 (dd, J = 7.6, 4.8 Hz, 1H), 3.10 - 2.98 (m, 2H), 2.96 - 2.87 (m, 1H), 2.42 - 2.28 (m, 1H). 422.1 Example 689 Method 3 Single     unknown stereoisomer ++++ X 0     VNH2 QI / / n F (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylthiophene-2-carboxamide white solid, yield: 12.03% 1H NMR (400 MHz, DMSO-d6) 5 7.86 (dd, J = 12.8, 2.4 Hz, 2H), 7.69 (dt, J = 9.2, 1.6 Hz, 1H), 7.49 (s, 1H), 7.43 - 7.37 (m, 2H), 7.32 (q, J = 11.2, 7.2 Hz, 5H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 3.08 - 2.97 (m, 2H), 2.96 - 2.86 (m, 1H), 2.36 - 2.30 (m, 1H), 2.07 (s, 3H). 451.1 Example 690 Method 3 Single     unknown stereoisomer ++++ ^-^N' F (S)-3-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylisoxazole-5-carboxamide white solid, yield: 7.09% 1H NMR (400 MHz, DMSO-d6) 5 8.21 (brs, 1H), 7.96 (brs, 1H), 7.88 (dd, J = 12.4, 2.4 Hz, 1H), 7.79 - 7.71 (m, 1H), 7.64 - 7.55 (m, 1H), 7.44 - 7.37 (m, 2H), 7.37 - 7.30 (m, 3H), 5.33 (dd, J = 7.6, 4.8 Hz, 1H), 3.10 - 2.88 (m, 3H), 2.40 - 2.28 (m, 1H), 2.19 (s, 3H). 436.1 Example 691 Method 3 Single     unknown stereoisomer ++ / =,          ovnh2 0       0 / =\ >N r° F (S)-5-(2-fluoro-4-(3-oxo-5- white solid, yield: 2.89% 1H NMR (400 MHz, DMSO-d6) 5 8.57 (brs, 1H), 8.18 (brs, 1H), 7.99 - 7.91 (m, 1H), 7.77 - 7.71 (m, 1H), 7.71 -7.66 (m, 1H), 7.43 - 7.37 (m, 2H), 7.36 - 7.30 (m, 3H), 5.33 (dd, J = 7.6, 423.1 2023224057   06 Oct 2026 phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-1,3,4- oxadiazole-2-carboxamide 5.2 Hz, 1H), 3.09 - 2.98 (m, 2H), 2.97 - 2.89 (m, 1H), 2.38 - 2.27 (m, 1H). Example 692 Method 3 Single     unknown stereoisomer ++++ / ¾              o vJ* o     ~n'NY^nh2 \* J .--, >N v-^n' 'y F 5-[2-fluoro-4-[(5S)-3-oxo-5- phenyl-6,7-dih.ydro-5H- pyrrolo[2,1-c][1,2,4]triazol-2- yl]phenoxy]-1-methyl-1,2,4- triazole-3-carboxamide white solid, yield: 39% 1H NMR (400 MHz, Methanol-d4) 5 7.93 (dd, J = 12.4, 2.4 Hz, 1H), 7.84 (dt, J = 8.8, 2.0 Hz, 1H), 7.60 (t, J = 8.8 Hz, 1H), 7.46 - 7.17 (m, 5H), 5.35 (dd, J = 7.8, 4.8 Hz, 1H), 3.91 (s, 3H), 3.12 - 2.91 (m, 3H), 2.54 - 2.43 (m, 1H). 436.1 Example 693 Method 3 Single     unknown stereoisomer ++++ Z=\               o o           7 nh2 Gyyh 5-[2-fluoro-4-[(5S)-3-oxo-5- phenyl-6,7-dihydro-5H- pyrrolo[2,1-c][1,2,4]triazol-2- yl]phenoxy]-1,4-dimethyl-imidazole-2-carboxamid white solid, yield: 23% 1H NMR (400 MHz, Methanol-d4) 5 7.77 (dd, J = 12.8, 2.4 Hz, 1H), 7.57 (dt, J = 9.2, 2.0 Hz, 1H), 7.37 - 7.12 (m, 5H), 6.88 (t, J = 9.2 Hz, 1H), 5.21 (dd, J = 7.6, 4.8 Hz, 1H), 3.21 (s, 3H), 3.05 - 2.75 (m, 3H), 2.44 - 2.25 (m, 1H), 1.92 (s, 3H). 449.2 Example 694 Method 3 Single     unknown stereoisomer ++++ o      "-y     nh2 yK-o7° F (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylfuran-2-carboxamide White solid, yield: 17% 1H NMR (400 MHz, Methanol-d4) 7.75 (dd, J = 12.8, 2.4 Hz, 1H), 7.61 (dt, J = 9.2, 2.0 Hz, 1H), 7.35 - 7.15 (m, 5H), 7.01 (t, J = 9.2 Hz, 1H), 6.95 (s, 1H), 5.22 (dd, J = 8.0, 4.4 Hz, 1H), 3.04 - 2.79 (m, 3H), 2.38 - 2.26 (m, 1H), 1.83 (s, 3H). 435.1 Example 695 Method 3 Single     unknown stereoisomer ++++ Q o o.»F yycy-% F (S)-5-(2-fluoro-4-(3-oxo-5- white solid, yield: 37% 1H NMR (400 MHz, DMSO-d6) 5 8.05 (brs, 1H), 7.91 (dd, J = 12.8, 2.8 Hz, 1H), 7.81 (brs, 1H), 7.75 (ddd, J = 9.2, 2.4, 1.2 Hz, 1H), 7.49 (t, J = 9.2 Hz, 436.3 2023224057   06 Oct 2026 phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-4- methylisoxazole-3-carboxamide 1H), 7.43 - 7.28 (m, 5H), 5.32 (dd, J = 8.0, 4.8 Hz, 1H), 3.09 - 2.96 (m, 2H), 2.95 - 2.86 (m, 1H), 2.38-2.30 (m, 1H), 1.93 (s, 3H). Example 696 Method 3 Single     unknown stereoisomer ++++ v An NH2 n F (S)-4-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dih.ydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-5- methyloxazole-2-carboxamide white solid, yield: 21.2% 1H NMR (400 MHz, Chloroform-d) 5 7.85 (dd, J = 12.4, 2.8 Hz, 1H), 7.70 (dt, J = 9.0, 2.0 Hz, 1H), 7.43 - 7.30 (m, 3H), 7.26 - 7.22 (m, 2H), 7.09 (t, J = 8.8 Hz, 1H), 6.73 (brs, 1H), 5.78 (brs, 1H), 5.28 (dd, J = 7.6, 4.4 Hz, 1H), 3.11 - 2.98 (m, 2H), 2.97 - 2.87 (m, 1H), 2.57 - 2.46 (m, 1H), 2.38 (s, 3H). 436.4 Example 697 Method 3 Single     unknown stereoisomer ++++ o X / °          U AyAA n \ F (S)-5-(2-fluoro-4-(3-oxo-5- phenyl-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)phenoxy)-1,4-dimethyl- 1H-pyrrole-2-carboxamide white solid, yield: 31.7% 1H NMR (400 MHz, Chloroform-d) 5 7.86 (d, J = 12.8 Hz, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.43-7.31 (m, 3H), 7.267.24 (m, 2H), 7.00 (brs, 1H), 6.68 (t, J = 8.8 Hz, 1H), 6.44 (s, 1H), 5.37 (brs, 1H), 5.28 (dd, J = 8.0, 4.4 Hz, 1H), 3.73 (s, 3H), 3.12 - 2.97 (m, 2H), 2.96 - 2.84 (m, 1H), 2.55-2.45 (m, 1 H), 1.85 (s, 3H). 448.3 Example 698 Method 3 Single     unknown stereoisomer ++++ NH2 F 5-(2-fluoro-4-((5S,7S)-7-fluoro- 5-(2-fluorophenyl)-3-oxo-6,7- dihydro-3 H-pyrrolo [2,1- c][1,2,4]triazol-2(5H)- yl)phenoxy)-4-methylthiazole-2-carboxamide white solid, yield: 2.8% 1H NMR (400 MHz, Chloroform-d) 5 7.94 (dd, J = 12.4, 2.4 Hz, 1H), 7.77 (d, J = 8.8 Hz, 1H), 7.38-7.32 (m, 1H), 7.23 - 7.06 (m, 4H), 7.00 (brs, 1H), 5.84 (dd, J = 54.8, 6.4 Hz, 1H), 5.705.55 (m, 2H), 3.41-3.34 (m, 1H), 2.78 (dd, J = 23.2, 15.6 Hz, 1H), 2.36 (s, 3H). 488.2 2023224057   06 Oct 2026 Example 699 Method 3 Single     unknown stereoisomer ++++ F               \ F 5-(2-fluoro-4-((5S,7S)-7-fluoro-5-(2-fluorophenyl)-3-oxo-6,7-dihydro-3 H-pyrrolo [2,1-c][1,2,4]triazol-2(5H)-yl)phenoxy)-1 -methyl-1H-pyrazole-3 -carboxamide white solid, yield: 1.89% 1H NMR (400 MHz, Chloroform-d) 5 7.96 (dd, J = 12.0, 2.4 Hz, 1H), 7.80 (dt, J = 9.2, 2.0 Hz, 1H), 7.40 - 7.30 (m, 1H), 7.29 - 7.23 (m, 2H), 7.21 -7.10 (m, 2H), 6.70 (brs, 1H), 6.07 (s, 1H), 5.94 - 5.74 (m, 1H), 5.63 (dt, J = 8.8, 2.4 Hz, 1H), 5.38 (brs, 1H), 3.83 (s, 3H), 3.52 - 3.32(m, 1H), 2.85 -2.71(m, 1H) 471.1 Example 700 Method 3 Single     unknown stereoisomer ++++ F N NH2 F (S)-5-(2-fluoro-4-(5-(5- fluoropyridin-3-yl)-3-oxo-6,7- dihydro-3 H-pyrrolo [2,1- c][1,2,4]triazol-2(5H)- yl)phenoxy)-4-methylthiazole-2-carboxamide White solid, yield: 14.8% 1H NMR (400 MHz, DMSO-d6) 5 8.57 (d, J = 2.8 Hz, 1H), 8.54 (t, J = 1.8 Hz, 1H), 8.09 (s, 1H), 7.92 - 7.83 (m, 2H), 7.79 (s, 1H), 7.72 - 7.66 (m, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.42 (t, J = 6.7 Hz, 1H), 3.11 - 3.00 (m, 2H), 2.98 - 2.82 (m, 1H), 2.48 - 2.36 (m, 1H), 2.31 (s, 3H). 471.4 Example 701 Method 3 Single     unknown stereoisomer ++++ v Ao NH2 n V^ / ^o F (S)-5-(4-(5-(2,6-difluorophenyl)- 3-oxo-6,7-dihydro-3H- pyrrolo [2,1-c][1,2,4]triazol- 2(5H)-yl)-2-fluorophenoxy)-4- methyloxazole-2-carboxamide white solid, yield: 29% 1H NMR (400 MHz, Chloroform-d) 5 7.87 (dd, J = 12.4, 2.4 Hz, 1H), 7.69 (dt, J = 9.2, 2.0 Hz, 1H), 7.37 - 7.28 (m, 1H), 7.09 (t, J = 8.8 Hz, 1H), 6.94 (t, J = 8.4 Hz, 2H), 6.71 (brs, 1H), 5.62 (dd, J = 8.8, 4.8 Hz, 1H), 5.43 (brs, 1H), 3.20 - 3.05 (m, 2H), 3.02-2.96 (m, 1H), 2.72-2.63 (m, 1H), 2.11 (s, 3H). 472.3 Example 702 Method 3 Single     unknown stereoisomer ++++ Oznh2 O        S "N F white solid, yield: 9.9% 1H NMR (400 MHz, CDCl3-d) 5 7.91 (dd, J = 12.4, 2.5 Hz, 1H), 7.73 (dd, J = 9.0, 1.7 Hz, 1H), 7.08 (t, J = 8.9 Hz, 1H), 6.98 (d, J = 10.5 Hz, 1H), 5.43 (s, 444.3 2023224057   06 Oct 2026 (S)-5-(4-(5-cyclopentyl-3-oxo- 6,7-dihydro-3 H-pyrrolo [2,1- c][1,2,4]triazol-2(5H)-yl)-2-fluorophenoxy^-methylthiazole- 2-carboxamide 1H), 4.22 (td, J = 7.6, 3.4 Hz, 1H), 2.98 - 2.72 (m, 2H), 2.68 - 2.54 (m, 1H), 2.45 - 2.23 (m, 5H), 1.90 (dd, J = 11.8, 4.4 Hz, 1H), 1.80 - 1.47 (m, 6H), 1.42 - 1.29 (m, 1H) Example 37: Method 4 F Step 1: 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-2,4-dihydro- 3H-1,2,4-5 triazol-3-one A solution of methyl 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy) -3-fluorophenyl)-4-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (3.192 g, 6.5 mmol), TfOH (2.87 g, 19.0 mmol) in TFA (15 mL) was stirred at 80°C for 16h. The resulted solution was diluted with EA (150 mL), washed with water (150 mL) and brine (1000 mL), dried over Na2SO4, concentrated 10 and purified by Combi-Flash with EA : PE = 0:1 ~ 2:1 to obtain methyl 5-(2-fluoro-4-(5-oxo- 4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole-2-carboxylate (1.445 g, yield: 60%) as a green solid. LCMS (m / z): 371.3[M+H]+. Step 2: 5-(2-fluoro-4-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole -2-carbonitrile 15 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (800 mg, 2.155 mmoL) and CuCN (231.6 mg, 2.586 mmoL) were dissolved in 6 mL NMP. The reactions mixture was stirred at 150oC for 2h. Water was added to the solution and extracted with EA (30 mL X 3).The organic layers were combined and evaporated to dryness and purified by C18 column to give 5-(2-fluoro-4-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4- 20 methylthiazole-2-carbonitrile as off-white solid (400 mg, yield: 58.5%) . LCMS (m / z): 318.3[M+H]+. 2023224057   06 Oct 2026 Step 3: 5-(4-(4-((3-chloropyridin-2-yl)methyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorophenoxy)-4-methylthiazole-2-carbonitrile To a solution of 2-(bromomethyl)-3-chloro-pyridine (1.00 eq, 200 mg, 0.969 mmol) in DMF (5 mL) was added K2CO3 (3.00 eq, 401 mg, 2.91 mmol), 5-[2-fluoro-4-(5-oxo-4H-1,2,4-triazol-1- 5 yl)phenoxy]-4-methyl-thiazole-2-carbonitrile (1.00 eq, 307 mg, 0.969 mmol), the mixture was stirred for 30 min at 25 oC under nitrogen. The reaction mixture was concentrated to dryness and the residue was taken up in EA (50 mL) and the organics washed with 2 x 20 mL water then 1 x 20mL saturated brine solution. The organics were then separated and dried (MgSO4) before concentration to dryness. The crude was then purified by flash column chromatography eluted 10 with 50%ACN in H2O. The desired fractions were concentrated to dryness in vacuo to afford 5-[4-[4-[(3-chloro-2-pyridyl)methyl]-5-oxo-1,2,4-triazol-1-yl]-2-fluoro-phenoxy]-4-methyl-thiazole-2-carbonitrile (80 mg, 0.168 mmol, 17.34 % yield) as a white solid. MS (m / z): 443.2 [M+H]+.1H NMR (400 MHz, Chloroform-d) 8 8.49 - 8.43 (m, 1H), 8.02 (dd, J = 12.4, 2.4 Hz, 1H), 7.92 - 7.84 (m, 1H), 7.80 - 7.71 (m, 2H), 7.29 - 7.24 (m, 1H), 7.17 (t, J = 8.8 Hz, 1H), 5.17 15 (s, 2H), 2.44 (s, 3H). Example 38 was synthesized using a similar method to that used in Example 37. Compound No. Method Activity Structure and Name Appearanc e and Yield 1H NMR Data MS(m / z) [M+H]+ Example 37 Method 4 ++++ 0         o / A / YM X M F 1 AA'ci             \\ N 5-(4-(4-((3-chloropyridin-2- yl)methyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1-yl)-2- fluorophenoxy)-4-methylthiazole- 2-carbonitrile white solid, yield: 17.34 % 1H NMR (400 MHz, Chloroform-d) 8 8.49 - 8.43 (m, 1H), 8.02 (dd, J = 12.4, 2.4 Hz, 1H), 7.92 - 7.84 (m, 1H), 7.80 - 7.71 (m, 2H), 7.29 - 7.24 (m, 1H), 7.17 (t, J = 8.8 Hz, 1H), 5.17 (s, 2H), 2.44 (s, 3H). 443.2 Example 38 Method 4 ++++ ci         0        ,F % A Jr \ N 5-(4-(4-((4-chloropyridin-3 - yl)methyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1-yl)-2- white solid, yield: 23.5% 1H NMR (400 MHz, DMSO-d6) 8 8.64 (s, 1H), 8.55 (d, J = 5.2 Hz, 1H), 8.40 (s, 1H), 7.99 - 7.86 (m, 1H), 7.80 -7.67 (m, 1H), 7.62 (d, J = 5.2 Hz, 1H), 7.52 (t, J = 9.2 Hz, 1H), 5.04 (s, 2H), 443.3 2023224057   06 Oct 2026 fluorophen.oxy)-4-methylth.iazole- 2-carbonitrile 2.36 (s, 3H). Example 39: Method 5 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazol-2-yl)cyclobutane-1-carbonitrile To an 8 mL vial equipped with a stir bar was added photocatalyst Ir[dF(CF3)ppy]2(dtbbpy)PF6 (1.51 mg, 10.4 pmol, 0.05 equiv.), 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (100 mg, 0.21 mmol), 3-iodocyclobutane-1-carbonitrile (41.63 mg, 0.2 mmol), tris(trimethylsilyl)silane (103.47 mg, 0.42 mmol). The vial 10 was sealed and placed under nitrogen before DME (4 mL) was added. To a separate vial was added NiCl2(dtbbpy) (4.15 mg, 10.4 pmol) and 2,6-lutidine (44.6 mg, 0.41 mmol). The catalyst vial was sealed, purged with nitrogen and then to it was added DME (2 mL). The precatalyst solution was sonicated or stirred for 5 minutes, after which, 1 mL (0.5 mol% catalyst, 2.5 ^mol, 0.005 equiv.) was syringed into the reaction vessel. The solution was degassed by sparging with 15 nitrogen while stirring for 10 minutes before sealing with Parafilm. The reaction was stirred and irradiated with a 34 W blue LED lamp (7 cm away), with cooling fan to keep the reaction temperature at 25 °C for 12 hours. The resulted mixture was diluted with water (5 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The combined Organic layers were washed with brine (4 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was 20 concentrated under reduced pressure. The residue was purified by flash chromatography with the following conditions: column: Gemini 5u C18 150 x 21.2 mm; Mobile phase B: ACN; Flow rate: 20 mL / min; Gradient: 40%B-60%B in 20 min; Detector: 214 nm. Concentrated under reduced pressure to afford the titled compound (1.6 mg, 1.6 % yield) as a white solid. LC-MS (m / z): 480.1 [M+H]+. 1H NMR (400 MHz, CDCl3) 8 ppm7.97 (d, J = 8.4 Hz, 2H), 7.57 (s, 1H), 7.3225 7.40 (m, 1H), 7.04-7.06(m, 2H), 6.95-6.99 (m, 2H), 4.97 (s, 2H), 4.08-4.06 (m, 1H), 3.12-3.18 (m, 1H), 2.91-2.98 (m, 2H), 2.71-2.64 (m, 2H), 2.35 (s, 3H). Examples (Compounds) 40-42 were synthesized using a similar method to that used in Example 2023224057   06 Oct 2026 39. Compound No. Method Activity Structure and Name Appearanc e and Yield 1H NMR Data MS(m / z) [M+H]+ Example 39 Method 5 ++++ r... ,-CN rs nl              0 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)cyclobutane-1 -carbonitrile white solid, yield:1.6 % 1H NMR (400 MHz, CDCl3) 5 7.97 (d, J = 8.4 Hz, 2H), 7.57 (s, 1H), 7.327.40 (m, 1H), 7.04-7.06(m, 2H), 6.956.99 (m, 2H),4.97 (s, 2H), 4.08-4.06 (m, 1H), 3.12-3.18 (m, 1H), 2.91-2.98 (m, 2H), 2.71-2.64 (m, 2H), 2.35 (s, 3H). 480.1 Example 40 Method 5 ++++ ^cn X- A / =C>S CTl N-W° 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)cyclobutane-1-carbonitrile white solid, yield:5.0% 1H NMR (400 MHz, CDCl3) 5 7.90 (dd, J = 12.2, 2.3 Hz, 1H), 7.74 (d, J= 8.2 Hz, 1H), 7.60 (s, 1H), 7.39-7.36 (m, 1H), 7.00 (dd, J = 17.1, 9.5 Hz, 3H), 4.98 (s, 2H), 4.02 (d, J = 8.0 Hz, 1H), 3.29 (s, 1H), 2.82 (d, J = 8.1 Hz, 4H), 2.32 (s, 3H). 498.1 Example 41 Method 5 ++++ rN^°C N ^F tert-butyl         3-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro- 1H-1,2,4-triazol-1 -yl)-2- fluorophenoxy)^-methylthiazol- 2-yl)azetidine-1 -carboxylate white solid, yield:4.3% 1H NMR (400 MHz, ) 5 7.89 (dd, J = 12.2, 2.5 Hz, 1H), 7.72-7.69 (m, 1H), 7.57 (s, 1H), 7.38-7.34 (m, 1H), 6.98 (td, J = 8.6, 4.8 Hz, 3H), 4.96 (s, 2H), 4.30 (dd, J = 11.1, 6.1 Hz, 2H), 4.11 (dd, J = 8.6, 6.0 Hz, 2H), 3.95 (ddd, J = 8.7, 7.3, 4.4 Hz, 1H), 2.28 (s, 3H), 1.43 (s, 9H). 574.2 Example 42 Method 5 ++++ " A UN 4-(2,6-difluorobenzyl)-2-(4-((4- methyl-2-(oxetan-3-yl)thiazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- white solid, yield:14.3 % 1H NMR (400 MHz, CDCl3) 5 7.947.90 (m, 2H), 7.58 (s, 1H), 7.38-7.34 (m, 1H), 7.04-6.99 (m, 4H), 5.06 (dd, J = 8.4, 6.3 Hz, 2H), 4.98 (s, 2H), 4.88 (t, J = 6.5 Hz, 2H), 4.54 (td, J = 8.3, 4.1 Hz, 1H), 2.27 (s, 3H) 457.1 2023224057   06 Oct 2026 1,2,4-triazol-3-one Example 43: Method 6 Step 1: (2S,3S)-1-benzhydryl-2-methylazetidin-3-yl methanesulfonate 5 To a stirred solution of (2S,3S)-1-benzhydryl-2-methylazetidin-3-ol (1 g, 3.95 mmol), MsCl (533.52 mg, 4.68mmol) and TEA (472.68 mg, 4.68 mmol) in DCM (50mL). The resulted mixture was stirred for additional 1 h at 25C . The resulted mixture was diluted with 1N HCl (10mL). The organic was diluted with NaHCO3 solvent. The mixture was extracted with EtOAc (3 x 30 mL). The combined Organic layers were dried over anhydrous Na2SO4, after filtration, the 10 filtrate was concentrated under reduced pressure. No further purification was performed. (2S,3S)-1-benzhydryl-2-methylazetidin-3-yl methanesulfonate (800 mg, yield: 61.5%) as an oil. LC-MS (m / z): 332.1 [M+H]+. Step 2: (2S,3R)-1-benzhydryl-2-methylazetidine-3-carbonitrile To a stirred solution of (2S,3S)-1-benzhydryl-2-methylazetidin-3-yl methanesulfonate (800 mg, 15 2.4 mmol), KCN (234 mg, 3.6 mmol) and TEA (363.6 mg, 3.6 mmol) in DMSO (50 mL). The resulted mixture was stirred for additional 2 h at 70 °C. The resulted mixture was diluted with water (50mL). The resulted mixture was extracted with EtOAc (3x50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash 20 chromatography (PE: EtOAc = 1: 1 ) to afford (2S,3R)-1-benzhydryl-2-methylazetidine-3-carbonitrile (410 mg, yield: 65.2%) as a yellow solid. LC-MS (m / z): 263.3 [M+H]+. Step 3: (2S,3R)-2-methylazetidine-3-carbonitrile To a stirred solution of (2S,3R)-1-benzhydryl-2-methylazetidine-3-carbonitrile ( 200 mg, 0.76 mmol), 1-chloroethyl carbonochloridate (163.0 mg, 1.14 mmol) in DCE (20 mL). The resulted 25 mixture was stirred for additional 12 h at 70 C . The reaction mixture was concentrated under reduced pressure to give a residue. MeOH (20mL) was added in mixture. The resulted mixture 2023224057   06 Oct 2026 was stirred for additional 1 h at 70 °C. The resulted mixture was diluted with water (50 mL). The resulted mixture was extracted with EtOAc (3 x 50 mL). The combined Organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography ( PE : 5 EtOAc = 1: 1) to afford (2S,3R)-2-methylazetidine-3-carbonitrile (60 mg, yield: 82.3%) as a white solid. LC-MS (m / z): 97.07 [M+H]+. Step 4: (2S,3R)-1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) phenoxy)-4-methylthiazol-2-yl)-2-methylazetidine-3-carbonitrile To a stirred solution of (2S,3R)-2-methylazetidine-3-carbonitrile (60 mg, 0.62 mmol), 2-(4-((2 10 bromo-4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (297.0 mg, 0.62mmol), BINAP (38.5 mg, 0.06 mmol) Pd2(dba)3 (35.6 mg, 0.062mmol) and Cs2CO3 (606.4 mg, 1.86 mmol) in Toluene (20 mL). The reaction mixture was stirred at 110C for 2 h. The resulted mixture was diluted with water (20mL). The resulted mixture was extracted with EtOAc (3x30 mL). The combined organic layers were washed with brine (10 mL), 15 dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography with the following conditions: column: Gemini 5u C18 150 x 21.2 mm; Mobile phase B: ACN; Flow rate: 20 mL / min; Gradient: 40%B-60%B in 20 min; Detector: 214 nm. The desired fractions were concentrated under reduced pressure to afford the titled compound (28.8 mg, yield: 9.4%) as a white solid LC-MS 20 (m / z): 495.1 [M+H]+. 1H NMR (400 MHz, CDCh) 8 7.91 (d, J = 8.1 Hz, 2H), 7.58 (s, 1H), 7.397.35 (m, 1H), 7.02-6.98 (m, 4H), 4.98 (s, 2H), 4.70 (s, 1H), 4.38 (d, J = 30.9 Hz, 2H), 3.78 (d, J = 19.8 Hz, 1H), 2.16 (s, 3H), 1.70 (s, 3H) Examples 44-58 were synthesized using a similar method to that used in Example 43. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 43 Method 6 ++++ F       o L II L -               )—s       / N N (2S,3R)-1-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro- 1H-1,2,4-triazol-1 - yl)phenoxy)-4-methylthiazol-2- yl)-2-methylazetidine-3- white solid, yield:9.4% 1H NMR (400 MHz, CDCl3) 8 7.91 (d, J = 8.1 Hz, 2H), 7.58 (s, 1H), 7.39-7.35 (m, 1H), 7.02-6.98 (m, 4H), 4.98 (s, 2H), 4.70 (s, 1H), 4.38 (d, J = 30.9 Hz, 2H), 3.78 (d, J = 19.8 Hz, 1H), 2.16 (s, 3H), 1.70 (s, 3H) 495.1 2023224057   06 Oct 2026 carbonitrile Example 44 Method 6 ++++ F       0 rFN3-O'Vs , (2S,3S)-1-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro- 1H-1,2,4-triazol-1 - yl)phenoxy)-4-methylthiazol-2- yl)-2-methylazetidine-3- carbonitrile white solid, yield:3% 1H NMR (400 MHz, CDCl3) 5 7.94 -7.85 (m, 2H), 7.56 (s, 1H), 7.39-7.31 (m, 1H), 7.08 - 6.93 (m, 4H), 4.97 (s, 2H), 4.52 - 4.44 (m, 1H), 4.25 (m, 1H), 4.13 (t, J = 7.9 Hz, 1H), 3.22 (q, J = 15.8, 8.0 Hz, 1H), 2.11 (s, 3H), 1.58 (d, J = 6.2 Hz, 3H). 495.1 Example 45 Method 6 ++++ ny"y, f / X ^CN ^^F N 3-((5-(4-(4-(2,6-difluorobenzyl)- 5-oxo-4,5-dihydro-1H-1,2,4- triazol-1 -yl)phenoxy)-4- methylthiazol-2- yl)amino)bicyclo [1.1.1 ]pentane- 1-carbonitrile white solid, yield: 4.4% 1H NMR (400 MHz, CDCl3) 5 7.927.83 (m, 2H), 7.55 (s, 1H), 7.42-7.29 (m, 1H), 7.07 -6.94 (m, 4H), 4.97 (s, 2H), 2.11 (s, 3H), 2.36-2.20 (m, 2H), 2.16-2.11 (m, 2H), 2.08-1.98 (m, 2H). 506.9 Example 46 Method 6 ++++ pV-cn N^N-J X- A XX-F 1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)-3-methylazetidine-3- carbonitrile yellow solid,yield:1 9% 1H NMR (400 MHz, CDCl3) 5 7.90 (dd, J = 9.6, 2.5 Hz, 2H), 7.57 (s, 1H), 7.39-7.35 (m, 1H), 7.05 -6.94 (m, 4H), 4.97 (s, 2H), 4.45 (s, 2H), 4.03 (s, 2H), 2.13 (s, 3H), 1.78 (s, 3H). 495.1 Example 47 Method 6 ++++ N^N-J V I,-, 1        / 5 fPV-VT0 V<F X 2-(4-((2-(3-cyclopropoxyazetidin- 1-yl)-4-methylthiazol-5- yl)oxy)phenyl)-4-(2,6- yellow solid,yield:1 0% 1H NMR (400 MHz, CDCl3) 5 7.87 (m, 2H), 7.56 (s, 1H), 7.36 (m, 1H), 7.04 -6.95 (m, 4H), 4.97 (s, 2H), 4.57 (m, 1H), 4.28 (s, 2H), 4.01 (s, 2H), 3.29 (m, 1H), 2.10 (s, 3H), 0.62 (d, J = 3.8 Hz, 2H), 0.50 (m, 2H) 512.1 2023224057   06 Oct 2026 difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one Example 48 Method 6 ++++ \,cn n 6-^ / ° 1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)-2-methylazetidine-3-carbonitrile white solid, yield: 8.6% 1H NMR (400 MHz, CDCl3) 5 7.927.83 (m, 2H), 7.55 (s, 1H), 7.42-7.29 (m, 1H), 7.07 -6.94 (m, 4H), 4.97 (s, 2H), 4.58 (s, 1H), 4.33-4.20 (m, 2H), 3.67 (s,1H), 2.11 (s, 3H), 0.91-0.78 (m, 3H). 495.1 Example 49 Method 6 ++++ ,..... / 0, V-nJ J 0 N 4-(2,6-difluorobenzyl)-2-(4-((2- (3 -(difluoromethoxy)azetidin-1 - yl)-4-methylthiazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield: 11% 1H NMR (400 MHz, DMSO-d6) 5 8.28 (s, 1H), 7.87 - 7.77 (m, 2H), 7.53 - 7.44 (m, 1H), 7.21 - 7.08 (m, 4H), 6.97 (s, 0.25H), 6.79 (s, 0.5H), 6.60 (s, 0.25H), 5.16 - 5.07 (m, 1H), 4.97 (s, 2H), 4.29 (dd, J = 9.0, 7.3 Hz, 2H), 3.94 (dd, J = 9.5, 4.0 Hz, 2H), 1.99 (s, 3H). 522.0 Example 50 Method 6 ++++ N^N-J F       0            J 6%-c^ 4-(2,6-difluorobenzyl)-2-(4-((2- ((2S,3R)-3-hydroxy-2- methylazetidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)- 2,4-dihydro-3H-1,2,4-triazol-3-one white solid, yield: 0.96% 1H NMR (400 MHz, CDCl3) 5 7.88 (d, J = 9.1 Hz, 2H), 7.56 (s, 1H), 7.39 - 7.34 (m, 1H), 7.06 - 6.96 (m, 4H), 4.97 (s, 2H), 4.32-4.15 (m, 4H), 2.13 (s, 3H), 1.50 (d, J = 6.3 Hz, 3H). 486.0 Example 51 Method 6 ++++ F       O '' 4-(2,6-difluorobenzyl)-2-(4-((2- ((2S,3S)-3-fluoro-2- methylazetidin-1 -yl)-4- white solid, yield: 6.6 % 1H NMR (400 MHz, DMSO-d6) 5 8.28 (s, 1H), 7.90 - 7.76 (m, 2H), 7.55 - 7.42 (m, 1H), 7.13 (ddd, J = 11.6, 9.2, 5.1 Hz, 4H), 4.97 (s, 2H), 4.15 - 4.03 (m, 2H), 3.95 - 3.87 (m, 488.0 2023224057   06 Oct 2026 methylthiazol-5-yl)oxy)phenyl)- 2,4-dihydro-3 H-1,2,4-triazol-3 -one 1H), 3.51 (dd, J = 6.9, 5.2 Hz, 1H), 1.99 (s, 3H), 1.35 (d, J = 6.4 Hz, 3H). Example 52 Method 6 ++++ F       O rr'l'^-^lkvs — Jr\~ N NJ<>OH ^(S)\ (S)-4-(2,6-difluorobenzyl)-2-(4- ((2-(3-(1-hydroxyethyl)azetidin- 1-yl)-4-methylthiazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield: 1H NMR (400 MHz, CDCl3) 5 7.88 (d, J = 9.1 Hz, 2H), 7.56 (s, 1H), 7.39 - 7.34 (m, 1H), 7.06 - 6.96 (m, 4H), 4.97 (s, 2H), 4.32-4.15 (m, 4H), 2.13 (s, 3H), 1.50 (d, J = 6.3 Hz, 3H). 500.1 Example 53 Method 6 ++++ X-I / =7^5 nYY / 0 1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)azetidine-3 -carbonitrile white solid, yield: 1H NMR (400 MHz, CDCl3) 5 7.93 - 7.86 (m, 2H), 7.56 (s, 1H), 7.45 - 7.31 (m, 1H), 7.11 - 6.92 (m, 4H), 4.97 (s, 2H), 4.41 - 4.22 (m, 4H), 3.72-3.63 (m, 1H), 2.10 (s, 3H). 481.2 Example 54 Method 6 ++++ F       0 Ci N N N__ 1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)pyrrolidine-3-carbonitrile white solid, yield: 1H NMR (400 MHz, CDCl3) 5 7.92 -7.85 (m, 2H), 7.56 (s, 1H), 7.40-7.32 (m, 1H), 7.09 - 6.94 (m, 4H), 4.97 (s, 2H), 3.90 - 3.48 (m, 4H), 3.35 - 3.21 (m, 1H), 2.56 - 2.34 (m, 2H), 2.11 (s, 3H). 495.2 Example 55 Method 6 ++++ CN Hun-Y / 0 1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)-3-methoxyazetidine-3-carbonitrile white solid, yield:20.9% 1H NMR (400 MHz, CDCl3) 5 7.91 -7.86 (m, 2H), 7.56 (s, 1H), 7.37 (ddd, J = 8.4, 7.5, 4.2 Hz, 1H), 7.06 - 6.95 (m, 4H), 4.97 (s, 2H), 4.45 (d, J = 8.9 Hz, 2H), 4.21 (d, J = 8.5 Hz, 2H), 3.49 (s, 3H), 2.12 (s, 3H). 511.1 2023224057   06 Oct 2026 Example 56 Method 6 ++++ F        o       ,F 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)oxazolidin-2-one white solid, yield:28.5% 1H NMR (400 MHz, CDCl3) 5 7.88 (dd, J = 12.3, 2.5 Hz, 1H), 7.69 (ddd, J = 9.1,2.5, 1.6 Hz, 1H), 7.57 (s, 1H), 7.40 - 7.31 (m, 1H), 7.01 - 6.94 (m, 3H), 4.95 (s, 2H), 4.65 - 4.54 (m, 2H), 4.39 - 4.25 (m, 2H), 2.22 (s, 3H). 503.9 Example 57 Method 6 ++++ F       0 ¢1 ni5~OVs N Nv\°y.F 4-(2,6-difluorobenzyl)-2-(4-((4- methyl-2-(3-methyl-3- (trifluoromethoxy)azetidin-1 -yl)thiazol- 5 -yl)oxy)phenyl)-2,4-dihydro-3 H-1,2,4-triazol-3-one White solid, yield: 8.7% 1H NMR (400 MHz, DMSO-d6) 5 8.28 (s, 1H), 7.86-7.79 (m, 2H), 7.48 (tt, J = 8.5, 6.7 Hz, 1H), 7.22-7.07 (m, 4H), 4.97 (s, 2H), 4.15 (d, J = 9.1 Hz, 2H), 4.07 (d, J = 9.1 Hz, 2H), 2.00 (s, 3H), 1.75 (s, 3H). 554.1 Example 58 Method 6 ++++ F       o q i5-Cv । a Al A 1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazol-2-yl)-2-methylpyrrolidine-3-carbonitrile White solid, yield: 4.5% 1H NMR (400 MHz, DMSO-d6) 5 8.29 (d, J = 5.6 Hz, 1H), 7.89-7.77 (m, 2H), 7.48 (tt, J = 8.5, 6.7 Hz, 1H), 7.22-7.06 (m, 4H), 4.97 (s, 2H), 3.65-3.11 (m, 3H), 2.96-2.85 (m, 1H), 2.24-2.08 (m, 4H), 1.98-1.86 (m, 1H), 1.20 (d, J = 6.1 Hz, 3H). 509.1 Example 59: Method 7 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-methylthiazol-5-yl)methyl)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one Stepl Pd(OAc)2, dppf.KOAc,dioxane,110nC, 1h Step 4 2023224057   06 Oct 2026 Step 1: methyl 4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorobenzoate A mixture solution of 4-[(2,6-difluorophenyl)methyl]-2H-1,2,4-triazol-3-one (4 g, 0.0189 mol), methyl 4-bromo-2-fluorobenzoate (5.6 g, 0.0227 mmol), Copper(I) iodide (3.6 g, 0.0189 mmol), DMDACH (8.07g, 0.0567 mol) and K2CO3 (5.21 g, 0.0378 mol) in dioxane (50 mL) was stirred at 110 °C for 1 hr. After cooling, the reaction mixture was diluted with water (40 mL), extracted three times with ethyl acetate (40 mL). The organic layer were combined, and the solvent was removed under vacuum and the crude was purified through silica gel chromatography (PE / EA=1:1) to give methyl 4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorobenzoate (5 g, 66.67% yield) as a white solid. MS (m / z): 378.0 [M+H]+. Step 2: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-(hydroxymethyl)phenyl)-2,4-dihydro -3H-1,2,4-triazol-3-one A solution of methyl 4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorobenzoate (11 g, 0.0303 mol) and LiAlH4 (1.39 g, 0.03672 mol) in THF (20 mL) was stirred under 1 atm of N2 atmosphere at 25 °C for 1 hr. After filtration of the reaction mixture, the filtrate was concentrated and the residue was purified through silica gel chromatography ( DCM / CH3OH = 10 : 1) to give 4-(2,6-difluorobenzyl)-2- (3-fluoro-4-(hydroxymethyl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (10.5 g, 100% yield) as an orange solid. MS (m / z): 336.1 [M+H]+. Step 3: 2-(4-(bromomethyl)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro -3H-1,2,4-triazol-3-one A mixture of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-(hydroxymethyl)phenyl)-2,4-dihydro -3H-1,2,4-triazol-3-one (10.5 g, 0.0313 mol), and PBr3 (9.3 g, 0.0344 mol) in DCM (20 mL) was stirred at 25 °C for 2 hrs. The reaction mixture was diluted with water (40 mL), extracted three times with ethyl acetate (40 mL). The organic layer were combined, and the solvent was removed under vacuum and the crude was purified through silica gel chromatography ( DCM / CH3OH = 10 : 1) to give 2-(4-(bromomethyl)-3-fluorophenyl)-4- (2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (9.0 g, 72.3% yield) as white solid. MS (m / z): 398.0 [M+H]+. Step 4: 2-(4-(bromomethyl)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro -3H-1,2,4-triazol-3-one A solution of 2-[4-(bromomethyl)-3-fluorophenyl]-4-[(2,6-difluorophenyl) methyl]-1,2,4-triazol-3-one (500 mg, 1.26 mmol) , 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-- 108 - 2023224057   06 Oct 2026 dioxaborolan-2-yl)-1,3,2-dioxaborolane (637 mg,2.51 mmol), potassium acetate (370 mg, 3.77 mmol), (acetyloxy)palladio acetate (56 mg, 0.25 mmol) and dppf (278 mg, 0.50 mmol) in dioxane (40 mL) was heated to 110°C for 1 h under nitrogen, then cooled to rt and the solvent was removed under vacuum and the crude was purified through silica gel chromatography (DCM 5 / MeOH = 10 : 1) to give 2-(4-(bromomethyl)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (0.2 g, 34.0% yield) as white solid. MS (m / z): 446.1 [M+H]+. Step 5: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-methylthiazol-5-yl)methyl)phenyl) -2,4-dihydro-3H-1,2,4-triazol-3-one To a solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4,4,5,5-tetramethyl -1,3,2-dioxaborolan-10 2-yl)methyl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (1.00 eq, 100 mg, 0.225 mmol), 5- Bromo-4-methylthiazole (2.00 eq, 80 mg, 0.449 mmol) and Cs2CO3 (2.00 eq, 146 mg, 0.449 mmol) in 1,4-dioxane (6 mL), was added Bis(tri-tert-butylphosphine)palladium(0) (0.300 eq, 35 mg, 0.0674 mmol) at room temperature under N2. After addition, the mixture was stirred at 85 oC for 5 h. LCMS of the reaction mixture indicated 30% product conversion. Then the 15 reaction mixture was cooled and added water (20 mL) and extracted with EtOAc (20 mL x 3). The organics were then combined and dried (Na2SO4) before concentration to dryness. The crude was purified with Prep-TLC (PE / EtOAc = 1 / 1) to give the product (20 mg, 18.60% yield) as a yellow solid. MS (m / z): 417.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 8 8.81 (s, 1H), 8.33 (s, 1H), 7.71-7.65 (m, 2H), 7.50-7.45 (m, 1H), 7.37 (t, J = 8.4 Hz, 1H), 7.15 (t, J = 8.1 Hz, 2H), 20 4.97 (s, 2H), 4.13 (s, 2H), 2.37 (s, 3H). Example 60: Method 7 2-(4-((2-(3-amino-3-(trifluoromethyl)pyrrolidin-1-yl)-4-methylthiazol-5-yl)methyl)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 25 Step 1: 1-(5-bromo-4-methylthiazol-2-yl)-3-(trifluoromethyl)pyrrolidin-3-amine Tert-butyl (3-(trifluoromethyl)-1l2-pyrrolidin-3-yl)carbamate (500 mg, 1.97 mmoL),2,5-dibromo-4-methylthiazole (558 mg, 2.17 mmoL) and Cs2CO3(1.284 g, 3.94 mmoL) were mixed in 10 mL NMP. Let it stir at 140oC for 16 h. Water was added to the reaction mixture and extracted with EtOAc (30 mL X 3). The organic layers were combined and evaporated to dryness 2023224057   06 Oct 2026 and purified by C18 lolumn chromatography to give 1-(5-bromo-4-methylthiazol-2-yl)-3-(trifluoromethyl)pyrrolidin-3-amine (364 mg, yield: 56%) as a brown oil. MS (m / z): 331.2 [M+H]+. Step 2: 2-(4-((2-(3-amino-3-(trifluoromethyl)pyrrolidin-1-yl)-4-methylthiazol-5-yl) 5 methyl)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a solution of 4-[(2,6-difluorophenyl)methyl]-2-[3-fluoro-4-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]phenyl]-1,2,4-triazol-3-one (1.20 eq, 125 mg, 0.280 mmol), Cs2CO3 (2.00 eq, 152 mg, 0.466 mmol), 1-(5-bromo-4-methyl-thiazol-2-yl)-3-(trifluoromethyl) pyrrolidin-3-amine (1.00 eq, 77 mg, 0.233 mmol) in 1,4-dioxane (6 mL), was added Bis(tri-tert- 10 butylphosphine)palladium(0) (0.300 eq, 36 mg, 0.0700 mmol) at room temperature under N2. After addition, the mixture was stirred at 110 oC for 5 h. LCMS of the reaction mixture indicated 20% product conversion. Then cooled and added water (20 mL) and extracted with EtOAc (20 mL x 3). The organics were then combined and dried (Na2SO4) before concentration to dryness. The crude was purified with Prep-HPLC (0.1% TFA as additive) to give the product (6.0 mg, 15 3.77% yield) as a yellow solid. MS (m / z): 569.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 8 8.32 (d, J = 2.9 Hz, 1H), 7.72-7.61 (m, 2H), 7.57-7.41 (m, 2H), 7.33 (t, J = 8.4 Hz, 1H), 7.19-7.12 (m, 2H), 4.97 (s, 2H), 3.93 (s, 2H), 3.52-3.43 (m, 2H), 3.28-3.23 (m, 2H), 2.14 (s, 3H), 2.03-1.96 (m, 2H). Examples (Compounds) 61-67 were synthesized using a similar method to that used in Example 20   59. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 59 Method 7 ++++ f       o 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((4-methylthiazol- 5 - yl)methyl)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3 -one yellow solid, yield: 18.60% 1H NMR (400 MHz, DMSO-d6) 8 8.81 (s, 1H), 8.33 (s, 1H), 7.71-7.65 (m, 2H), 7.50-7.45 (m, 1H), 7.37 (t, J = 8.4 Hz, 1H), 7.15 (t, J = 8.1 Hz, 2H), 4.97 (s, 2H), 4.13 (s, 2H), 2.37 (s, 3H). 417.1 Example 60 Method 7 ++++ yellow solid, yield: 3.77% 1H NMR (400 MHz, DMSO-d6) 8 8.32 (d, J = 2.9 Hz, 1H), 7.72-7.61 569.2 2023224057   06 Oct 2026 N O 2-(4-((2-(3-amino-3- (trifluoromethyl)pyrrolidin-1 -yl)- 4-methylthiazol-5-yl)methyl)-3- fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one formate (m, 2H), 7.57-7.41 (m, 2H), 7.33 (t, J = 8.4 Hz, 1H), 7.19-7.12 (m, 2H), 4.97 (s, 2H), 3.93 (s, 2H), 3.52-3.43 (m, 2H), 3.28-3.23 (m, 2H), 2.14 (s, 3H), 2.03-1.96 (m, 2H). Example 61 Method 7 ++++ Vxh N N^J (2S,3S)-1-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro-1H-1,2,4-triazol-1-yl)-2-fluorobenzyl)-4-methylthiazol-2-yl)-2-methylazetidine-3- carbonitrile formate yellow solid, yield: 2.94% 1H NMR (400 MHz, DMSO-d6) 8 10.15 (s, 1H), 8.49 (s, 1H), 8.33 (s, 1H), 7.69-7.62 (m, 2H), 7.50-7.45 (m, 1H), 7.35 (t, J = 8.5 Hz, 1H), 7.19-7.12 (m, 2H), 4.97 (s, 2H), 4.36-4.29 (m, 1H), 4.11-4.06 (m, 1H), 3.95 (s, 2H), 3.87 (t, J = 7.6 Hz, 1H), 3.65-3.58 (m, 1H), 2.16 (s, 3H), 1.42 (d, J = 6.0 Hz, 3H). 511.2 Example 62 Method 7 ++++ 2-(4-((2-(3-amino-3- (fluoromethyl)azetidin-1-yl)-4- methylthiazol-5 -yl)methyl)-3 - fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3 -one trifluoroacetate yellow solid, yield: 1.87% 1H NMR (400 MHz, Methanol-d4) 8 8.42 (s, 3H), 7.90 (s, 1H), 7.58 (d, J = 10.1 Hz, 2H), 7.39-7.31 (m, 1H), 7.16 (t, J = 8.3 Hz, 1H), 6.96 (t, J = 8.1 Hz, 2H), 4.93 (s, 2H), 4.50-4.45 (m, 1H), 4.23-4.15 (m, 1H), 4.03 (dd, J = 9.2, 6.9 Hz, 1H), 3.85 (s, 2H), 3.70 (dd, J = 9.3, 3.7 Hz, 1H), 2.09 (s, 3H), 1.26-1.18 (m, 3H). 502.1 Example 63 Method 7 ++++ R' c o z yellow solid, yield: 2.62% 1H NMR (400 MHz, DMSO-d6) 8 8.27 (s, 1H), 7.80-7.74 (m, 2H), 7.49 (d, J = 6.9 Hz, 1H), 7.26 (d, J = 8.6 493.2 2023224057   06 Oct 2026 (2S,3S)-1-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro- 1H-1,2,4-triazol-1 - yl)benzyl)-4-methylthiazol-2-yl)- 2-methylazetidine-3-carbonitrile Hz, 2H), 7.15 (t, J = 8.1 Hz, 2H), 4.96 (s, 2H), 4.35-4.30 (m, 1H), 4.11-4.06 (m, 1H), 3.94 (s, 2H), 3.87 (t, J = 7.6 Hz, 1H), 3.64-3.58 (m, 1H), 2.16 (s, 3H), 1.42 (d, J = 6.2 Hz, 3H). Example 64 Method 7 ++++ \.oh is ofX .njC / 4-(2,6-difluorobenzyl)-2-(4-((2- ((2S,3S)-3-hydroxy-2- methylazetidin-1 -yl)-4- methylthiazol-5 - yl)methyl)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3 -one yellow solid, yield: 2.84% 1H NMR (400 MHz, DMSO-d6) 8 8.26 (s, 1H), 7.76 (d, J = 8.6 Hz, 2H), 7.50-7.45 (m, 1H), 7.25 (d, J = 8.5 Hz, 2H), 7.15 (t, J = 8.0 Hz, 2H), 5.49 (d, J = 6.0 Hz, 1H), 4.96 (s, 2H), 4.49-4.41 (m, 1H), 4.22-4.17 (m, 1H), 4.01-3.95 (m, 1H), 3.90 (s, 2H), 3.64-3.58 (d, J = 8.4 Hz, 1H), 2.12 (s, 3H), 1.21 (d, J = 6.6 Hz, 3H). 484.2 Example 65 Method 7 ++++ o 4-benzyl-2-(4-benzylphenyl)-5-methyl-2,4-dihydro-3 H-1,2,4-triazol-3-one NMR (400 MHz, CDCl3) 8 7.90 -7.85 (m, 2H), 7.38 - 7.27 (m, 8H), 7.24 - 7.15 (m, 4H), 4.87 (s, 2H), 3.98 (s, 2H), 2.18 (s, 3H). 355.8 Example 66 Method 7 ++++ O nA / =\ / N    '—'         4- benzyl-2-(4-ben2ylphenyl)-2,4- dihydro-3H-1,2,4-triazol-3-one 1H NMR (400 MHz, CDCl3) 8 7.90 - 7.85 (m, 2H), 7.43 (s,1 H), 7.41 - 7.26 (m, 8H), 7.25 - 7.16 (m, 4H), 4.86 (s, 2H), 3.99 (s, 2H). 341.8 Example 67 Method 7 +++ O nA / =\ / 1   N—<\ / >—N / AN'  aa  \ 4-benzyl-5-methyl-2-(4-(methyl(phenyl)amino)phenyl)-2,4-dihydro-3 H-1,2,4-triazol-3 - 1H NMR (400 MHz, CDCl3) 8 7.89 -7.81 (m, 2H), 7.39 - 7.27 (m, 7H), 7.13 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 7.6 Hz, 2H), 6.96 (t, J = 7.2 Hz, 1H), 4.89 (s, 2H), 3.33 (s, 3H), 2.20 (s, 3H). 370.8 2023224057   06 Oct 2026 one Example 68: Method 8 2-(4-((2-(3-(2-aminopropan-2-yl)azetidin-1-yl)-4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one Step 1: tert-butyl (2-(1-(5-(4-(4-(2,6 -difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) phenoxy)-4-methylthiazol-2-yl)azetidin-3-yl)propan-2-yl)carbamate To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy) phenyl)-4-(2,6- 10 difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (50 mg, 0.1 mmol) and tert-butyl (2-(azetidin-3-yl)propan-2-yl)carbamate (38 mg, 0.15 mmol) in toluene (1 mL) were added BINAP (12 mg, 0.02 mmol), Pd2(dba)3 (9 mg, 0.01 mmol), and Cs2CO3 (100 mg, 0.3 mmol). The resulted mixture was stirred for additional 2 h at 100 oC under N2. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (10mL). The resulted mixture was extracted 15 with EtOAc (3*10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: EtOAc = 1:1) to afford tert-butyl (2-(1-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H- 1,2,4-triazol-1-yl)phenoxy)-4-methylthiazol-2-yl)azetidin-3-yl)propan-2-yl)carbamate (20 mg, 36 % yield) as a 20 white solid. MS (m / z): 613.2 [M+H]+. 1H NMR (400 MHz, MeOD) 8 7.88 (s, 1H), 7.77-7.66 (m, 2H), 7.40-7.29 (m, 1H), 7.00-6.90 (m, 4H), 4.93 (s, 2H), 3.94-3.75 (m, 4H), 2.15-2.02 (m, 1H), 1.93 (s, 3H), 1.31 (s, 9H), 1.26-1.20 (m, 6H). Step 2: 2-(4-((2-(3-(2-aminopropan-2-yl)azetidin-1-yl)-4-methylthiazol-5-yl)oxy)phenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 25 To a stirred solution of tert-butyl (2-(1-(5-(4-(4-(2,6-difluorobenzyl) -5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazol-2-yl)azetidin-3-yl)propan-2-yl)carbamate (20 mg, 0.03 mmol) in DCM (5 mL) was added 4N HCl in dioxane or TFA (0.5 mL) at rt. The resulted mixture was stirred for additional 2 h at 25°C. The resulted mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the 2023224057   06 Oct 2026 following conditions: column: Spherical C18 40-60 um, 40 g; Mobile phase B: ACN; Flow rate: 40 mL / min; Gradient: 35%B-60%B in 20 min; Detector: 254 nm. The fractions containing the desired product were concentrated under reduced pressure to afford the titled compound 2-(4-((2-(3-(2-aminopropan-2-yl)azetidin-1-yl)           -4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6- 5 difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (3.4 mg, 21% yield) as an off-white solid. LC-MS (m / z): 513.2 [M+H]+. 1H NMR (400 MHz, MeOD) 8 7.91 (s, 1H), 7.83 (d, J = 5.2 Hz, 2H), 7.42-7.28 (m, 1H), 7.20-6.90 (m, 4H), 4.94 (s, 2H), 4.43-4.19 (m, 2H), 3.69-3.45 (m, 2H), 2.25-1.90 (m, 4H), 1.57-1.25 (m, 6H). Examples (Compounds) 69-73 were synthesized using a similar method to that used in Example 10 68. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 68 Method 8 ++++ Lnh2 _N„-N-J n iAn-CP 2-(4-((2-(3-(2-aminopropan-2-yl)azetidin-1 -yl)-4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one off-white solid, yield: 21% 1H NMR (400 MHz, MeOD) 8 7.91 (s, 1H), 7.83 (d, J = 5.2 Hz, 2H), 7.42-7.28 (m, 1H), 7.20-6.90 (m, 4H), 4.94 (s, 2H), 4.43-4.19 (m, 2H), 3.69-3.45 (m, 2H), 2.25-1.90 (m, 4H), 1.57-1.25 (m, 6H). 513.2 Example 69 Method 8 ++++ F       0 Ar^-CkVs , N V^'-NHs 2-(4-((2-((2S,3R)-3-amino-2- methylazetidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4- dih.ydro-3 H-1,2,4-triazol-3-one white solid, yield: 24 % 1H NMR (400 MHz, MeOD) 8 8.40 (s, 2H), 7.89 (s, 1H), 7.73 (d, J = 9.1 Hz, 2H), 7.42 - 7.28 (m, 1H), 7.01 -6.90 (m, 4H), 4.94 (s, 2H), 4.13 (t, J = 7.9 Hz, 1H), 4.02 - 3.87 (m, 1H), 3.66 - 3.43 (m, 2H), 1.95 (s, 3H), 1.42 - 1.35 (m, 3H). 485.2 Example 70 Method 8 ++++ F       0 ~N     Jr\ Jm 'n^nJ (R)-2-(4-((2-(2- (aminomethyl)azetidin-1 -yl)-4- white solid, yield: 1H NMR (400 MHz, MeOD) 8 8.01 (s, 1H), 7.92 (s, 2H), 7.51-7.40 (m, 1H), 7.30-7.00 (m, 4H), 5.05 (s, 2H), 4.50-4.20 (m, 2H), 3.80-3.41 (m, 485.1 2023224057   06 Oct 2026 methylthiazol-5-yl)oxy)phenyl)- 4-(2,6-difluorobenzyl)-2,4- dihydro-3 H-1,2,4-triazol-3-one 3H), 2.95 -2.55 (m, 2H), 2.22 (s, 3H). Example 71 Method 8 ++++ F       o r              JT \       OH n NCV nh2 2-(4-((2-(3-amino-3- (hydroxymethyl)azetidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)- 4-(2,6-difluorobenzyl)-2,4- dih.ydro-3 H-1,2,4-triazol-3-one off-white solid, yield: 1H NMR (400 MHz, MeOD) 5 7.90 (s, 1H), 7.82 (s, 2H), 7.34 (dd, J = 13.9, 7.0 Hz, 1H), 7.20- 6.95 (m, 4H), 4.94 (s, 2H), 4.41 (s, 3H), 3.87 (s, 2H), 3.70 - 3.51 (m, 2H), 2.11 (s, 3H). 501.1 Example 72 Method 8 ++++ F       O N JCkA N O'"'NH2 2-(4-((2-((2S,3R)-3-amino-2- methylazetidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)- 4-(2,6-difluorobenzyl)-2,4- dih.ydro-3 H-1,2,4-triazol-3-one white solid, yield:55.6% 1H NMR (400 MHz, MeOD) 5 7.87 - 7.81 (m, 2H), 7.54 (s, 1H), 7.34 (tt, J = 8.4, 6.5 Hz, 1H), 7.04 -7.00 (m, 2H), 6.99 - 6.93 (m, 2H), 4.95 (s, 2H), 4.23 (t, J = 7.6 Hz, 1H), 4.00 - 3.87 (m, 1H), 3.66 - 3.49 (m, 2H), 2.07 - 2.03 (m, 3H), 1.47 (d, J = 6.3 Hz, 3H). 485.2 Example 73 Method 8 ++++ F       O F 2-(4-((2-((2S,3S)-3-amino-2- methylazetidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4- dih.ydro-3 H-1,2,4-triazol-3-one white solid, yield: 1H NMR (400 MHz, DMSO-d6) 5 8.28 (s, 1H), 7.85 - 7.78 (m, 2H), 7.52-7.44 (m, 1H), 7.21 - 7.07 (m, 4H), 4.97 (s, 2H), 4.34 (p, J=7.2 Hz, 1H), 4.14 - 4.03 (m, 1H), 3.91-3.86 (m, 1H), 3.65-3.60 (m, 1H), 1.98 (s, 3H), 1.31 (d, J = 6.8 Hz, 3H). 485.2 Example 74: Method 9 4-(2,6-difluorobenzyl)-2-(4-((2-(3-ethoxyazetidin-1-yl)-4-methylthiazol-5-yl)oxy)phenyl)- 2,4-dihydro-3H-1,2,4-triazol-3-one 2023224057   06 Oct 2026 To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)phenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (100 mg, 0.21 mmol), 73-ethoxyazetidine (32 mg, 0.32 mmol) and Cs2CO3 (102 mg, 0.32 mmol) in MeCN (5 mL) were added. The reaction mixture was stirred at 100^ for 2 h. The resulted mixture was diluted with EtOAc (10 mL), the 5 solution was successively washed with water (2*5 mL) and brine (5 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by TLC, layered with (DCM:MeOH) (50:1) to afford the titled compound (32 mg, 30.5% yield) as a white solid. MS (m / z): 500.2 [M+H]+. 1H NMR (400 MHz, CDCl3) 8 7.92-7.83 (m, 2H), 7.55 (s, 1H), 7.42-7.29 (m, 1H), 10 7.07 -6.94 (m, 4H), 4.97 (s, 2H), 4.54-4.40 (m, 1H), 4.3-4.21 (m, 2H), 4.04-3.93 (s, 2H), 3.48 (q, J = 7.2 Hz, 2H), 2.11 (s, 3H), 1.23 (t, J = 6.8 Hz, 3H). Example (Compound) 75 was synthesized using a similar method to that used in Example 74. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 74 Method 9 ++++ F       0 ^'F N      J \ „  \ 4-(2,6-difluorobenzyl)-2-(4-((2- (3 -ethoxyazetidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)- 2,4-dihydro-3H-1,2,4-triazol-3- one white solid, yield: 30.5% 1H NMR (400 MHz, CDCl3) 8 7.927.83 (m, 2H), 7.55 (s, 1H), 7.42-7.29 (m, 1H), 7.07 -6.94 (m, 4H), 4.97 (s, 2H), 4.54-4.40 (m, 1H), 4.3-4.21 (m, 2H), 4.04-3.93 (s, 2H), 3.48 (q, J = 7.2 Hz, 2H), 2.11 (s, 3H), 1.23 (t, J= 6.8 Hz, 3H). 500.2 Example 75 Method 9 ++++ F       O rV^'CyYs ^'F       FS 4-(2,6-difluorobenzyl)-2-(4-((4- methyl-2-(7-oxa-2- azaspiro [3.5 ]nonan-2-yl)thiazol- 5-yl)oxy)phenyl)-2,4-dih.ydro- 3H-1,2,4-triazol-3-one white solid, yield: 15.8% NA 526.1 2023224057   06 Oct 2026 Example 76: Method 10 (S)-4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(4-hydroxy-2-oxopyrrolidin-1-yl)-4- methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 5 To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (50 mg, 0.10 mmol) and (S)-4-hydroxypyrrolidin-2-one (10 mg, 0.10 mmol) in dioxane (10 mL) were added CuI (10 mg, 0.05 mmol), (1R,2R)-N,N'-Dimethyl-1,2-cyclohexanediamine (7 mg, 0.05 mmol) K2CO3 (42 mg, 0.03 mmol) at rt. The resulted mixture was stirred for additional 2 h at 110°C under Ar. The 10 mixture was allowed to cool down to rt. The resulted mixture was diluted with water (30 mL). The resulted mixture was extracted with EtOAc (3 x 15 mL). The combined Organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: EtOAc = 1: 1) to afford the titled compound (30 mg, 57.7% 15 yield) as an off-white solid. LC-MS (m / z): 518.0 [M+H]+. 1H NMR (400 MHz, DMSO) 8 8.33 (s, 1H), 7.86 (dd, J = 12.6, 2.4 Hz, 1H), 7.65 (d, J = 9.2 Hz, 1H), 7.51 - 7.43 (m, 1H), 7.21 -7.08 (m, 3H), 5.45 (d, J = 3.8 Hz, 1H), 4.97 (s, 2H), 4.53 - 4.41 (m, 1H), 4.07 (dd, J = 11.4, 4.9 Hz, 1H), 3.91 - 3.83 (m, 1H), 2.95 (dd, J = 17.4, 5.9 Hz, 1H), 2.38 (d, J = 17.5 Hz, 1H), 2.15 (s, 3H). 20 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 76 Method 10 ++++ nNi° (S)-4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((2-(4-hydroxy-2- oxopyrrolidin-1 -yl)-4- methylthiazol-5-yl)oxy)phenyl)- off-white solid, yield: 57.7% 1H NMR (400 MHz, DMSO-d6) 8 8.33 (s, 1H), 7.86 (dd, J = 12.6, 2.4 Hz, 1H), 7.65 (d, J = 9.2 Hz, 1H), 7.51-7.43 (m, 1H), 7.21-7.08 (m, 3H), 5.45 (d, J = 3.8 Hz, 1H), 4.97 (s, 2H), 4.53-4.41 (m, 1H), 4.07 (dd, J = 11.4, 4.9 Hz, 1H), 3.91- 518.0 2023224057   06 Oct 2026 2,4-dihydro-3 H-1,2,4-triazol-3 - one 3.83 (m, 1H), 2.95 (dd, J = 17.4, 5.9 Hz, 1H), 2.38 (d, J = 17.5 Hz, 1H), 2.15 (s, 3H). Example 77: Method 11 2-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)thiazole-5-carbonitrile K2CO3, DMF,50 C, 16 h A solution of 4-[(2,6-difluorophenyl)methyl]-2-(4-hydroxyphenyl)-1,2,4-triazol-3-one (50 mg, 0.16 mmol), 2-bromo-1,3-thiazole-5-carbonitrile (47 mg, 0.24 mmol), K2CO3 (46 mg, 0.33 mmol) in DMSO (2 mL) was stirred at 50C for 16h. The resulted mixture was diluted with water (20 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The combined organic 10 layers were washed with brine (20 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EtOAc : PE = 1 : 1) to afford 2-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)thiazole-5-carbonitrile (21.1 mg, 28.8% yield) as a white solid. LC-MS (m / z): 412.0 [M+H]+. 1H NMR (400 MHz, CDCh) 8 8.15 - 8.08 (m, 1H), 7.76 (s, 1H), 7.61 (s, 1H), 7.42 - 15 7.31 (m, 2H), 7.03 - 6.94 (m, 4H), 4.99 (s, 2H). Examples (Compounds) 78-79 were synthesized using a similar method to that used in Example 77. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 77 Method 11 +++ F      0 nTv-O0 '-N 2-(4-(4-(2,6-difluorobenzyl)-5 - oxo-4,5 -dihydro- 1H-1,2,4-triazol- 1 -yl)phenoxy)thiazole-5- white solid, yield:28.8% 1H NMR (400 MHz, CDCh) 8 8.15 -8.08 (m, 1H), 7.76 (s, 1H), 7.61 (s, 1H), 7.42 - 7.31 (m, 2H), 7.03 - 6.94 (m, 4H), 4.99 (s, 2H). 412.0 2023224057   06 Oct 2026 carbonitrile Example 78 Method 11 +++ jF      A 4-(2,6-difluorobenzyl)-2-(4-((4,5- dimethylthiazol-2- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3 -one white solid, yield: 1H NMR (400 MHz, DMSO-d6) 8 8.32 (s, 1H), 7.94 - 7.87 (m, 2H), 7.53 - 7.43 (m, 1H), 7.41 - 7.34 (m, 2H), 7.21 - 7.12 (m, 2H), 4.97 (s, 2H), 2.22 (d, J = 0.7 Hz, 3H), 2.09 (d, J = 0.8 Hz, 3H). 415.0 Example 79 Method 11 ++++ , o cr 5-(4-(4-(2,6-difluorobenzyl)-5 - oxo-4,5 -dihydro- 1H-1,2,4-triazol- 1 -yl)phenoxy)thiazole-2- carbonitrile white solid, yield: 1H NMR (400 MHz, DMSO-d6) 8 8.34 (s, 1H), 7.96 (s, 1H), 7.95 - 7.90 (m, 2H), 7.54 - 7.46 (m, 1H), 7.46 -7.41 (m, 2H), 7.17 (t, J = 8.1 Hz, 2H), 4.98 (s, 2H). 412.0 Example 80: Method 12 5-(2-fluoro-4-(7-fluoro-3-oxo-5-phenyl-3,5,6,7-tetrahydro-2H-pyrrolo[2,1-c][1,2,4]triazol-2-yl)phenoxy)-4-methylthiazole-2-carboxamide 5 fert-butyl hypochlorite,Nai, 2,6-Lutidine,dioxane, r.t. step 1 Step 1: methyl 3-phenyl-4,5-dihydroisoxazole-5-carboxylate To a stirred solution of benzaldehyde oxime (120 g, 0.99 mol) in 1,4-dioxane (1200 mL) was added methyl prop-2-enoate (94 g, 1.09 mol), NaI (164 g, 1.09 mmol), 2,6-lutidine (117 g, 1.09 2023224057   06 Oct 2026 mol) and tert-butyl hypochlorite (118 g, 1.09 mmol) batchwise at 25oC. The resulted mixture was stirred for additional 18 h at 25°C. The resulted mixture was quenched with water (1000 mL). The resulted mixture was extracted with EtOAc (3X800 mL). The combined organic layers were washed with brine (500 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel, eluted with (PE:EtOAc) (10:1) to afford crude methyl 3-phenyl-4,5-dihydroisoxazole-5-carboxylate (140 g, 65.4% yield) as a yellow solid. MS (m / z): 206.0 [M+H]+. Step 2: ethyl 5-bromo-4-methylisoxazole-3-carboxylate To a solution of methyl 3-phenyl-4,5-dihydroisoxazole-5-carboxylate (46 g, 224 mmol) in EtOH (1000 mL) was added Pd / C (23 g) at 25°C. The mixture was stirred at 25°C under H2 50 psi for 5 hours. The reaction solution was filtered, and the filtrate was concentrated in vacuo to give crude 3-hydroxy-5-phenylpyrrolidin-2-one (48 g crude) 74% purity in LCMS as a yellow oil. LC-MS (m / z) 178.0[M+H]+. Step 3: 3-((tert-butyldimethylsilyl)oxy)-5-phenylpyrrolidin-2-one To a mixture of 3-hydroxy-5-phenylpyrrolidin-2-one (75 g, 423.2 mmol) in DCM (750 mL) was added imidazole (57.5 g, 0.85 mol) and TBSCl (95.5 g, 0.64 mmol) batchwise at rt, the reaction mixture was stirred at 30^ for 18 h. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (300 mL). The resulted mixture was extracted with DCM (3*500 mL). The combined organic layers were washed with brine (800 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel, eluted with (PE: EtOAc) (10:1) to afford 3-((tert-butyldimethylsilyl)oxy)-5-phenylpyrrolidin-2-one (86 g, 69.9% yield) as a yellow solid. LC-MS (m / z) 292.1[M+H]+. Step 4: 4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-phenyl-3,4-dihydro-2H-pyrrole To a stirred solution of 3-((tert-butyldimethylsilyl)oxy)-5-phenylpyrrolidin-2-one (86 g, 291 mmol) in DCM (800 mL) was added trimethyloxonium tetrafluoroborate (47.5 g, 320 mmol). The reaction mixture was stirred at 25°C for 18 h. The reaction solution was used directly in the next step. Step 5: methyl 2-(4-((tert-butyldimethylsilyl)oxy)-2-phenyl-3,4-dihydro-2H-pyrrol-5-yl) hydrazine-1-carboxylate To a solution of 4-((tert-butyldimethylsilyl)oxy)-5-methoxy-2-phenyl-3,4-dihydro-2H-pyrrole in DCM (750 mL) was added a solution of methoxycarbohydrazide (29.5 g, 320 mmol) in DCM - 120 - 2023224057   06 Oct 2026 (200 mL) dropwise at 25°C under N2, and the mixture was stirred at 25°C for 6 h, the mixture was quenched with ice-water. The mixture was extracted with DCM (100 mLx3). The combined organic layers were washed with water (500 mL x 2), brine (500 mL), dried over Na2SO4 and concentrated. The residue was purified by silica gel, eluted with (DCM:MeOH) (30:1) to afford methyl 2-(4-((tert-butyldimethylsilyl)oxy)-2-phenyl-3,4- dihydro-2H-pyrrol-5-yl)hydrazine-1carboxylate (67 g, 62.6% yield of 2 steps) as a yellow solid. LC-MS (m / z): 364.2 [M+H]+. Step 6: methyl 2-(4-((tert-butyldimethylsilyl)oxy)-2-phenyl-3,4-dihydro-2H-pyrrol-5-yl) hydrazine-1-carboxylate Methyl 2-(4-((tert-butyldimethylsilyl)oxy)-2-phenyl-3,4-dihydro-2H-pyrrol-5-yl)hydrazine -1-carboxylate (30 g, 82.5 mmol) in a single-neck bottle was heated at 170°C for 4 hours without solvent under N2. The mixture was cooled to r.t to afford crude 7-((tert-butyldimethylsilyl)oxy)-5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one (27 g crude) 88% purity in LCMS as a yellow solid. LC-MS (m / z): 332.1 [M+H]+. Step 7: 7-hydroxy-5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one To a stirred solution of 7-((tert-butyldimethylsilyl)oxy)-5-phenyl-2,5,6,7-tetrahydro -3H-pyrrolo[2,1-c][1,2,4]triazol-3-one (27 g, 81.5 mmol) in MeOH (270 mL) was added 4M HCl in dioxane (30 mL) at 25°C. The reaction mixture was stirred at 25°C for 3 hours. The mixture was treated with sat. Na2CO3 solution to adjust to pH = 9 and concentrated. The residue was purified by silica gel, eluted with (DCM:MeOH) (20:1) to afford 7-hydroxy-5-phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-one (4 g, 21.8% yield) as a yellow solid. LC-MS (m / z): 218.1 [M+H]+. 1H NMR (400 MHz, DMSO_d6) 8 11.47 (d, J = 11.6 Hz, 1H), 7.38 -7.22 (m, 5H), 5.955.99 (m, 1H), 5.28-4.89 (m, 2H), 3.26-3.19 (m, 0.5H), 2.74-2.68 (m, 0.5 H), 2.58-2.53 (m, 0.5 H), 2.13-2.08 (m, 0.5 H). Step 8: 5-(2-fluoro-4-(7-hydroxy-3-oxo-5-phenyl-3,5,6,7-tetrahydro-2H-pyrrolo [2,1-c][1,2,4]triazol-2-yl)phenoxy)-4-methylthiazole-2-carboxamide To a solution of 7-hydroxy-5-phenyl-6,7-dihydro-2H-pyrrolo[2,1-c][1,2,4]triazol-3(5H)-one (1.00 eq, 200 mg, 0.92 mmol) in DMF (4 mL), was added CuI (0.500 eq, 88 mg, 0.46 mmol), K2CO3 (2.00 eq, 254 mg, 1.84 mmol), 5-(4-bromo-2-fluorophenoxy) -4-methylthiazole-2-carboxamide (1.00 eq, 302 mg, 0.92 mmol), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (1.00 eq, 132 mg, 0.92 mmol). The reaction mixture was stirred for 1 h at 110 oC under nitrogen. The reaction was quenched with water (20 mL) and extracted with EtOAc (20 mL x 3). The - 121 - 2023224057   06 Oct 2026 combined organic layers were washed with brine (4 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE:EtOAc) (1:2) to afford 5-(2-fluoro-4-(7-hydroxy-3-oxo-5-phenyl -3,5,6,7-tetrahydro-2H-pyrrolo[2,1-c][1,2,4]triazol-2-yl)phenoxy)-4-5 methylthiazole-2-carboxamide (300 mg, 70 % yield) as a brown yellow oil. LC-MS (m / z): 468.1[M+H]+. Step 9: 5-(2-fluoro-4-(7-fluoro-3-oxo-5-phenyl-3,5,6,7-tetrahydro-2H-pyrrolo [2,1-c][1,2,4]triazol-2-yl)phenoxy)-4-methylthiazole-2-carboxamide To a solution of 5-(2-fluoro-4-(7-hydroxy-3-oxo-5-phenyl-3,5,6,7-tetrahydro -2H-pyrrolo[2,1-10 c][1,2,4]triazol-2-yl)phenoxy)-4-methylthiazole-2-carboxamide (1.00 eq, 77 mg, 0.16 mmol) in DCM (1 mL), was added dropwise DAST (1.5 eq, 17 pL 0.24 mmol) in DCM(0.6 mL) and stirred for 1 h at 0 oC under nitrogen. The reaction was quenched with sat. NaHCO3 (2 mL) and extracted with DCM (10 mL x 3),The combined Organic layers were dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue 15 was purified by silica gel column chromatography, eluted with (PE:EtOAc) (1:1) to afford 5-(2- fluoro-4-(7-fluoro-3-oxo-5-phenyl-3,5,6,7- tetrahydro-2H-pyrrolo[2,1-c][1,2,4]triazol-2- yl)phenoxy)-4-methylthiazole-2-carboxamide: polar spot (35 mg, 45 % yield) and less polar spot (28.7 mg, 37% yield) as a brown yellow oil. LC-MS (m / z) : 470.1[M+H]+. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 80 Method 12 Polar spot ++++ Q a / w (^>NN    F sf F               HjbT 0 5-(2-fluoro-4-(7-fluoro-3-oxo-5- phenyl-3,5,6,7-tetrahydro-2H- pyrrolo[2,1-c][1,2,4]triazol-2- yl)ph.enoxy)-4-meth.ylthiazole-2- carboxamide brown yellow oil, yield: 45% NA 470.1 2023224057   06 Oct 2026 Example 82: Method 13 K2CO3, DMF,100°C, 16h 2-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)thiazole-5-5 carboxamide A solution of 4-[(2,6-difluorophenyl)methyl]-2-(4-hydroxyphenyl)-1,2,4-triazol-3-one (80 mg, 0.26mmol), 2-bromo-1,3-thiazole-5-carbonitrile (75 mg, 0.4 mmol), K2CO3 (73 mg, 0.5 mmol) in DMF (2 mL) was stirred at 100oC for 16 h. The resulted mixture was diluted with water (20 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The combined Organic layers 10 were washed with brine (20 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EtOAc : PE = 1 : 1) to afford the product (25.1 mg, 20.8% yield) as a white solid. LC-MS (m / z): 430.0 [M+H]+. 1H NMR (400 MHz, CDCI3) 8 8.08 (d, J = 9.1 Hz, 2H), 7.61 (d, J = 15.1 Hz, 2H), 7.42 - 7.31 (m, 3H), 7.04 - 6.94 (m, 2H), 5.61 (s, 2H), 4.99 (s, 2H). 15 2023224057   06 Oct 2026 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 82 Method 13 +++ o nvlr 2-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4-triazol- 1 -yl)phenoxy)thiazole- 5 -carboxamide white solid, yield:28.8% 1H NMR (400 MHz, CDCl3) 8 8.08 (d, J = 9.1 Hz, 2H), 7.61 (d, J = 15.1 Hz, 2H), 7.42 - 7.31 (m, 3H), 7.04 -6.94 (m, 2H), 5.61 (s, 2H), 4.99 (s, 2H). 430.0 Example 83: Method 14 4-(2,6-difluorobenzyl)-2-(4-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one A solution of 4-[(2,6-difluorophenyl)methyl]-2-(4-hydroxyphenyl)-1,2,4-triazol-3-one (50mg, 0.16 mmol), 2-bromo-4,5,6,7-tetrahydro-1,3-benzothiazole (72 mg, 0.3 mmol), NaH (8 mg, 0.2 mmol) in DMF (3 mL) was stirred at 80°C for 16h. The resulted mixture was diluted with water (20mL). The resulted mixture was extracted with EtOAc (3*10 mL). The combined organic 10 layers were washed with brine (20 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford 4-(2,6-difluorobenzyl)-2-(4-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl) oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (1.1 mg, 1.5% yield) as a white solid. 1H NMR (400 MHz, CDCl3) 8 8.00 (d, J = 9.1 Hz, 2H), 7.58 (s, 1H), 7.37 (s, 1H), 7.29 (d, J = 9.1 Hz, 2H), 7.02 - 15 6.95 (m, 2H), 4.98 (s, 2H), 2.62 (d, J = 5.6 Hz, 4H), 1.85 - 1.81 (m, 4H). 2023224057   06 Oct 2026 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 83 Method 14 +++ F v / ¾. ,n-ZX L / N VZ-CJ s 4-(2,6-difluorobenzyl)-2-(4- ((4,5,6,7- tetrahydrobenzo[d]thiazol-2- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:1.5% 1H NMR (400 MHz, CDCl3) 5 8.00 (d, J = 9.1 Hz, 2H), 7.58 (s, 1H), 7.37 (s, 1H), 7.29 (d, J = 9.1 Hz, 2H), 7.02 - 6.95 (m, 2H), 4.98 (s, 2H), 2.62 (d, J = 5.6 Hz, 4H), 1.85 - 1.81 (m, 4H). 441.1 Example 84: Method 15 4-(2,6-difluorobenzyl)-2-(4-((2-(3-ethoxyazetidin-1-yl)thiazol-5-yl)oxy)phenyl)-2,4- dihydro-3H-1,2,4-triazol-3-one 5            Step 3                                                      Step 4 Step 1: 5-(4-bromophenoxy)thiazol-2-amine To a stirred solution of 5-bromothiazol-2-amine (5 g, 27.9 mmol) in acetone (100 mL) were added 4-bromophenol (4.8 g, 27.9 mmol) and Cs2CO3 (18.2 g, 56 mmol). The resulted mixture was stirred for additional 6 h at 60^ under N2. The mixture was allowed to cool down to rt. The 10 resulted mixture was diluted with water (100 mL). The resulted mixture was extracted with EtOAc (3 x 100 mL). The combined Organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: EtOAc = 2: 1) to afford 5-(4-bromophenoxy)thiazol-2-amine (460 mg, 6 % yield) as a white solid. MS (m / z): 15 270.9 [M+H]+. Step 2: 2-bromo-5-(4-bromophenoxy)thiazole To a stirred solution of 5-(4-bromophenoxy)-1,3-thiazol-2-amine (460 mg, 1.7 mmol) in MeCN 2023224057   06 Oct 2026 (10 mL) was added CuBr2 (758 mg, 3.4 mmol), and the reaction mixture was cooled to 0°C. Then Isoamyl nitrite (400 mg, 3.4 mmol) was added dropwise. The resulted mixture was stirred for additional 1 h at 25 C. The mixture was quenched with NH4Cl (10 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The combined Organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: EtOAc = 5:1) to afford 2-bromo-5-(4-bromophenoxy)thiazole (280 mg, 27% yield) as a white solid. MS (m / z): 335.8 [M+H]+. Step 3: 5-(4-bromophenoxy)-2-(3-ethoxyazetidin-1-yl)thiazole To a stirred solution of 2-bromo-5-(4-bromophenoxy)thiazole (280 mg, 0.83 mmol) and 3-ethoxyazetidine (115 mg, 0.83 mmol) in DMSO (5 mL) were added K2CO3 (345 mg, 2.5 mmol). The resulted mixture was stirred for additional 2 h at 150 C under N2. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (10 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The combined Organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE:EtOAc = 1:1) to afford 5-(4-bromophenoxy)-2-(3-ethoxyazetidin-1-yl)thiazole (140 mg, 47 % yield) as a white solid. MS (m / z): 354.9 [M+H]+. Step 4: 4-(2,6-difluorobenzyl)-2-(4-((2-(3-ethoxyazetidin-1-yl)thiazol-5-yl)oxy)phenyl) -2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 5-(4-bromophenoxy)-2-(3-ethoxyazetidin-1-yl)thiazole (130 mg, 0.366 mmol) and 4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (78 mg, 0.366 mmol) in DMF (5 mL) were added (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (25 mg, 0.18 mmol), CuI (34 mg, 0.18 mmol), K2CO3 (138 mg, 1 mmol). The resulted mixture was stirred for additional 2 h at 105C under N2. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (10 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The combined Organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: column: Spherical C18 40-60 um, 40 g; Mobile phase B: ACN; Flow rate: 40 mL / min; Gradient: 35%B-60%B in 20 min; Detector: 254 nm. The fractions containing the desired product were concentrated under reduced pressure to afford 4-(2,6-difluorobenzyl)-2-(4-((2-(3-- 126 - 2023224057   06 Oct 2026 ethoxyazetidin-1-yl)thiazol-5-yl)oxy)phenyl) -2,4-dihydro-3H-1,2,4-triazol-3-one (24 mg, 13% yield) as an off-white solid. LC-MS (m / z): 486.1 [M+H]+. 1H NMR (400 MHz, CDCI3) 8 7.94 -7.84 (m, 2H), 7.56 (s, 1H), 7.35 (td, J = 8.4, 4.2 Hz, 1H), 7.14 - 7.05 (m, 2H), 6.98 (p, J = 3.5 Hz, 2H), 6.85 (s, 1H), 4.97 (s, 2H), 4.52 -4.39 (m, 1H), 4.30 - 4.16 (m, 2H), 3.96 (dd, J = 8.8, 5 4.4 Hz, 2H), 3.48 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.0 Hz, 3H). Example (Compound) 85 was synthesized using a similar method to that used in Example 84. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 84 Method 15 ++++ F       o OT^-O'Ys ^^f n     ri 4-(2,6-difluorobenzyl)-2-(4-((2- (3-ethoxyazetidin-1 -yl)thiazol-5 -yl)oxy)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one off-white solid, yield:13% 1H NMR (400 MHz, CDCl3) 8 7.94 - 7.84 (m, 2H), 7.56 (s, 1H), 7.35 (td, J = 8.4, 4.2 Hz, 1H), 7.14 - 7.05 (m, 2H), 6.98 (p, J = 3.5 Hz, 2H), 6.85 (s, 1H), 4.97 (s, 2H), 4.52 - 4.39 (m, 1H), 4.30 - 4.16 (m, 2H), 3.96 (dd, J = 8.8, 4.4 Hz, 2H), 3.48 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.0 Hz, 3H). 486.1 Example 85 Method 15 + f       o N 4-(2,6-difluorobenzyl)-2-(4-((5- (3-ethoxyazetidin-1 -yl)-2- methylthiophen- 3- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield: 6.6 % 1H NMR (400 MHz, DMSO-d6) 8 9.49 (s, 1H), 7.64 - 7.57 (m, 2H), 7.37 - 7.26 (m, 1H), 6.97 (t, J = 8.2 Hz, 2H), 6.83 - 6.77 (m, 2H), 5.81 (s, 1H), 4.91 (s, 2H), 4.37 - 4.28 (m, 1H), 4.01 - 3.91 (m, 2H), 3.52 (dd, J = 8.2, 4.8 Hz, 2H), 3.39 (q, J = 7.0 Hz, 2H), 2.11 (s, 3H), 1.10 (t, J = 7.0 Hz, 3H). 499.2 2023224057   06 Oct 2026 Example 86: Method 16 5-(2-chloro-4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole-2-carbonitrile 5 Step 1: 2-(3-chloro-4-((4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 2-(3-chloro-4-hydroxyphenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro -3H-1,2,4-triazol-3-one (2 g, 5.92 mmol) and 5-bromo-4-methylthiazole (1.27 g, 7.11 mmol) in NMP 10 (100 mL) were added K2CO3 (2.46 g, 17.77 mmol) at rt. The resulted mixture was stirred for additional 2 h at 150C. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (200mL). The resulted mixture was extracted with EtOAc (3X150 mL). The combined Organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by 15 silica gel column chromatography, eluted with (PE: EtOAc = 1: 0 to 1: 1) to afford 2-(3-chloro-4-((4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (2.6 g, quantitative) as a brown yellow solid. MS (m / z): 436.2 [M+H]+. Step 2: 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-chlorophenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one 20 To a stirred solution of 2-(3-chloro-4-((4-methylthiazol-5-yl)oxy)phenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one (2.6 g, 5.98 mmol) in MeCN (100 mL) were added NBS (2.13 g, 11.96 mmol) at rt. The resulted mixture was stirred for additional 10 min at 90 °C. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (40 mL). The resulted mixture was extracted with EtOAc (3 * 80 mL). The combined Organic layers were 25 washed with brine (80 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: EtOAc = 1:0-1:1) to afford 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-chlorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (1.68 g, 2023224057   06 Oct 2026 54.7% yield) as a brown solid. MS (m / z): 513.1 [M+H]+. Step 3: 5-(2-chloro-4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) phenoxy)-4-methylthiazole-2-carbonitrile To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-chlorophenyl)-4- (2,65 difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (300 mg, 0.58 mmol) in NMP (15 mL) was added CuCN (131 mg, 1.46 mmol) at rt. The resulted mixture was stirred for additional 4 h at 150°C. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (40 mL). The resulted mixture was extracted with EtOAc (3 x 80 mL). The combined Organic layers were washed with brine (80 mL), dried over anhydrous Na2SO4, and after filtration, the 10 filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: EtOAc = 1:0 to 1:1) to afford 5-(2-chloro-4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-4-methylthiazole-2-carbonitrile (1.2 mg, 0.45% yield) as a white solid. LC-MS (m / z): 461.1[M+H]+. 1H NMR (400 MHz, CDCl3) 8 8.22 (d, J = 2.5 Hz, 1H), 7.98 - 7.93 (m, 1H), 7.61 (s, 1H), 7.37 (td, J = 8.3, 4.1 15 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 6.99 (t, J = 7.9 Hz, 2H), 4.98 (s, 2H), 2.43 (s, 3H). Examples (Compounds) 87-88 were synthesized using a similar method to that used in Example 86. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 86 Method 16 ++++ N^CN ^F    ^<c| 5-(2-chloro-4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 -yl)phenoxy)^-methylthiazole- 2-carbonitrile white solid, yield:0.45% 1H NMR (400 MHz, CDCl3) 8 8.22 (d, J = 2.5 Hz, 1H), 7.98 -7.93 (m, 1H), 7.61 (s, 1H), 7.37 (td, J = 8.3, 4.1 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 6.99 (t, J = 7.9 Hz, 2H), 4.98 (s, 2H), 2.43 (s, 3H). 460.1 Example 87 Method 16 ++++ R R z co— O z white solid, yield:60.8% 1H NMR (400 MHz, DMSO-d6) 8 8.33 (s, 1H), 7.91 (d, J = 9.1 Hz, 2H), 7.56 - 7.41 (m, 1H), 7.34 (d, 426.1 2023224057   06 Oct 2026 5-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- triazol-1 -yl)phenoxy)-4- methylthiazole-2-carbonitrile J = 9.1 Hz, 2H), 7.16 (t, J = 8.1 Hz, 2H), 4.98 (s, 2H), 2.32 (s, 3H). Example 88 Method 16 ++++ 0 -   «   -y / "' F                Cl 5-(2-chloro-4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 - yl)phenoxy)-4-methylthiazole- 2-carboxamide white solid, yield:0.45% 1H NMR (400 MHz, CDCl3) 5 8.18 (d, J = 2.5 Hz, 1H), 7.89 (dd, J = 9.0, 2.5 Hz, 1H), 7.59 (s, 1H), 7.41 - 7.32 (m, 1H), 7.03 (d, J = 9.0 Hz, 1H), 6.99 (t, J = 7.9 Hz, 3H), 4.97 (s, 2H), 2.34 (s, 3H). 478.1 Example 89: Method 17 N-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)acetamide Step 1: 2-(4-((2-amino-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-(2,6-difluorobenzyl)-2- (3-fluoro-4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (400 mg, 1.25 mmol) and 5-bromo-4-methylthiazol-2-amine (264 mg, 1.37 10 mmol) in DMF (20 mL) were added Cs2CO3 (1.22 g, 3.74 mmol) at rt. The resulted mixture was stirred for additional 3 h at 60°C. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (100mL). The resulted mixture was extracted with EtOAc (3*80 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue 15 was purified by silica gel column chromatography, eluted with (PE: EtOAc = 1:0 to 1:1) to afford 2-(4-((2-amino-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (140 mg, 25.94% yield) as a brown yellow solid. MS (m / z): 434.3 [M+H]+. 2023224057   06 Oct 2026 Step 2:    N-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2- fluorophenoxy)-4-methylthiazol-2-yl)acetamide To a stirred solution of 2-(4-((2-amino-4-methylthiazol-5-yl)oxy) -3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (140 mg, 0.32 mmol) and TEA (98 mg, 0.97 5 mmol) in DCM (15 mL) were added acetyl chloride (28 mg, 0.36 mmol) at rt. The resulted mixture was stirred for additional 2 h at rt. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford N-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)acetamide (10.4 mg, 6.77% yield) as a white solid. MS (m / z): 476.1 [M+H]+. 1HNMR (400 MHz, CDCI3) 8 7.88 (dd, 10 J = 12.3, 2.2 Hz, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.57 (s, 1H), 7.42 - 7.31 (m, 1H), 7.03 - 6.94 (m, 3H), 4.97 (s, 2H), 2.23 (s, 3H), 2.19 (s, 3H). Examples (Compounds) 90-91 were synthesized using a similar method to that used in Example 89. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 89 Method 17 ++++ F     O    f NF F-Q N-<    \e O un    Fl K N-(5-(4-(4-(2,6-difluorobenzyl)-5 -oxo-4,5 -dihydro-1 H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)acetamide white solid, yield:6.77% 1H NMR (400 MHz, CDCl3) 8 7.88 (dd, J = 12.3, 2.2 Hz, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.57 (s, 1H), 7.42 - 7.31 (m, 1H), 7.03 -6.94 (m, 3H), 4.97 (s, 2H), 2.23 (s, 3H), 2.19 (s, 3H). 476.1 Example 90 Method 17 +++ n^nh2 f       V FFt <nFF° 2-(4-((2-aminothiazol-5- yl)oxy)phenyl)^-(2,6- difluorobenzyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one white solid, yield: 1H NMR (400 MHz, CDCl3) 8 ppm 7.93 - 7.87 (m, 2H), 7.57 (s, 1H), 7.36 (m, 1H), 7.15 - 7.08 (m, 2H), 7.03 - 6.93 (m, 2H), 6.77 (s, 1H), 4.97 (s, 2H). 402.1 2023224057   06 Oct 2026 Example 92: Method 18 methyl 2-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenoxy)-5-methylthiazole-4-carboxylate A solution of 4-[(2,6-difluorophenyl)methyl]-2-(4-hydroxyphenyl)-1,2,4-triazol-3-one (80 mg, 0.26 mmol), methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate (93 mg, 0.4 mmol), K2CO3 (73 mg, 0.52 mmol) in DMF (2 mL) was stirred at 100^ for 16 h. The resulted mixture was diluted with water (20 mL). The resulted mixture was extracted with EtOAc (3 x 10 mL). The 10 combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EtOAc : PE = 1 : 1) to afford the product (20.1 mg, 15.8% yield) as a white solid. MS (m / z): 459.0 [M+H]+. 1H NMR (400 MHz, CDCk) 8 8.09 - 7.98 (m, 2H), 7.59 (s, 1H), 7.40 - 7.28 (m, 3H), 7.04 - 6.94 (m, 2H), 4.98 (s, 2H), 3.88 (s, 3H), 2.67 (s, 3H). 15 Examples (Compounds) 93-96 were synthesized using a similar method to that used in Example 92. 2023224057   06 Oct 2026 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 92 Method 18 +++ o3 LJ rX'5 n^v'v 0 methyl             2-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 - yl)phenoxy)-5-methylthiazole-4- carboxylate white solid, yield:15.8% 1H NMR (400 MHz, CDCl3) 5 8.09 - 7.98 (m, 2H), 7.59 (s, 1H), 7.40 - 7.28 (m, 3H), 7.04 - 6.94 (m, 2H), 4.98 (s, 2H), 3.88 (s, 3H), 2.67 (s, 3H). 459.0 Example 93 Method 18 +++ Lo s 1__ 1  ? Sr" [XXXX ethyl                4-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 -yl)-2 - fluorophenoxy)thiazole-5- carboxylate yellow solid, yield: 60.7% 1H NMR (400 MHz, CDCl3) 5 8.54 (s, 1H), 7.93 (dd, J = 12.0, 2.3 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 7.57 (s, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 6.98 (t, J = 7.8 Hz, 2H), 4.97 (s, 2H), 4.37 (d, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). 477.0 Example 94 Method 18 ++ J     o      nN / \= / 4-(2,6-difluorobenzyl)-2-(4-((1- methyl- 1H-1,2,4-triazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:12 % 1H NMR (400 MHz, CDCl3) 5 8.08 - 7.99 (m, 2H), 7.58 (d, J = 3.6 Hz, 2H), 7.42 - 7.30 (m, 3H), 7.04 - 6.94 (m, 2H), 4.98 (s, 2H), 3.79 (s, 3H). 385.1 Example 95 Method 18 +++ F      O 1  _   11    / =\ A s mCXX / 0 4-(2,6-difluorobenzyl)-2-(4-((1- methyl-4-nitro-1H-pyrazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- white solid, yield: 1H NMR (400 MHz, CDCl3) 5 8.09 (s, 1H), 7.99 - 7.94 (m, 2H), 7.56 (s, 1H), 7.40 - 7.31 (m, 1H), 7.01 - 6.93 (m, 4H), 4.96 (s, 2H), 3.76 (s, 3H). 428.8 2023224057   06 Oct 2026 1,2,4-triazol-3-one Example 96 Method 18 +++ F       0 rCNA-O°>N N 4-(2,6-difluorobenzyl)-2-(4-((4-(hydroxymethyl)thiazol-2-yl)oxy)phenyl) -2,4-dihydro-3H-1,2,4-triazol-3-one off-white solid, yield: 46.24% 1H NMR (400 MHz, CDCh) S 8.08 - 8.00 (m, 2H), 7.59 (s, 1H), 7.43 - 7.29 (m, 3H), 7.03 - 6.92 (m, 2H), 6.69 (s, 1H), 4.98 (s, 2H), 4.60 (s, 2H). 417.4 Example 97: Method 19 4-(2,6-difluorobenzyl)-2-(4-((2,4-dimethylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-[(2,6-difluorophenyl)methyl]-2-(4-hydroxyphenyl) -1,2,4-triazol-3-one ( 200 mg, 0.6595 mmol), 5-bromo-2,4-dimethyl-1,3-thiazole (152.01 mg, 0.7914 mmol), and 1-N,2-N-dimethylcyclohexane-1,2-diamine (18.76 mg, 0.1319 mmol) in DMF were added CuI (25.12 mg, 0.1319 mmol) and Cs2CO3(537.2 mg, 1.6487 mmol). The resulted mixture was 10 stirred for additional 16 h at 110°C. After filtration, the filtrate was concentrated under reduced pressure. The resulted mixture was diluted with water (100mL). The resulted mixture was extracted with EtOAc (3*50mL). The combined Organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The resulted mixture was concentrated under reduced pressure. The residue 15 was purified by Flash (PE:EA=1:2) to obtain the titled compound (65 mg, 24.48% yield) as a white solid. LC-MS (m / z): 415.4 [M+H]+. 1H NMR (400 MHz, CDCh) S 8.03 - 7.84 (m, 2H), 7.56 (s, 1H), 7.42 - 7.31 (m, 1H), 7.05 - 6.94 (m, 4H), 4.97 (s, 2H), 2.63 (s, 3H), 2.22 (s, 3H). Examples (Compounds) 98-99 were synthesized using a similar method to that used in Example 97. 20 2023224057   06 Oct 2026 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 97 Method 19 ++++ ■7       0      -"A-S -■■f   n 4-(2,6-difluorobenzyl)-2-(4-((2,4- dimethylthiazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:24.48 % 1H NMR (400 MHz, CDCl3) 5 8.03 - 7.84 (m, 2H), 7.56 (s, 1H), 7.42 - 7.31 (m, 1H), 7.05 - 6.94 (m, 4H), 4.97 (s, 2H), 2.63 (s, 3H), 2.22 (s, 3H). 415.4 Example 98 Method 19 +++ F       O N 4-(2,6-difluorobenzyl)-2-(4-((4- methylthiazol-2- yl)methoxy)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one white solid, yield: 1H NMR (400 MHz, CDCl3) 5 8.01 (s, 1H), 7.85 (d, J = 9.1 Hz, 2H), 7.55 (s, 1H), 7.07 - 6.95 (m, 4H), 6.90 (s, 1H), 5.34 (s, 2H), 4.97 (s, 2H), 2.47 (s, 3H). 415.4 Example 99 Method 19 ++++ J / A / =\ n v-w0 < / - F l~n 4-(2,6-difluorobenzyl)-2-(4-((2-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3 H-1,2,4-triazol-3 - one white solid, yield:10.95 % 1H NMR (400 MHz, CDCl3) 5 7.87 - 7.83 (m, 1H), 7.50 (s, 2H), 7.31 - 7.26 (m, 1H), 7.14 (s, 1H), 7.07 - 7.00 (m, 2H), 6.94 - 6.87 (m, 2H), 4.90 (s, 2H), 2.57 (s, 3H). 401.4 Example 100: Method 20 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazole-4-carboxamide NH3in MeOH, 90 °C in a sealed tube A solution of methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2- 2023224057   06 Oct 2026 fluorophenoxy)-2-methylthiazole-4-carboxylate (332 mg, 0.697 mmol) in NH3 in MeOH (20 mL) was stirred for 16 h at 90°C in a sealed tube. The resulted mixture was diluted with water (20 mL). The resulted mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was 5 concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: column: Spherical C18 40-60 um, 40 g; Mobile phase B: ACN; Flow rate: 40 mL / min; Gradient: 35%B-60%B in 20 min; Detector: 254 nm. The fractions containing the desired product were collected at 51% B and concentrated under reduced pressure to afford the titled compound 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-10 1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazole-4-carboxamide (139 mg, 41% yield) as a white solid. LC-MS (m / z): 462.1 [M+H]+. 1H NMR (400 MHz, CD3OD) 8 8.02 (s, 1H), 7.91 (dd, J = 12.3, 2.4 Hz, 1H), 7.78 (d, J = 8.9 Hz, 1H), 7.50 - 7.41 (m, 1H), 7.35 (t, J = 8.9 Hz, 1H), 7.06 (t, J = 8.1 Hz, 2H), 5.04 (s, 2H), 2.58 (s, 3H). Examples (Compounds) 101-104 were synthesized using a similar method to that used in 15 Example 100. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 100 Method 20 +++ 1         P             H2N uTl °w"° ^^^F N     p S^N 5-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- triazol-1 -yl)-2-fluorophenoxy)- 2-methylthiazole-4- carboxamide white solid, yield:41% 1H NMR (400 MHz, CD3OD) 8 8.02 (s, 1H), 7.91 (dd, J = 12.3, 2.4 Hz, 1H), 7.78 (d, J = 8.9 Hz, 1H), 7.50 - 7.41 (m, 1H), 7.35 (t, J = 8.9 Hz, 1H), 7.06 (t, J = 8.1 Hz, 2H), 5.04 (s, 2H), 2.58 (s, 3H). 462.1 Example 101 Method 20 +++ h2n s 1 Hl ,n-O"° N         F 4-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4- white solid, yield: 8.1% 1H NMR (400 MHz, CDCl3) 8 8.57 (s, 1H), 7.98 (dd, J = 12.0, 2.4 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.59 (s, 1H), 7.42 - 7.35 (m, 2H), 7.00 (d, J = 7.7 Hz, 3H), 4.98 (s, 448.0 2023224057   06 Oct 2026 triazol-1-yl)-2- fl uorophenoxy)thi azole-5-carboxamide 2H). Example 102 Method 20 ++++ F 1-(2-fluoro-4-(3-oxo-5-phenyl- 6,7-dihydro-3 H-pyrrolo [2,1- c][1,2,4]triazol-2(5H)- yl)benzyl)-2-methyl-1H- imidazole-4-carboxamide white solid, yield: 5.2% 1H NMR (400 MHz, CDCl3) 5 7.89 (m, 2H), 7.58 (s, 1H), 7.39 (m, 3H), 7.21 (m, 3H), 5.28 (s, 1H), 5.14 (s, 2H), 3.02 (m,4H), 2.70 (s, 3H). 433.1 Example 103 Method 20 +++ o F     °       mJ A   jj   / =\ / N ^F 1-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- triazol-1 -yl)-2-fluorobenzyl)-2- methyl-1 H-imidazole-4- carboxamide white solid, yield: 10.6% 1H NMR (400 MHz, CDCl3) 5 7.90 (m, 2H), 7.58 (d, J = 20.0 Hz, 2H), 7.41 - 7.33 (m, 1H), 7.16 (m, 1H), 7.01 - 6.96 (m, 2H), 5.12 (s, 2H), 4.97 (s, 2H), 2.59 (s, 3H). 443.1 Example 104 Method 20 ++++ F       0 1  „  ji    / =\ ,N y-NH2 -N v /    ° ^F N ^F 1-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorobenzyl)-2- methyl-1 H-imidazole-5- carboxamide white solid, yield: 2.4% 1H NMR (400 MHz, CDCl3) 5 8.17 (s, 1H), 7.84 (d, J = 11.9 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.57 (s, 1H), 7.36 (m, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.97 (d, J = 8.1 Hz, 2H), 5.72 (s, 2H), 4.96 (s, 2H), 2.53 (s, 3H). 443.1 2023224057   06 Oct 2026 Example 105: Method 21 Methyl            5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2- fluorophenoxy)thiazole-2-carboxylate 5 Step 1: 2-(4-((2-aminothiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-hydroxyphenyl)-2,4-dihydro -3H-1,2,4-triazol-3-one (5.0 g, 15.56 mmol) and 5-bromothiazol-2-amine (3.1 g, 17.31 mmol) in 1,4-dioxane (50 mL) were added Cs2CO3 (12.7 g, 38.98 mmol) at rt. The resulted mixture was stirred 10 for additional 1 h at 70°C. The mixture was allowed to cool down to rt and concentrated under pressure 50 C. The resulted mixture was diluted with water (100mL). The resulted mixture was extracted with EtOAc (3*50 mL). The combined Organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 15  (CH2Cl2 / MeOH) (1:1) to afford 2-(4-((2-aminothiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (2.2 g, 33.48% yield) as a yellow solid. MS (m / z): 419.9 [M+H]+. Step 2: 2-(4-((2-bromothiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one 20 To a stirred solution of 2-(4-((2-aminothiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one (450 mg, 1.07 mmol) and Isoamyl nitrite (151 mg, 1.29 mmol) in ACN (5 mL) were added CuBr2 (287 mg, 1.29 mmol) at -10oC. The resulted mixture was stirred for additional 1 h at -10C. The mixture was allowed to warm to rt. The resulted mixture was diluted with water (30mL). The resulted mixture was extracted with EtOAc (30 mL). 25 The combined Organic layers were washed with brine (60 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (DCM / MeOH) (20:1) to afford 2-(4-((2- 2023224057   06 Oct 2026 10 15 bromothiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (70 mg, 12.15% yield) as a yellow oil. MS (m / z): 482.7 [M+H]+. Step 3: methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorophenoxy)thiazole-2-carboxylate To a stirred solution of 2-(4-((2-bromothiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl) -2,4-dihydro-3H-1,2,4-triazol-3-one (60 mg, 0.12 mmol) , Pd(OAc)2 (6 mg, 0.02 mmol) and Xantphos (22 mg 0.04 mmol) in MeOH (3 mL) was added TEA (126 mg, 0.12 mmol) at rt. The resulted mixture was stirred for additional 16 h at 70°C. The solution was filtered, and the filtrate was collected. The reaction mixture was concentrated under reduced pressure at 40C. The resulted mixture was extracted with EtOAc (3X15 mL). The combined Organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE:EtOAc) (1:1) to afford methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)thiazole-2-carboxylate (19 mg, 33.06% yield) as a white solid. LC-MS (m / z) 462.9 [M+H]+. 1H NMR (400 MHz, CDCh) 8 7.98 (dd, J = 12.0, 2.5 Hz, 1H), 7.85 (ddd, J = 9.0, 2.5, 1.6 Hz, 1H), 7.61 (s, 1H), 7.45 (s, 1H), 7.42 -7.34 (m, 1H), 7.28 (m, J = 8.8 Hz, 1H), 7.03 - 6.95 (m, 2H), 4.98 (s, 2H), 3.97 (s, 3H). Examples (Compounds) 106-108 were synthesized using a similar method to that used in Example 105. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 105 Method 21 +++ F       O n N O methyl            5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)thiazole-2- carboxylate white solid, yield:33.06 % 1H NMR (400 MHz, CDCl3) 8 7.98 (dd, J = 12.0, 2.5 Hz, 1H), 7.85 (ddd, J = 9.0, 2.5, 1.6 Hz, 1H), 7.61 (s, 1H), 7.45 (s, 1H), 7.42 - 7.34 (m, 1H), 7.28 (m, J = 8.8 Hz, 1H), 7.03 - 6.95 (m, 2H), 4.98 (s, 2H), 3.97 (s, 3H). 462.9 Example 106 ++++ Pr' A A0 oA o / white solid, yield: 12.5% 1H NMR (400 MHz, DMSO-d6) 8 8.42 (d, J = 1.2 Hz, 1H), 7.91 (dd, J = 12.4, 2.8 Hz, 1H), 7.78 (dd, J 484.0 2023224057   06 Oct 2026 Example 108 Method 21 Example 107 Method 21 Method 21 + + + + + + + + 0 C      A AA'Ox / YY^CnY< y AAf Un I3 S^N oY methyl            5-(4-(4-(2,5- difluorobenzy 1)-5 -oxo-4,5 -dihydro-1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methylthiazole-2-carboxylate F         F S^N 0^0 1 methyl     5-(2-fluoro-4-(4-(2- fluorobenzyl)-5-oxo-4.5-dihydro-1H-1,2,4-triazol-1 -yl)phenoxy)-4-methylthiazole-2-carboxylate methyl     5-(4-(4-(2-cyano-6- fluorobenzyl)-5-oxo-4.5-dihydro-1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methylthiazole-2-carboxylate white solid, yield: 74.9% white solid, yield: 73.2% ‘H NMR (400 MHz, DMSO-Jj 8 8.38 (s, 1H), 7.94 (dd, J = 12.6, 2.5 Hz, 1H), 7.76 (ddd, J = 9.1, 2.6, 1.4 Hz, 1H), 7.47 (t, J = 9.1 Hz, 1H), 7.38-7.19 (m, 3H), 4.95 (s, 2H), 3.87 (s, 3H), 2.34 (s, 3H). ‘H NMR (400 MHz, DMSO-rfj 8 8.38 (s, 1H), 7.94 (dd, J = 12.6, 2.5 Hz, 1H), 7.76 (ddd, J = 9.0, 2.6, 1.5 Hz, 1H), 7.53-7.37 (m, 3H), 7.33-7.18 (m, 2H), 4.96 (s, 2H), 3.87 (s, 3H), 2.34 (s, 3H). = 6.8, 2.0 Hz, 1H), 7.75 -7.70 (m, 1H), 7.70 - 7.60 (m, 2H), 7.45 (t, J = 92 Hz, 1H), 5.13 (s, 2H), 3.87 (s, 3H), 2.34 (s, 3H). 477.1 459.1 2023224057   06 Oct 2026 Step 1: 2-(4-((2-(3-(benzyloxy)-1-hydroxycyclobutyl)-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (5 g, 10.1 mmol) in THF (100 mL) at -78°C, 5 under N2 atmosphere, was added n-BuLi in a THF solution (4.1 mL, 2.5M, 10.1 mmol). Then the mixture solution was stirred at -78°C for 20 min. To the reaction mixture, was added 3-(benzyloxy) cyclobutan-1-one (2.7 g, 15.2 mmol), and the resulted mixture solution was stirred at -78°C for 100 min. The reaction was quenched with saturation NH4CI solution and was diluted with EtOAc (100 mL), and then the resulted solution was washed with water (30 mL) and brine 10   (30 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (2:1) to afford 2-(4-((2-(3-(benzyloxy)-1-hydroxycyclobutyl)-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (2.4 g, 40.0% yield) as a yellow solid. MS (m / z): 595.1 [M+H]+. 1H NMR (400 MHz, CDCk) 8 7.90 15 (dd, J = 12.0, 2.4 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 7.44 - 7.27 (m, 6H), 7.09 -6.92 (m, 3H), 4.97 (s, 2H), 4.48 (s, 2H), 4.13 (p, J = 6.4 Hz, 1H), 3.06 - 2.96 (m, 2H), 2.53 -2.43 (m, 2H), 2.29 (s, 3H). Step 2:      2-(4-((2-(3-(benzyloxy)-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy)-3- fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 20 To a stirred solution of 2-(4-((2-(3-(benzyloxy)-1-hydroxycyclobutyl)-4-methylthiazol-5-yl) oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (2.4 g, 4.04 mmol) in DCM (30 mL), was added Diethylamino sulfur trifluoride (0.78 g, 4.85 mmol) and the mixture solution was stirred at rt for 1 h. The resulted mixture was diluted with water (20 mL). The resulted mixture was extracted with DCM (3*20 mL). The combined organic layers 25 were washed with brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (2:1) to afford 2-(4-((2-(3-(benzyloxy)-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (1.5 g, 61.9% yield) as a white solid. MS (m / z): 597.2 [M+H]+. 30  1H NMR (400 MHz, CDCl3) 8 7.90 (dd, J = 12.0, 2.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.58 (s, 1H), 7.44 - 7.28 (m, 6H), 7.06 - 6.94 (m, 3H), 4.97 (s, 2H), 4.49 (s, 2H), 4.47 - 4.41 (m, 1H), 2.94 - 2.66 (m, 4H), 2.31 (s, 3H). 2023224057   06 Oct 2026 Step 3: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(1-fluoro-3-hydroxycyclobutyl) -4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 2-(4-((2-(3-(benzyloxy)-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy) -3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (1.5 g, 2.5 mmol) in DCM (20 mL) at -78°C, under N2 atmosphere, was added BBn in DCM solution (3.0 mL, 1M, 2.0 mmol). Then the mixture solution was stirred at -78C for 1h. The reaction was quenched with a saturated NaHCO3 solution and was diluted with DCM (20 mL), and the resulted solution was washed with water (20 mL) and brine (20 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (1:1) to afford 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(1-fluoro-3-hydroxycyclobutyl)-4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (600 mg, 47.4% yield) as a white solid. MS (m / z): 507.2 [M+H]+. 1H NMR (400 MHz, CDCI3) 8 7.98 - 7.87 (m, 1H), 7.73 (t, J = 10.8 Hz, 1H), 7.58 (d, J = 2.8 Hz, 1H), 7.44 - 7.32 (m, 1H), 7.12 - 6.95 (m, 3H), 4.97 (s, 2H), 4.60 - 4.29 (m, 1H), 3.25 - 2.95 (m, 2H), 2.88 - 2.57 (m, 2H), 2.32 (d, J = 26.8 Hz, 3H). Step 4: 2-(4-((2-(3-azido-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy)-3-fluorophenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(1-fluoro-3-hydroxycyclobutyl) -4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (200 mg, 0.40 mmol) in THF (10 mL) at 0C, under N2 atmosphere, wad successively added PPh3 (157 mg, 0.60 mmol) and DIAD (121 mg, 0.60 mmol). Then the mixture solution was stirred at 0C for 15 min. The reaction mixture was then added Diphenyl- phosphoryl azide (165 mg, 0.60 mmol), and stirred at rt for 16 h. The reaction was quenched with a saturated NaHCO3 solution and was diluted with EtOAc (10 mL), the resulted solution was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (2:1) to afford 2-(4-((2-(3-azido-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy)-3- fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one(130 mg, 61.2% yield) as a white solid. MS (m / z): 531.2[M+H]+. Step 5: 2-(4-((2-(3-amino-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy)-3-fluorophenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 2-(4-((2-(3-azido-1-fluorocyclobutyl)-4-methylthiazol-5-yl)oxy) -3- 142 - 2023224057   06 Oct 2026 fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (110 mg, 0.22 mmol) in THF / H2O mixture solvent (10 / 1, 10 mL), under N2 atmosphere, was added PPh3 (86 mg, 0.33 mmol). The mixture solution was stirred at rt for 3 h. The resulted mixture was diluted with EtOAc (10 mL), the resulted solution was washed with water (10 mL) and brine (10 mL), dried 5 over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (DCM / MeOH) (15:1) to afford the titled compound as a white solid (60 mg, 54.1% yield) as a white solid. MS (m / z): 506.2 [M+H]+. 1H NMR (400 MHz, CDCI3) 8 7.90 (d, J = 12.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 7.44 - 7.30 (m, 1H), 7.06 - 6.92 (m, 3H), 4.97 (s, 2H), 3.51-3,38 (m, 1H), 3.18 - 10 2.81 (m, 2H), 2.65 - 2.32 (m, 2H), 2.29 (s, 3H). Examples (Compounds) 110-112 were synthesized using a similar method to that used in Example 109. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 109 Method 22 ++++ nZXv—nh2 N 2-(4-((2-(3-amino-1- fluorocyclobutyl)-4- methylthiazol-5-yl)oxy)-3- fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:54.1%) 1H NMR (400 MHz, CDCl3) 8 7.90 (d, J = 12.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 7.44 - 7.30 (m, 1H), 7.06 - 6.92 (m, 3H), 4.97 (s, 2H), 3.51-3,38 (m, 1H), 3.18 - 2.81 (m, 2H), 2.65 - 2.32 (m, 2H), 2.29 (s, 3H). 506.2 Example 110 Method 22 ++++ n4XNoh nV n vf° ^F N 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((2-(1-fluoro-3- hydroxycyclobutyl)-4- methylthiazol-5-yl)oxy)phenyl)- 2,4-dihydro-3 H-1,2,4-triazol-3 - white solid, yield:47.4% 1H NMR (400 MHz, CDCl3) 8 7.98 -7.87 (m, 1H), 7.73 (t, J = 10.8 Hz, 1H), 7.58 (d, J = 2.8 Hz, 1H), 7.44 -7.32 (m, 1H), 7.12 - 6.95 (m, 3H), 4.97 (s, 2H), 4.60 - 4.29 (m, 1H), 3.25 - 2.95 (m, 2H), 2.88 - 2.57 (m, 2H), 2.32 (d, J = 26.8 Hz, 3H). 507.2 2023224057   06 Oct 2026 one Example 111 Method 22 ++++ OBn F     0     Xx I 6x><P 2-(4-((2-(3-(benzyloxy)-1 - fluorocyclobutyl)-4- methylthiazol-5-yl)oxy)-3- fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:61.9% 1H NMR (400 MHz, CDCl3) 5 7.90 (dd, J = 12.0, 2.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.58 (s, 1H), 7.44 -7.28 (m, 6H), 7.06 - 6.94 (m, 3H), 4.97 (s, 2H), 4.49 (s, 2H), 4.47 - 4.41 (m, 1H), 2.94 - 2.66 (m, 4H), 2.31 (s, 3H). 597.2 Example 112 Method 22 +++ HO. / \ OBn F 0 XJ 2-(4-((2-(3-(benzyloxy)-1 - hydroxycyclobutyl)-4- methylthiazol-5-yl)oxy)-3- fluorophenyl)-4-(2,6- difluorobenzyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:40% 1H NMR (400 MHz, CDCl3) 5 7.90 (dd, J = 12.0, 2.4 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 7.44 -7.27 (m, 6H), 7.09 - 6.92 (m, 3H), 4.97 (s, 2H), 4.48 (s, 2H), 4.13 (p, J = 6.4 Hz, 1H), 3.06 - 2.96 (m, 2H), 2.53 - 2.43 (m, 2H), 2.29 (s, 3H). 595.1 Example 113: Method 23 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)- 4-methylthiazol-2-yl) cyclobutane-1-carboxamide Step 1: methyl 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2- fluorophenoxy)-4-methylthiazol-2-yl)-3-hydroxycyclobutane-1-carboxylate To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl) oxy)-3-fluorophenyl)-4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (800 mg, 1.61 mmol) in THF (10 mL) at - 2023224057   06 Oct 2026 78°C, under N2 atmosphere, was added n-BuLi in a THF solution (0.64 mL, 2.5M, 1.61 mmol). Then the mixture solution was stirred at -78°C for 20 min. The reaction mixture was added methyl 3-oxocyclobutane-1-carboxylate (309 mg, 2.42 mmol), and stirred at -78°C for 100 min. The reaction was quenched with a saturated NH4Cl solution and was diluted with EtOAc (20 mL), the resulted solution was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (2:1) to afford methyl 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)-3-hydroxycyclobutane-1-carboxylate (350 mg, 39.8% yield) as a yellow solid. MS (m / z): 547.1[M+H]+. Step 2:   3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)   -2- fluorophenoxy)-4-methylthiazol-2-yl) cyclobutane-1-carboxylic acid A solution of methyl 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorophenoxy)-4-methylthiazol-2-yl)-3-hydroxycyclobutane-1-carboxylate (150 mg, 0.27 mmol) in TFA / TES (3 / 1, 5 mL) was stirred at 80^ for O / N (overnight). The resulted mixture was diluted with a saturated NaHCO3 solution (10 mL). The resulted mixture was extracted with DCM (3*10 mL). The combined Organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (DCM / MeOH) (15:1) to afford 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4- triazol-1-yl)-2-fluorophenoxy) -4-methylthiazol-2-yl) cyclobutane-1-carboxylic acid (80 mg, 57.4% yield) as a white solid.MS (m / z): 517.2 [M+H]+. Step 3:   3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)   -2- fluorophenoxy)-4-methylthiazol-2-yl) cyclobutane-1-carboxamide A solution of 3-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4- triazol-1-yl)-2-fluorophenoxy) -4-methylthiazol-2-yl) cyclobutane-1-carboxylic acid (80 mg, 0.16 mmol), Ammonium chloride (13 mg, 0.24 mmol), HATU (93 mg, 0.16 mmol) and DIEA (31 mg, 0.24 mmol) in DMF (5 mL) was under N2 atmosphere and stirred at rt for 1 h. The resulted mixture was diluted with EtOAc (10 mL), the solution was washed with water (3 * 5 mL) and brine (5 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (DCM / MeOH = 10:1) to afford the titled compound as a white solid (25.5 mg, 30.9% yield) as - 145 - 2023224057   06 Oct 2026 a white solid. MS (m / z): 516.2 [M+H]+.1H NMR (400 MHz, CDCI3) 8 7.97 (t, J = 13.2 Hz, 1H), 7.87-7.76 (m, 1H), 7.60 (d, J = 4.4 Hz, 1H), 7.46-7.28 (m, 1H), 7.19 -6.93 (m, 3H), 4.98 (s, 2H), 4.03 (s, 1H), 3.38-3.09 (m, 1H), 2.98-2.72 (m, 4H), 2.50 (d, J = 14.0 Hz, 3H). Examples (Compounds) 114-115 were synthesized using a similar method to that used in 5 Example 113. Compound No. Method Activity Structure and Name Appearan ce and Yield 1H NMR Data MS(m / z) [M+H]+ Example 113 Method 23 ++++ 0 N-.X-J 3-(5-(4-(4-(2,6-difluorobenzyl)- 5 -oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4- methylthiazol-2-yl)cyclobutane- 1-carboxamide white solid, yield:30.9 % 1H NMR (400 MHz, CDCl3) 8 7.97 (t, J = 13.2 Hz, 1H), 7.87-7.76 (m, 1H), 7.60 (d, J = 4.4 Hz, 1H), 7.467.28 (m, 1H), 7.19 -6.93 (m, 3H), 4.98 (s, 2H), 4.03 (s, 1H), 3.38-3.09 (m, 1H), 2.98-2.72 (m, 4H), 2.50 (d, J = 14.0 Hz, 3H). 516.2 Example 114 Method 23 single unknown stereoisomer ++++ Q o / x _ / =\Xs xNx° F (S)-2-(3-fluoro-4-((2-(3- hydroxyoxetan-3-yl)-4- methylthiazol-5-yl)oxy)phenyl)- 5 -phenyl-2,5,6,7-tetrahydro-3H- pyrrolo[2,1-c][1,2,4]triazol-3-one white solid, yield: 1H NMR (400 MHz, CDCl3) 8 7.89 (dd, J = 12.4, 2.0 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.45-7.25 (m, 5H), 7.06-6.99 (m, 1H), 5.32-5.34 (m, 1H), 4.92 (d, J = 6.8 Hz, 2H), 4.86 (d, J = 6.8 Hz, 2H), 3.15-2.86 (m, 4H), 2.33 (s, 3H). 481.2 Example 115 Method 23 ++ F       o N / X0 1 nh2 2-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-3-fluorophenoxy)- 1,4-dimethyl- 1H-imidazole-5- white solid, yield:40.1 % 1H NMR (400 MHz, DMSO-d6) 8 8.27 (s, 1H), 7.56 (t, J = 8.7 Hz, 1H), 7.53 - 7.42 (m, 2H), 7.24 (br, 2H), 7.21 - 7.12 (m, 3H), 4.97 (s, 2H), 3.59 (s, 3H), 2.23 (s, 3H). 459.1 2023224057   06 Oct 2026 carboxamide Example 116: Method 24 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)- 4-methylthiazol-2-yl)-2,2-difluoroacetamide Step 1: ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorophenoxy)-4-methylthiazol-2-yl)-2-oxoacetate To a stirred solution of 2-(4-((2-bromo-4-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4- (2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (500 mg, 1.01 mmol) in THF (10 mL) at -10  78°C, under N2 atmosphere, added n-BuLi in THF solution (0.41 mL, 2.5M, 1.01 mmol). Then the mixture solution was stirred at -78°C for 20 min. The reaction mixture was added diethyl oxalate (221 mg, 1.52 mmol), and stirred at -78°C for 100 min. The reaction was quenched with saturated NH4Cl solution and was diluted with EtOAc (10 mL), the resulted solution was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the 15 filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (2:1) to afford ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)-2-oxoacetate (200 mg, 38.2% yield) as a white solid. MS (m / z): 519.1 [M+H]+. Step 2: ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-20 fluorophenoxy)-4-methylthiazol-2-yl)-2,2-difluoroacetate To a stirred solution of ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5- dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)-2-oxoacetate (150 mg, 0.29 mmol) in DCM (10 mL), was added Diethylamino sulfur trifluoride (140 mg, 0.87 mmol) and the reaction mixture was stirred at rt for 16 h. The resulted mixture was diluted with water (10 mL). The 25 resulted mixture was extracted with DCM (3*10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column 2023224057   06 Oct 2026 10 chromatography, eluted with (PE / EtOAc) (2:1) to afford ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)-2,2-difluoroacetate (100 mg, 63.9% yield) as a white solid.MS (m / z): 541.2 [M+H]+. Step 3:   2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)   -2- fluorophenoxy)-4-methylthiazol-2-yl)-2,2-difluoroacetamide A solution of ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorophenoxy)-4-methylthiazol-2-yl)-2,2-difluoroacetate (50 mg, 0.09 mmol) in NH3 in MeOH solution (5 mL, 7M) was stirred at 50°C for 16 h. The resulted solution was allowed to cool down to r.t. and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM / MeOH = 20 / 1) to afford the titled compound as a white solid (25 mg, yield: 54.4%). MS (m / z): 512.2 [M+H]+.1H NMR (400 MHz, CDCl3) 8 7.95 (dd, J = 12.0, 2.4 Hz, 1H), 7.77 (d, J = 9.2 Hz, 1H), 7.59 (s, 1H), 7.45-7.29 (m, 1H), 7.15-6.91 (m, 3H), 4.97 (s, 2H), 2.36 (s, 3H). Examples (compounds) 117-118 were synthesized using a similar method to that used in Example 116. 15 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 116 Method 24 ++++ F       O __7 n nA2t°vs o N7> 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)-2,2-difluoroacetamide white solid, yield:54.4% 1H NMR (400 MHz, CDCla) 8 7.95 (dd, J = 12.0, 2.4 Hz, 1H), 7.77 (d, J = 9.2 Hz, 1H), 7.59 (s, 1H), 7.457.29 (m, 1H), 7.15-6.91 (m, 3H), 4.97 (s, 2H), 2.36 (s, 3H). 512.2 Example 117 Method 24 +++ F      O __ / N \\ o ethyl              2-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro- 1H-1,2,4-triazol-1 -yl)-2- fluorophenoxy)-4-methylthiazol- 2-yl)-2-oxoacetate white solid, yield:38.2% NA 519.1 2023224057   06 Oct 2026 Example 118 Method 24 +++ F         O __,F ^F UN nVf ethyl              2-(5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5- dihydro- 1H-1,2,4-triazol-1 -yl)-2- fluorophenoxy)^-methylthiazol- 2-yl)-2,2-difluoroacetate white solid, yield:63.9% NA 541.2 Example 119: Method 25 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(3-hydroxy-3-methylcyclobutyl)-4-methylthiazol- 5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one Step 1: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-methyl-2-(3-oxocyclobut-1-en-1-yl) thiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(1-fluoro-3-hydroxycyclobutyl) -4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (300 mg, 0.59 mmol) in 10 DCM (10 mL), was added pyridinium chlorochromate (153 mg, 0.71 mmol), and the mixture solution was stirred at rt for 2 hrs. The reaction was quenched with saturated NH4Cl solution and was diluted with DCM (20 mL), the resulted solution was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 15 (PE / EtOAc = 2:1) to afford 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-methyl-2-(3-oxocyclobut-1-en-1-yl)thiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (160 mg, 56.0% yield) as a white solid. MS (m / z): 485.1[M+H]+. Step 2: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(3-hydroxy-3-methylcyclobut-1-en-1-yl) -4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 20 To a stirred solution of ethyl 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-4-methylthiazol-2-yl)-2-oxoacetate (160 mg, 0.33 mmol) in THF 2023224057   06 Oct 2026 (10 mL) at 0^, under N2 atmosphere, was added MeMgCl in a THF solution (0.2 mL, 3 M, 0.66 mmol). The reaction was quenched with a saturated NH4Cl solution and was diluted with EtOAc (20 mL), the resulted solution was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The 5 residue was purified by silica gel column chromatography, eluted with (PE / EtOAc) (1:1) to afford 4-(2,6-difluorobenzyl)-2-(3-fluoro-4- ((2-(3-hydroxy-3-methylcyclobut-1-en-1-yl)-4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (100 mg, 60.6% yield) as a white solid. MS (m / z): 501.2 [M+H]+. Step 3: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(3-hydroxy-3-methylcyclobutyl) -410 methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((2-(3-hydroxy-3-methylcyclobut -1-en-1-yl)-4-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (100 mg, 0.20 mmol) in MeOH (10 mL) was added Pd / C (10%, 20 mg) under H2 atmosphere and the reaction solution was stirred at rt for 4 hrs. The resulted solution was filtrated and concentrated under 15 reduced pressure. The residue was purified by TLC. (DCM / MeOH) (30 / 1) to afford the titled compound product-1 (50 mg, 49.8% yield) as a white solid. MS (m / z): 503.2 [M+H]+.1H NMR (400 MHz, CDCI3) 8 7.92 (d, J = 12.0 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.58 (s, 1H), 7.43-7.32 (m, 1H), 7.09-6.96 (m, 3H), 4.97 (s, 2H), 4.06-3.92 (m, 1H), 2.62 (t, J = 9.2 Hz, 2H), 2.53-2.45 (m, 2H), 2.39 (s, 3H), 1.44 (s, 3H). 20 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 119 Method 25 ++++ OH n^x^-7 N 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((2-(3-hydroxy-3- methylcyclobutyl)-4- methylthiazol-5-yl)oxy)phenyl)- 2,4-dihydro-3 H-1,2,4-triazol-3 - one white solid, yield:49.8% 1H NMR (400 MHz, CDCl3) 8 7.92 (d, J = 12.0 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.58 (s, 1H), 7.437.32 (m, 1H), 7.09-6.96 (m, 3H), 4.97 (s, 2H), 4.06-3.92 (m, 1H), 2.62 (t, J = 9.2 Hz, 2H), 2.53-2.45 (m, 2H), 2.39 (s, 3H), 1.44 (s, 3H). 503.2 2023224057   06 Oct 2026 Example 120: Method 26 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazole-4-carbonitrile To a stirred solution of 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1- yl)-2-fluorophenoxy)-2-methylthiazole-4-carboxamide (139 mg, 0.301 mmol) and TEA (91mg, 0.904 mmol) in DCM (10 mL) were added TFAA (127 mg, 0.602 mmol). The resulted mixture was stirred for additional 1 h at 0°C. The resulted mixture was diluted with water (10 mL). The 10 resulted mixture was extracted with EtOAc (3*20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: column: Spherical C18 40-60 um, 40 g; Mobile phase B: ACN; Flow rate: 40 mL / min; Gradient: 35%B-60%B in 20 min; Detector: 254 nm. The 15  fractions containing the desired product were collected at 51% B and concentrated under reduced pressure to afford the titled product (9.1 mg, 6% yield) as a white solid. LC-MS (m / z): 444.0 [M+H]+. 1H NMR (400 MHz, DMSO) 8 8.39 (s, 1H), 7.96 (dd, J = 12.5, 2.4 Hz, 1H), 7.80 (d, J = 9.1 Hz, 1H), 7.70 (t, J = 8.9 Hz, 1H), 7.55 - 7.43 (m, 1H), 7.16 (t, J = 8.1 Hz, 2H), 4.99 (s, 2H), 2.58 (s, 3H). 20 Examples (Compounds) 121-125 were synthesized using a similar method to that used in Example 120. Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Method 26 Example 120 ++++ F          O        ,F OTNA<y°ys n jt x cn^n^ 5-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- white solid, yield: 6% 1H NMR (400 MHz, DMSO-d6) 8 8.39 (s, 1H), 7.96 (dd, J = 12.5, 2.4 Hz, 1H), 7.80 (d, J = 9.1 Hz, 1H), 7.70 (t, J = 8.9 Hz, 1H), 7.55 -7.43 (m, 1H), 7.16 (t, J = 8.1 Hz, 444.0 2023224057   06 Oct 2026 triazol-1 -yl)-2-fluorophenoxy)- 2-methylthiazole-4-carbonitrile 2H), 4.99 (s, 2H), 2.58 (s, 3H). Example 121 Method 26 +++ F     O    f OoA-ChV N     -nOkcn 2-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- triazol-1 -yl)-2-fluorophenoxy)- 1 -methyl-1 H-imidazole-4- carbonitrile white solid, yield:65.1% 1H NMR (400 MHz, DMSO-d6) 5 8.37 (s, 1H), 7.95 (s, 1H), 7.90 (dd, J = 12.4, 2.4 Hz, 1H), 7.77 (d, J = 9.1 Hz, 1H), 7.61 (t, J = 8.9 Hz, 1H), 7.53 - 7.44 (m, 1H), 7.16 (t, J = 8.1 Hz, 2H), 4.99 (s, 2H), 3.64 (s, 3H). 427.0 Example 122 Method 26 ++++ F        O __ / F -"S^CN 1-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4-triazol-1 -yl)-2-fluorobenzyl)- 2,5 -dimethyl- 1H-imidazole-4-carbonitrile white solid, yield: 9.0% 1H NMR (400 MHz, CDCl3) 5 7.89 (m, 1H), 7.81 (m, 1H), 7.58 (s, 1H), 7.40 - 7.34 (m, 1H), 7.09 (m, 1H), 6.98 (m, 2H), 5.15 (s, 2H), 4.97 (s, 2H), 2.39 (s, 3H), 2.35 (s, 3H). 439.1 Example 123 Method 26 +++ 1         0   ,-( 1-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- triazol-1 -yl)-2-fluorobenzyl)- 2,4-dimethyl- 1H-imidazole-5- carbonitrile white solid, yield: 1.9% 1H NMR (400 MHz, CDCl3) 5 7.91 (m, 1H), 7.76 (m, 1H), 7.59 (s, 1H), 7.41 - 7.34 (m, 1H), 6.99 (m, 2H), 6.69 (m, 1H), 5.06 (s, 2H), 4.97 (s, 2H), 2.35 (s, 3H), 2.29 (s, 3H). 439.1 Example 124 Method 26 ++++ / xXN F       O 1-(4-(4-(2,6-difluorobenzyl)-5- oxo-4,5 -dihydro- 1H-1,2,4- triazol-1 -yl)-2-fluorobenzyl)- 2,5 -dimethyl- 1H-pyrrole-3 - carbonitrile white solid, yield: 9% 1H   NMR (400 MHz, CD3OD_SPE) 5 8.01 (s, 1H), 7.79 (dd, J = 12.0, 2.0 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.05 (t, J = 8.1 Hz, 2H), 6.59 (t, J = 8.4 Hz, 1H), 6.13 (s, 1H), 5.19 (s, 2H), 5.03 (s, 2H), 2.29 (s, 3H), 2.13 (s, 3H). 438.1 2023224057   06 Oct 2026 Example 126: Method 27 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(2-hydroxypropan-2-yl)-2-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one o Step 1: methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) -2-fluorophenoxy)-2-methylthiazole-4-carboxylate To a stirred solution of 2,4-dichloro-5-fluoropyrimidine (300 mg, 0.934 mmol) and methyl 5-bromo-2-methylthiazole-4-carboxylate (220 mg, 0.934 mmol) in DMF (15 mL) was added 10  K2CO3 (194 mg, 1.40 mmol). The resulted mixture was stirred for additional 16 h at 110°C. The mixture was allowed to cool down to rt. The resulted mixture was diluted with water (30 mL). The resulted mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column 15 chromatography, eluted with (PE:EtOAc) (1:1) to afford methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazole-4-carboxylate(210 mg, 42.5% yield) as a yellow solid. MS (m / z): 477.0 [M+H]+. Step 2: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(2-hydroxypropan-2-yl) -2-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 20 To a stirred solution of methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazole-4-carboxylate(60 mg, 0.126 mmol) in THF (10 mL) were added CH3MgBr (1.26 mL, 1.26 mmol). The resulted mixture was stirred for 2023224057   06 Oct 2026 10 additional 1 h at 60°C. The resulted mixture was diluted with water (20 mL). The resulted mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: column: Spherical C18 40-60 um, 40 g; Mobile phase B: ACN; Flow rate: 40 mL / min; Gradient: 35%B-60%B in 20 min; Detector: 254 nm. The fractions containing the desired product were collected at 51% B and concentrated under reduced pressure to afford the titled compound 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(2-hydroxypropan-2-yl) -2-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (9.3 mg, 15% yield) as a white solid. LC-MS (m / z): 477.0 [M+H]+. 1H NMR (400 MHz, CD3OD) 8 8.00 (s, 1H), 7.84 (dd, J = 12.4, 2.4 Hz, 1H), 7.70 (dd, J = 9.1, 1.6 Hz, 1H), 7.51 - 7.39 (m, 1H), 7.19 (t, J = 9.0 Hz, 1H), 7.06 (t, J = 8.1 Hz, 2H), 5.03 (s, 2H), 2.57 (s, 3H), 1.57 (s, 6H). Examples (Compounds) 127-137 were synthesized using a similar method to that used in Example 126. 15 Compound No. Method Activity Structure and Name Appearance and Yield 1H NMR Data MS(m / z) [M+H]+ Example 126 Method 27 +++ J / =\    \£H nCN(2-N"v / “'w / ~N        S^pN 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(2-hydroxypropan- 2-yl)-2-methylthiazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one yellow solid, yield: 15% 1H NMR (400 MHz, CD3OD) 8 8.00 (s, 1H), 7.84 (dd, J = 12.4, 2.4 Hz, 1H), 7.70 (dd, J = 9.1, 1.6 Hz, 1H), 7.51 - 7.39 (m, 1H), 7.19 (t, J = 9.0 Hz, 1H), 7.06 (t, J = 8.1 Hz, 2H), 5.03 (s, 2H), 2.57 (s, 3H), 1.57 (s, 6H). 477.0 Example 127 Method 27 ++++ N     F S^N methyl            5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 -yl)- yellow solid, yield: 42.5% NA 477.0 2023224057   06 Oct 2026 2-fluorophenoxy)-2- methylthiazole-4-carboxylate Example 128 Method 27 +++ F       O              / 1       JJ / =\      °\ ^F      rA methyl            5-(4-(4-(2,6- difluorobenzyl)-5-oxo-4,5 - dihydro- 1H-1,2,4-triazol-1 -yl)- 2-fluorophenoxy)thiazole-4- carboxylate yellow solid, yield: 42.6% 1H   NMR (400 MHz, CD3OD_SPE) 8 8.53 (s, 1H), 8.03 (s, 1H), 7.96 (dd, J = 12.3, 2.5 Hz, 1H), 7.85 - 7.76 (m, 1H), 7.56 -7.35 (m, 2H), 7.06 (t, J = 8.1 Hz, 2H), 5.04 (s, 2H), 3.88 (s, 3H). 463.0 Example 129 Method 27 +++ ,N%-0H F 2-((1-(3-fluoro-4-((2-(2- hydroxypropan-2-yl)-4- methylthiazol-5-yl)oxy)phenyl)- 5 -oxo-1,5 -dihydro-4H-1,2,4- triazol-4- yl)methyl)nicotinonitrile off-white solid, yield: 11.6% 1H NMR (400 MHz, CDCl3) 8 8.76 (d, J = 2.4 Hz, 1H), 8.05 -7.98 (m, 1H), 7.95- 7.84 (m, 1H), 7.75 (d, J = 5.2 Hz, 2H), 7.397.44 (m, 1H), 7.03 (t, J = 8.8 Hz, 1H), 5.25 (s, 2H), 2.29 (s, 3H), 1.64 (s, 6H). 467.5 Example 130 Method 27 ++++ O       N%r0H 0     —N 7 x / "NX      ' F 2-(3-fluoro-4-((3-(2- hydroxypropan-2-yl)-1 -methyl- 1 H-pyrazol-5-yl)oxy)phenyl)- 5 -phenyl-2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3- one off-white solid, yield: 10.6% 1H NMR (400 MHz, CDCl3) 8 7.94 (d, J = 12.4 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.343-7.31 (m, 3H), 7.23 (d, J = 8.2 Hz, 4H), 5.44 (s, 1H), 5.32-5.26 (m, 1H), 3.90 (d, J = 13.1 Hz, 3H), 3.16 - 2.87 (m, 4H), 1.55 (s, 6H). 450.4 Example 131 Method 27 + Loh Ap ’A-IV0 ^F " 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((4-(2-hydroxypropan- off-white solid, yield:30.0% 1H NMR (400 MHz, MeOD) 8 8.47 (s, 1H), 8.01 (s, 1H), 7.88 (dd, J = 12.3, 2.4 Hz, 1H), 7.76 (d, J = 9.1 Hz, 1H), 7.49 - 7.39 (m, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.06 (t, J 460.1 2023224057   06 Oct 2026 2-yl)-1 -methyl-1 H-imidazol-2- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one = 8.1 Hz, 2H), 6.70 (s, 1H), 5.03 (s, 2H), 3.54 (s, 3H), 1.43 (s, 6H). Example 132 Method 27 ++ F       O N \ nLY°H 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((5-(2-hydroxypropan- 2-yl)-1 -methyl-1 H-imidazol-2- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:26.2 % 1H NMR (400 MHz, CDCl3) 5 7.97 (s, 1H), 7.84 (dd, J = 11.1,6.5 Hz, 1H), 7.57 (s, 1H), 7.35 (m, 1H), 7.25 (s, 1H), 6.98 (dd, J = 9.2, 6.6 Hz, 3H), 4.95 (s, 2H), 3.83 (s, 3H), 1.63 (s, 6H). 460.1 Example 133 Method 27 +++ OH S 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((2-(2-hydroxypropan- 2-yl)-1,4-dimethyl-1H- imidazol-5-yl)oxy)phenyl)-2,4- dihydro-3 H-1,2,4-triazol-3 -one white solid, yield:4.2% 1H NMR (400 MHz, CDCl3) 8 7.96 (dd, J = 12.3, 2.3 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.58 (s, 1H), 7.37 (t, J = 6.7 Hz, 1H), 6.99 (t, J = 8.0 Hz, 3H), 4.97 (s, 2H), 3.73 (s, 3H), 2.14 (s,3H), 1.72 (s, 6H). 474.1 Example 134 Method 27 ++++ Loh F       O iiV'YnYY0 ^F N‘ Y= 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((3-(2-hydroxypropan- 2-yl)-1 -methyl-1 H-pyrazol-5- yl)oxy)phenyl)-2,4-dihydro-3H- 1,2,4-triazol-3-one white solid, yield:45.6% 1H NMR (400 MHz, CDCl3) 8 7.99 - 7.89 (m, 1H), 7.87 - 7.77 (m, 1H), 7.58 (d, J = 9.5 Hz, 1H), 7.42 - 7.34 (m, 1H), 7.26 - 7.21 (m, 1H), 7.03 - 6.96 (m, 2H), 6.06 (d, J = 6.1 Hz, 1H), 5.34 (s, 1H), 4.97 (d, J = 7.4 Hz, 2H), 3.83 (s, 3H), 1.56 (s, 3H), 1.26 (s, 3H). 460.4 Example 135 Method 27 ++ J o -^NxLr0H LxkpY F 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((4-(2-hydroxypropan- 2-yl)-2,5-dimethyl-1H- white solid, yield: 4.5% 1H NMR (400 MHz, CDCl3) 8 7.90 (m, 1H), 7.75 (m, 1H), 7.59 (s, 1H), 7.37 (m, 1H), 6.98 (m, 3H), 6.69 (m, 1H), 5.06 (s, 2H), 4.97 (s, 2H), 2.47 (s, 3H), 2.21 (s, 3H), 1.62 (s, 6H). 472.1 2023224057   06 Oct 2026 imidazol-1 -yl)methyl)phenyl)- 2,4-dihydro-3 H-1,2,4-triazol-3 - one Example 136 Method 27 ++ 0 X o      X oh WX F 2-(3-fluoro-4-((4-(2- hydroxypropan-2-yl)-2-methyl- 1H-imidazol-1- yl)methyl)phenyl)- 5 -phenyl- 2,5,6,7-tetrahydro-3H- pyrrolo[2,1-c][1,2,4]triazol-3- one white solid, yield: 9.4% 1H NMR (400 MHz, CDCl3) 5 7.83 (m, 2H), 7.41 - 7.35 (m, 3H), 7.24 (s, 2H), 7.09 (m, 1H), 6.67 (s, 1H), 5.30 - 5.26 (m, 1H), 5.02 (s, 2H), 3.12 - 2.88 (m, 4H), 2.51 (s, 3H), 1.57 (s, 6H). 448.2 Example 137 Method 27 ++ Loh n LLr 4-(2,6-difluorobenzyl)-2-(3- fluoro-4-((4-(2-hydroxypropan- 2-yl)-2-methyl-1 H-imidazol-1 - yl)methyl)phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one white solid, yield: 10.2% 1H NMR (400 MHz, CDCl3) 5 7.94 - 7.86 (m, 2H), 7.61 (s, 1H), 7.37 (m, 1H), 7.18 (m, 1H), 6.99 (m, 2H), 6.67 (s, 1H), 5.06 (s, 2H), 4.98 (s, 2H), 2.61 (s, 3H), 1.59 (s, 6H). 458.2 Example 138: Method 28 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)- 2-methylthiazol-4-yl)acetamide Step 1: 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(hydroxymethyl)-2-methylthiazol -5- yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 2023224057   06 Oct 2026 To a stirred solution of methyl 5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazole-4-carboxylate (323 mg, 0.678 mmol) in THF (10 mL) were added LiAlH4 (51.5 mg, 1.36 mmol). The resulted mixture was stirred for additional 2 h at 25C. The resulted mixture was quenched with water (0.5 mL), 10% NaOH solution (1.5 mL) and water (0.5 mL). The resulted mixture was filtered with celite and extracted with EtOAc (3*30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE:EtOAc) (1:1) to afford 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(hydroxymethyl)-2- methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (167 mg, 49.4% yield) as a yellow solid. MS (m / z): 449.1 [M+H]+. Step 2: 2-(4-((4-(chloromethyl)-2-methylthiazol-5-yl)oxy)-3-fluorophenyl)-4- (2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one To a stirred solution of 4-(2,6-difluorobenzyl)-2-(3-fluoro-4-((4-(hydroxymethyl) -2-methylthiazol-5-yl)oxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (167 mg, 0.372 mmol) in DCM (10 mL) was added SOCl2 (133 mg, 1.12 mmol). The resulted mixture was stirred for additional 1 h at 25C. The resulted mixture was adjusted to pH 8 with NaHCO3 and extracted with EtOAc (3*30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE:EtOAc) (10:1) to afford 2-(4-((4-(chloromethyl)-2-methylthiazol-5-yl)oxy)-3-fluorophenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (132 g, 68% yield) as a yellow oil. MS (m / z): 467.0 [M+H]+. Step 3:   2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)   -2- fluorophenoxy)-2-methylthiazol-4-yl)acetonitrile To a stirred solution of 2-(4-((4-(chloromethyl)-2-methylthiazol-5-yl)oxy)-3-fluorophenyl) -4-(2,6-difluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (132 mg, 0.283 mmol), were added TMSCN (42 mg, 0.424 mmol) and Cs2CO3 (184 mg, 0.565 mmol) in MeCN (10 mL). The resulted mixture was stirred for additional 2 h at 65°C. The resulted mixture was diluted with water (10 mL). The resulted mixture was extracted with EtOAc (3*20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column - 158 - 2023224057   06 Oct 2026 chromatography, eluted with (PE:EtOAc) (2:1) to afford 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-fluorophenoxy)-2-methylthiazol-4-yl)acetonitrile (89 mg, 62% yield) as a yellow solid. LC-MS (m / z): 458.1[M+H]+. Step 4:   2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)   -2 5 fluorophenoxy)-2-methylthiazol-4-yl)acetamide To a stirred solution of 2-(5-(4-(4-(2,6-difluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4- triazol-1-yl)-2-fluorophenoxy)-2-methylthiazol-4-yl)acetonitrile (89 mg, 0.195 mmol), were added CuO (30.7 mg, 0.389 mmol) and Acetaldoxime (34.4 mg, 0.584 mmol) in MeOH (5 mL) and H2O (5 mL). The resulted mixture was stirred for additional 16 h at 95°C. The resulted mixture was 10 diluted with water (10 mL). The resulted mixture was extracted wit...

Claims

1. A compound of the following structural Formula I:RingCFormula Ia tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein:X1is N; X2is N; X3is absent; X4 is C;Ring A is phenyl, 5- to 9-membered heteroaryl, 5- to 6-membered cycloalkyl, or 5- to 910 membered heterocyclyl;Ring B is phenyl, 5- to 9-membered heteroaryl, 4- to 6-membered cycloalkyl, or 4- to 8membered heterocyclyl;Ring C is phenyl, 5- to 6-membered heteroaryl, 5- to 6-membered cycloalkyl, or 5- to 6membered heterocyclyl;15 the bond between X2 and X4 is a double bond;Ra, for each occurrence, is independently selected from halogen, cyano, =O, NO2,C1 to C6 alkyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 20 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs;C2 to C6 alkenyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 25 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-32023224057   08 Oct 2026heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs;C2 to C6 alkynyl optionally substituted by 1 to 4 groups selected from halogen, CN, -ORs, -C(=O)NRpRq, -C(=O)ORs, -N3, =NRp, =NORs, -NRpRq, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, wherein the 3 to 10-membered cycloalkyl and the 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S are each optionally substituted by 1 to 4 groups selected from C1 to C6 alkyl, halogen, and ORs;3 to 10-membered cycloalkyl optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq;3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and optionally substituted by 1 to 4 groups selected from halogen, CN, ORs, -C(=O)NRpRq, -C(=O)ORs, and -NRpRq;-C(=O)Rs;-C(=O)ORs;-C(=O)(C=O)ORs;-C(=O)NRpNRpRq;-C(=O)NRpORs;-C(=O)NRpRq;-NRpRq;-NRpC(=O)Rs, wherein Rp and Rs are defined below in this claim or the Rp and Rs of NRpC(=O)Rs join and form a 5 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S;-NRp2C(=O)ORs2, wherein Rp2 and Rs2 are defined below in this claim or the Rp2 and Rs2 of -NRp2C(=O)ORs2 join and form a 5 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S;-ORs:wherein:Rp and Rq, for each occurrence, are independently selected from hydrogen and C1-C6 alkyl, wherein:the C1-C6 alkyl of any one of Rp and Rq is optionally substituted with 1 to 3 groups selected from halogen, -NRp1C(=O)ORs1, cyano, -ORs1, -O(C1 to C3 alkyl)ORs1, 3 to 10-membered - 453 -2023224057   08 Oct 2026cycloalkyl, 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and phenyl; whereinthe 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of any one of Rp and Rq, and the 3 to 10-membered cycloalkyl and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of the C1-C4 alkyl of any one of Rp and Rq, are each optionally substituted with 1 to 3 groups selected from halogen, CN, =O, NRp1Rq1, ORs1, -NRp1C(=O)Rs1, -NRp1C(=O)ORs1, 3 to 10-membered cycloalkyl, and C1 to C3 alkyl optionally substituted with C3-C4 cycloalkyl;Rs, for each occurrence, is independently selected from hydrogen, C1-C6 alkyl, phenyl, 5 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, 3 to 10membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S,wherein the C1-C6 alkyl, phenyl, 5 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, 3 to 10-membered cycloalkyl, and 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S of Rs are each optionally substituted with 1 to 3 groups selected from halogen, NRp1Rq1, -NRp1C(=O)ORs1, cyano, -OH, -O(C1 to C3 alkyl), -O(C1 to C3 alkyl)OH, -O(C1 to C3 alkyl)O(C1 to C3 alkyl), 3 to 10-membered cycloalkyl, 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and phenyl;Rp1 and Rq1, for each occurrence, are each independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH;Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH;Rp2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH;Rs2, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen, CN, and OH;Rb, for each occurrence, is independently selected from halogen, CN, =O, and C1-C4 alkyl optionally substituted by 1 to 3 groups of halogen;Rc, for each occurrence, is independently selected from halogen, CN, C1-C6 alkyl, ORs1, and -C(=O)ORs1;R1 is H,R2 is selected from H, halogen, CN, ORs1, -NRp1Rq1, and C1 to C3 alkyl optionally substituted by - 454 -2023224057   08 Oct 20261 to 3 groups selected from halogen, or R1 and R2 join to form a 5- to 6-membered heterocycle optionally substituted by 1 to 3 groups selected from halogen and C1 to C3 alkyl optionally substituted by 1 to 3 groups selected from halogen;R3 is absent;5 R4 is H;L is selected from -NRx-, -(CH2)uO(CH2)u-, -(CH2)uS(=O)w-(CH2)u-, -C(=O)-, and C1-C3 alkylene, wherein the C1-C3 alkylene of L is optionally substituted by 1 to 2 groups selected from OH and C1-C3 alkyl,; whereinRp1 and Rq1, for each occurrence, are each independently selected from hydrogen and C1-C410 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, and OH;Rs1, for each occurrence, is independently selected from hydrogen and C1-C4 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, and OH; andRx is selected from H and C1-C4 alkyl;m and p are each an integer independently selected from 0, 1, 2, 3, and 4;15 n is an integer selected from 0, 1, and 2;w, for each occurrence, is an integer independently selected from 0, 1, and 2;u, for each occurrence, is an integer independently selected from 0, 1, and 2;20       2. The compound of claim 1, the tautomer thereof, the stereoisomer of the compound orthe tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, whereinRing A is a phenyl, pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, pyrazolyl, imidazolyl, pyrrolyl, pyridazinyl, piperazinyl, oxazolyl, isoxazolyl, triazolyl, cyclopentyl,2023224057   08 Oct 202615cyclohexanyl, tetrahydro-furanyl, or tetrahydro-pyranyl group;Ring B is a phenyl, pyridinyl, thiazolyl, cyclopentenyl, cyclobutanyl, cyclohexanyl, piperidyl, or pyrrolidinyl group, or a 5- to 8-membered bicyclic group optionally containing one or two N atoms; and / orRing C is phenyl, pyridinyl, thiazolyl, isothiazolyl, oxazolyl, cyclopentyl, cyclopentenyl, cyclohexanyl, cyclohexenyl, isoxazolyl, tetrahydro-pyranyl, or dihydro-pyranyl group.

3. The compound of claim 1 or 2, wherein the compound has the following structural Formula IIa, Formula IIb, or Formula IIc:Formula IIa:10the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein R1 and R2 do not join to form a 5- to 6-membered heterocycle;Formula IIb:20the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein V1, V2, and V3 are each independently selected from C, O, and N, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, and q is selected from 0, 1, and 2; or2023224057   08 Oct 2026Formula IIc:Formula IIcthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the5 pharmaceutically acceptable salt of the foregoing, wherein V1 and V2 are each independently selected from C, O, and N, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, and q is selected from 0, 1, and 2.

4. The compound of claim 1 or 2, wherein the compound has the following structuralFormula IIIa, Formula IIIb, Formula IIIc, Formula IIId, Formula IIIe, or Formula IIIf:10 Formula IIIa:Ring AFormula IIIathe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Y1 and Y2 are each independently 15 selected from C and N;Formula IIIb:2023224057   08 Oct 2026the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Y1, is selected from S, C, O, and N, Y2 and Y3 are each independently selected from S, C, O and N;Formula IIIc:10Ring AFormula IIIcthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Y1 is selected from C and N, Y2 and Y3 are each independently C or absent;Formula IIId:15the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Y1 is selected from C and N;2023224057   08 Oct 2026Formula IIIe:the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or thepharmaceutically acceptable salt of the foregoing;Formula IIIf:Formula IIIf10the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Y1 is selected from C and N, and Y2 is C or absent.

5. The compound of claim 1 or 2, wherein the compound has the following structural Formula Va, Formula Vb, Formula Vc, or Formula Vd:Formula Va:152023224057   08 Oct 2026the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N;Formula Vb:the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, Q3, and Q4 are each independently selected from C, N, S, and O;10 Formula Vc:RingCFormula Vcthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1 is C, O, or absent;152023224057   08 Oct 2026Formula Vd:Ring CFormula Vdthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or thepharmaceutically acceptable salt of the foregoing, wherein Q1 is C or absent.

6. The compound of claim 1 or 2, wherein the compound has the following structuralFormula VIa:RingCFormula VIa1015the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1, Z2, and Z3, are each independently selected from S, O, C, and N, Z4 is selected from C and N.

7. The compound of claim 6, wherein the compound has the following structural Formula VIb:2023224057   08 Oct 2026the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ra, for each occurrence, is5 independently selected from halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), -OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, Ra1 is selected from optionally substituted C1-C3 alkyl, optionally substituted 3- to 6-membered cycloalkyl, optionally substituted 3- to 6-membered heterocyclyl, -NHC(=O)Rp2, and -NRp2Rq2; wherein Rp2 and Rq2, 10 for each occurrence, are each independently selected from hydrogen and optionally substitutedC1-C6 alkyl, or Rp2 and Rq2 join and form an optionally substituted 3 to 10-membered heterocyclyl.

8. The compound of claim 7, wherein the compound has the following structural Formula VIc, Formula VId, Formula VIe, or Formula VIf:15 Formula VIc:the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ra, for each occurrence, is20 independently selected from halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), OH, -O(C1-C3 alkyl), -2023224057   08 Oct 2026C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 5 to 10-membered heteroaryl;Formula VId:Formula VIdthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the 10 pharmaceutically acceptable salt of the foregoing, wherein L is selected from -O-, -N(Rx)-,-CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, Ra, for each occurrence, is independently selected from H and C1-C3 alkyl, Rb, for each occurrence, is independently selected from absent, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, CH3, -OCH3, and CN, p is 0, 1, or 2, and Rp2 and Rq2 are15 independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10-membered heteroaryl; provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N;2023224057   08 Oct 2026Formula VIe:Formula VIethe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the 5 pharmaceutically acceptable salt of the foregoing, wherein V1 and V2 are each independentlyselected from C, N, and O, L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, Ra, for each occurrence, is independently selected from H and C1-C3 alkyl, Rb, for each occurrence, is independently selected from absent, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, -10 OCH3, CH3, and CN, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, p is 0, 1, or 2, q is 0, 1, or 2, and Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10membered heteroaryl; provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-,15 -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N; orFormula VIf:Formula VIfthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the - 464 -2023224057   08 Oct 2026pharmaceutically acceptable salt of the foregoing, wherein V1, V2 , and V3 are each independently selected from C, N, and O, L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, Ra, for each occurrence, is independently selected from H and C1-C3 alkyl, Rb, for each5 occurrence, is independently selected from absent, F, Cl, Br, CH3, and CN, Rc is selected from F, Cl, Br, CH3, -OCH3, and CN, Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen, p is 0, 1, or 2, q is 0, 1, or 2, and Rp2 and Rq2 are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally10 substituted 3 to 10-membered heteroaryl; provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene optionally substituted by C3-C4 cycloalkyl, Z4 is C or N.

9. The compound of claim 1 or 2, wherein the compound has the following structural Formula VIIa, Formula VIIb, or Formula VIIc:15 Formula VIIa:R Ring BRing AFormula VIIathe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each20 independently selected from C and N, Y1 and Y2 are each independently selected from C and N;2023224057   08 Oct 2026Formula VIIb:Formula VIIbthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the 5 pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z1 is selected from C and N, Ra, for each occurrence, is independently selected from absent, halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), -OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, 10 OH, CN, and NH2, m’ is 0, 1, and 2, Ra1 is selected from optionally substituted C1-C3 alkyl, optionally substituted 3- to 6-membered cycloalkyl, optionally substituted 3- to 6-membered heterocyclyl, -NHC(=O)Rp2, and -NRp2Rq2, wherein Rp2 and Rq2, for each occurrence, are each independently selected from hydrogen and optionally substituted C1-C6 alkyl, or Rp2 and Rq2 join and form an optionally substituted 3 to 10-membered heterocyclyl; or15 Formula VIIc:the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each20 independently selected from C and N, Y1 and Y2 are each independently selected from C and N,2023224057   08 Oct 2026Z1 is selected from C and N, Ra, for each occurrence, is independently selected from halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), -OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, m’ is 0, 1, and 2, RP2 and Rq2, are independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl, and optionally substituted 3 to 10-membered heteroaryl.

10. The compound of claim 1 or 2, wherein the compound has the following structural Formula VIIIa, VIIIb, or VIIIc:10Formula VIIIaFormula VIIIb2023224057   08 Oct 2026the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each independently selected from C and N, Y1 and Y2 are each independently selected from C and N, Z’ is selected from C and N, Z1, Z2, and Z3, are each independently selected from S, O, C, and N,5 Z4 is selected from C and N, Ra, for each occurrence, is independently selected from halogen, CN, NO2, NH2, -NH(C1-C3 alkyl), -OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, CN, and NH2, Ring D is 3 to 10-membered heterocyclyl, Rg, for each occurrence, is independently selected from halogen, OH, CN, -O(C1-C3 alkyl), NH2, NHBoc, NH(C1-C3 alkyl),10 and C1-C3 alkyl optionally substituted with 1 to 3 groups selected from halogen, CN, NH2, NHBoc, and OH, s is an integer selected from 0, 1, and 2; orwherein the compound has the following structural Formula VIIId, VIIIe, or VIIIf:152023224057   08 Oct 2026Ring CFormula VIIIfthe tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Q1, Q2, and Q3 are each5 independently selected from C and N, Y1 and Y2 are each independently selected from C and N,Z’ is selected from C and N, Z1, Z2 and Z3 are each independently selected from S, O, C and N, Z4 is selected from C and N, Ra, for each occurrence, is independently selected from halogen, CN, NO2, NH2, NH(C1-C3 alkyl), OH, -O(C1-C3 alkyl), -C(=O)H, -C(=O)O(C1-C3 alkyl), -C(=O)NH2, and C1-C3 alkyl optionally substituted by 1 to 3 groups selected from halogen, OH, 10 CN, and NH2, Rh, for each occurrence, is independently selected from H, C1-C3 alkyl optionally substituted with 1-3 groups selected from halogen and 3 to 4- membered cycloalkyl, 3-6 membered cycloalkyl optionally substituted by 1 to 3 groups selected from halogen and C1-C3 alkyl, and 3-6 membered heterocyclyl optionally substituted by 1 to 3 groups selected from halogen and C1-C3 alkyl.15          11. The compound of claim 1 or 2, the tautomer thereof, the stereoisomer of thecompound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein:of Formula I is selected from:2023224057   08 Oct 2026Ring B substituted with n groups of Rb is selected from:Ring C substituted with p groups of Rc is selected from:andand L is selected from:

12. The compound of claim 1 or 2, the tautomer thereof,the stereoisomer of thecompound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing,whereinRing A substituted by m groups of   Ra   is selected from:10andand L is -SO2-.

13. The compound of claim 1 or 2, the tautomer thereof, the stereoisomer of thecompound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing,2023224057   08 Oct 2026whereinof Formula I is selected from:

14. The compound of claim 1 or 2, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing,oXi --------•*of Formula I is selected from:5 wherein the0NX4>a b, x.

15. The compound of claim 1 or 2, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ring A substituted by m groups of Ra is selected from:2023224057   08 Oct 2026RkVrRk ¥rk, *      , and I    , wherein Rk is selectedfrom -C(=O)NH2, -C(=O)NHCH3, -C(=O)N(CH3)2, and Rj, for each occurrence, is5 independently selected from F, Cl, CH3, and CN.

16. The compound of claim 1 or 2, the tautomer thereof, the stereoisomer of thecompound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing,wherein Ring B substituted by n groups of Rb is selected from:1017. The compound of claim 1 or 2, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ring C substituted by p groups of Rc is selected from:2023224057   08 Oct 202618. The compound of any one of claims 1-6, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein Ra is selected from NH2, NO2, =O, cyano, I, F, Cl, Br, -CH3, -CH(CH3)2, -5 CH2CN, -CF3, -CH2OH, -CH2CH2OH, -C(CH3)2OH, -CH2C(CH3)2OH, -CHF2, -CHCH3OH, -CH2CONH2, -CH2COOH, -CHCH3NH2, -CH2OH, -CH2CH2OH, -CH2N3, -CH2NH2, -CH2OCH3,2023224057   08 Oct 20260C(=O)NHNH2475LAHN—* HN—*476BocHN2023224057   08 Oct 20262023224057   08 Oct 2026CN* — N   O2023224057   08 Oct 2026, and NC19. The compound of any one of claims 1-6, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, whereinRb, for each occurrence, is independently selected from halogen, =O, and C1-C2 alkyl; orRc, for each occurrence, is independently selected from C1-C3 alkyl, CN, halogen, -ORs1, and -C(=O)ORs1, wherein Rs1 is H or C1-C4 alkyl.

20. The compound of any one of claims 1-6, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein R2 is selected from H, halogen, CN, ORs1, -NRp1Rq1, and C1 to C2 alkyl optionally substituted by 1 to 3 groups selected from halogen, wherein Rs1, Rp1, and Rq1 are independently selected from H and CH3.

21. The compound of any one of claims 1-6, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein R1 and R2 join to form a 5- to 6-membered ring optionally substituted by 1 to 2 groups selected from halogen and C1 to C2 alkyl optionally substituted by 1 to 2 groups selected from halogen.

22. The compound of any one of claims 1-6, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the - 479 -2023224057   08 Oct 2026foregoing, wherein L is selected from -N(Rx)-, -(CH2)uO(CH2)u-, -(CH2)uS(=O)w-(CH2)u-, -C(=O)-, and C1-C3 alkylene, wherein the C1-C3 alkylene of L is optionally substituted by 1 to 2 groups selected from OH and C1-C3 alkyl, wherein Rx is selected from H and C1-C2 alkyl, u, for each occurrence, is independently 0 or 1.5        23. A compound of the following structural Formula VIe:Formula VIea tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein:10        Q1, Q2, and Q3 are each independently selected from C and N,Y1 and Y2 are each independently selected from C and N,Z1, Z2, and Z3, are each independently selected from S, C, and N,Z4 is selected from C and N,V1 and V2 are each independently selected from C and N,15 L is selected from -O-, -N(Rx)-, -CH2-, -S-, -S(=O)-, -S(=O)2-, and C1-C3 alkylene optionally substituted by 1 to 2 groups selected from C1-C2 alkyl, wherein Rx is selected from H and C1-C4 alkyl,Ra, for each occurrence, is independently selected from absent, H, C1-C3 alkyl,Rb, for each occurrence, is independently selected from H, F, Cl, Br, CH3, and CN,20        Rc is selected from F, Cl, Br, -OCH3, CH3, and CN,Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen,Rp2 and Rq2 are each independently selected from H, optionally substituted C1 to C6 alkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 3 to 10-membered heterocyclyl comprising 1-3 heteroatoms selected from N, O, and S, and optionally substituted25 3 to 10-membered heteroaryl comprising 1-3 heteroatoms selected from N, O, and S,2023224057   08 Oct 2026p is 0, 1, or 2,q is 0, 1, or 2,provided that when L is -O- or -N(Rx)-, Z4 is C, and when L is -CH2-, -S-, -S(=O)-, -S(=O)2-, or C1-C3 alkylene, Z4 is C or N.5        24. The compound of claim 23, the tautomer thereof, the stereoisomer of the compoundor the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, wherein:Z1 is S,Z2is C,Z3is N,10        Z4is C,V1 and V2 are each independently selected from C and N,L is selected from -O-, -CH2-, -S(=O)-, and -S(=O)2-,Ra, when attached to Z2, is selected from H and C1-C3 alkyl, Ra, when attached to Z1, is absent,15        Rb, for each occurrence, is independently selected from H, F, Cl, Br, CH3, and CN,Rc is selected from F, Cl, Br, -OCH3, CH3, and CN,Rf, for each occurrence, is independently selected from C1-C3 alkyl and halogen,Rp2 and Rq2 are each independently selected from H and C1 to C6 alkyl,p is 0 or 1, and20 q is 0 or 1.4828 a XC Q 8" £>o NJ     UI NJ \,O Z O=\ Q □       F Xx> H 19 s 13 o tf >=o z-z ' Q -n O w—z °\ z^ y'^z -^N^Br 7 0      F 26 a d, ? * ' bj cx_ %^0-V; O^NH, 17 o —4 1 V-S; 14 11 OT^yC? rrd-^rx p 8 8 ss it, .Hl ? z I X^o M 24 0     F M<Kz 2zy h 21 0 3           N^>*^NM2 M<p" 15 O 0 F—(' Cl / nX / =0=^ 12 rO ■ ft '■-' •- 5483A rV § ¢) । o. o p rX Z.z>O * °4 X o z *       0 6A-Crnu \A’CN 43 p g A o 1 ’ -¾ 2 -¼ vF y X ci 0 f Ay-yA jHyc ( J      \= / Vs N      A'Y! 31 iW-cr 28 OS o-CYv^aj iA- °     =| pN^N HO'' Y vA O^J\ o 4 44 IP ? ° =1 r—<*n =09' NJ ? 0 / (YxKSi '^a'nz^^n 38 a? CA L JI □ \ I >® ° § y?- 0 % z            N. JL o         y Ai v 29 F       0 rrYOis , WF ^N‘    J Y J "SrN.X 51 \,CN NyNJ ,?? ,-V1 rrA ^YLY0 l^F UN ^-7 48 < a       ^Yn err"--W 45 ZP r\-^ "Yr p \-= / y n fY— ° ry*N o~J r._ ,.::t Y4<Y‘ 39 'h— •’ ril L II c—^'Z <J X f v° “ Y : - i OS p^yQ HTl 2. N-.        O       . S \ 0               v^Z484485£6 ,___x d,-'' ? V—     0     d / n J      o     -nN*7 A' \= / 94 n.nh, A XAF N 91 0 Anh2 X^i rCX flX -Nv4 0 ^F    ^<C| 88 F       0 oT^-CyMi < / F N           N^\ 98 C        O2N- / N F 0      V N At^n-C^0 n 95 -- Z Z=o o Zl, F     O J fi       Vs ° ^F X   VI X N^N 89 fA l      ° ':. / F N 99 F       0 u Av :' F N                           H 96 1  ? Vr" MCAXiy0 ^F N   F 93 06 ,k N-^ J Z o / VaX1 H     T 2HNyNs Y o ( 0 oAh2 7=\ Vs mYYn-v / "° ^F 82 -- / ■ £Yo d ¢1 / ^TZ° X-W / / / "Z. A rV zs Ao s V ( °>A o 98 io ?4>vW 1 >— ° d NO' N F / V-\ / ° W xnV    nV4 F 83 o=n f X F              H2N ° 80 VAX ^f x    Nr < X / >N 77 N^CN f 0 ~~Ys xa.f X 87 t’S O~^A °-CVNyN-~Xp o       d ^vcx Y^1'1      F SV F             H2N ° 81 F       0 tV6OVs ^F N 78486487X / =\ HO\ net nLlll=? N     F S^N 145 ..XXCN 1-7 / -XA nCt XF N   F 142 1       0 .-A rAXuAj Lo 1 I— '           —S / N :^F n    rw N 139 0 ^A —(   0      "X II OH F 136 OH 13      o        Vn AcnLnYl° x ^F N   F 133 O     .nJx O    —N X x L x / =\ / CvA^° F 130 F       0               / A / X J / =\   °V LYvnA LvL0 ■'^ 'N      F sC^N 127 Z^XCN A-7 / -AA mCnlnL / ^F N   F 124 F       O r^A^O'Vs / N HO 146 zN^^^NH2 f 0 "NyX o Laxx F “         , 143 F 0 7X“ fAX^xx0 -n 140 Loh N- / Y 1-7 / -XJ LjLX Y-x ^F N   F 137 Loh N^>\ f o ^'AA aaf a m 134 L°h F O ~NCi LiXnLn-£Vo <: x F ~N 131 'i          o                    / A    JJ / =\    °v L~iXi nA Lo\Lo N    F SX 128 NXCN A a AA LY^lnLt ^F N   F 125 LV\ O S J / 0       d F        0              F ^"F ~N     syM N V HO X 144 N^ru __ / / if CN f      O        \.J ,, A xu Hl vF x x 141 F     O       oX^2 dXL^ ^^F N    F S^N 138 F                                              / J     o     \ / N^Ur0H / =f / A L NX X— / \ F % LX F 135 C£l H°LxXN d\_ N_ d r' / Nxx>xyQ O       d N^Xon aa / -AA a„aA° F 129 F       0 A^ A / =\ V0H [YYx-N vX °7=< ""' f n       f s^.n 126488489NC .1 / 7 quAY -■''f N 190 1  « A -' F N 187 Br |        / 9   __.   ^J~N^ 6ctMA ^YF N 184 . 0 F 0   -nM0^ Y / / I / =\ >"N n i ^YY° 181 / ^CN F   0    A J / =\ Y YYY'Y / 191 ^ArJX' n l .nYj ^-F N 188 N F   0   YY Yvo7 cn Y> N 185 f   o    NAy x F 182 161 j,   N-, Jsz% ""OvY 0       d Y ’ ■■ .. / .-CN f o x / Yy f / ' f N 186 F      O fjYYYy / N              / / A. Y NCV 183-Y'NH F 0      )Y ^F N ^F 178 Yf o ^YY YnY YXnnA^° F 175 f o ~Npr YlY^^O'0 ^F N  \ 172 F        O       n / =¾. rY^^Nx yy YlY 1 L N / N 1<*^ / f N /     a 169 _zzN'N^ F     0       )=k mT^'CY0 N        F 179 ^Y ° ^Nv7 Yj^nY ry0Y\ F Y \= / 176 F       0 YYQv7 > " f n y Yy° 0 173 F         O        ,F YyYnYYVs ° ~~n    Y / Y-oh nYf 170 __z,N'N'^-x0H F       0 mTn^YY0 ^F N ^F 180 r-° _ / zN'N^ f o     yY uY^YZY0 N        F 177 o Y^ / A / =-An" YYnYnYZYo 174 UI ___      N... ^ / F::. HN v=yNy^\YY sYz°- O    j N   Q490\ N I. / OfAA 214 F       0 Afi A iv j k / S        ^J-Br 211 F X / ^nAiXTA nA 0- / Of 208 0 WF t("<r F 205 \ 0 -AA °'' 1 / - x / =aA Al n A / UN    - F 202 - - At $ A A v* / AAAnAA 1Af1 mf 196 h2n 1    ? z-x nA 606-0-7 N 193 F         °        ,F 0 215 III 4 / 91 ° T / \XN 1        / / z-X a 209 F 0 AXAi 206 J^A s V r° 0 7 / 0^ / AA AAAnAA ^-F N o 200 A Al / \ 1 ^N     F / = / > 197 F       0 6anaOOnA '' F N         Z 1CN 194 0 .^Aii °h 1 _ 1 z=\ rN AAt ^ F N A 216 ni \ Nr X"A d 0 o t ■> aA AiA aaf a 210 AlAi 207 0 1     0    - / f AoA / =v WF xnAa F 204 F a\-\ / °      J AAA O An y ,N Al M n lo^ Ao o — 201 0 —xA0^ A^ 1 xvA Art ,n AA X / F 198 S61 N— ox AOnAAQ ON492F       O =1=,=1 / =\ n      , OH 265 =n =x / F       o N A 262 F       O udAA ^F N ONH?0 259 o 7jAn / 7—A—° a F =N     Yn 256 F       0 (I 6 / 7yN zx a XZxF =n      / / -N= / _ 253 F         0       ,F n A / Vv i ZyY         / / -n / >-oh V-n 250 LPZ NO A N"%     N^ d Al n-\Y A-XnYY - rxxr y i Avn77° F      0         / ==1 Y-7 WxF =N 244 241 fNyNVo^ F      o        )= / tT^'O0 ^=7 266 rVAO F      0        )= / W-F    ^-7 263 ;  „ UpXZY 6A1 F               Cl 260 1    ° A TvA^AAa Ar 257 A"AA1 254 F          0        ,CI ifi uyA / Vx / ^ ZZYf -N       / Vn X-^ 251 8^1 NO “'sAyY'A io                o / = / AA mA i nA / 0   0 1>XF 245 \=N 242 L9Z NO 10 NO^     N=\ H* / / _ N„ hc / 7 O       d , o rz>-An3Z>° 01 =1 O-N 261 7-X z Mh i f 258 F       0 fi A-A / a m 1) un ^-7 VN ' 255 F       O TAi^-TA0^ / X F === F =N      / / -n / K^ Vd V 252 !; o 1 „ JJ / =N Tit<nAAA ^°h ZZxF N =\F / >-Nl<. y-n 249 9tZ NO =- v’ X d             o A z.zXo £ i Y ^,°493494495496497498499500LA O502LA O504506507919 N=\ XVX O XJ O X> ,s              \ / VV^ 'b N ,.a H2N a F           .. / NV' JI ,—V u i N-fy° = 7 F 613 0 F        -vVX"\ A r-\~rz H fVNVO-0 tf F            = / F 610 rV^X f n n-vv ^n' \=< F 607 o A    0 XnX / =\ 9 / =\ vXN" N —1 0 '—( o— 617 H2N . f 0 A'A> fVnAxV-3 ^N' X F 614 i ° vW ^F     = / F 611 0 / NxJt. J      As u-k ( Tl N-O-° \=< F 608 V.f >.„■ A_ / 0 618 XX —    °" W Q 0 £¥% N a-N 615 0     1 A ir HN nX 8i" 77 vX>X 612 609 d H sX^V"^ v> 0 Y 0AV-7 aaA'^o Oi »4X» ^N'  \={ F 604 i^^M7Xvs x AxnJ 0 601 F            0          ,F                                , 0 598 F       0      f fXAXx Vs H o n Xv 0 595 S09 ?x j XAAA) 0 0 O ° F XA / y°vs H '^XNz\f \ O 0 602 C!      0 J " N Aa- 0 599 1    0 A VVHS « M AV'NH2 0 596 o    -XNA'nh2 ,-N A JI ,--K XS (1l N-ry° ^^F N ^=( F 606 o X° ^^F N \=< F 603 0 600 1       0 rA 0 597508O 0 P' A' N 0 640 / "P M 1AF 637 / \   ^=N A"F 634 aaa / A \=N AA 631 O 0 P1 aA-Oas V-N 0 641 0 Q o zA“2 3a / =0" vV F 638 n Zy°-SJH2 CX xNXX Xn ° L AN 635 trF 632 XA H 642 6£9 d o9AA XX A A yNX i A 0 M 2hn^M=n            f ft o                  ~~ O % / NX mX < i nh Mo An' \— / 636 ^XAAA Aq vAF 633x^ pzA z-z o N>      A=A 00               CD A Ao <A      q An'X-x a o ,yy,'s-nxM n \w° 625 V 9 ryVA o AnAJ ° X=N 622 619 ,_0      NZ Cxvaaa V\ • ‘X PA HN—\ zz      0 A 0 Q 0 zmAV A A J J o 1 <N nAP M 629 9 7 —A MX AVAn^nAJ ,nAj o / n 626 X A / =\ 0 / —\ / x Am^Amam n^$° / M '—' 6 — / 623 X M - A An ^-7 0 620 9   / TA-o^^ XaX^xx XZnX €Xf n 630 £29 A 0 FV-An> AVsaJ a \ A'° ° o MO _ 0 An-x I A A-AV n N N"M_y b      — / An 624 tA?Z"Z" An ^-7 o 6215095102023224057   08 Oct 2026a tautomer thereof, a stereoisomer of the compound or the tautomer thereof, or a10pharmaceutically acceptable salt of the foregoing.

26. A pharmaceutical composition comprising the compound according to any one of claims 1 to 25, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, and at least one pharmaceutically acceptable carrier.

27. A method of treating a disease or condition mediated by receptor-interacting protein 1 (RIP1) signaling, comprising administering to a subject, a therapeutically effective amount of a compound according to any one of claims 1 to 25, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing, or the pharmaceutical composition according to claim 26; wherein the disease or condition mediated by RIP1 signaling is selected from the group consisting of an inflammatory disease, an immune disease, a necrotic cell disease, a neurodegenerative disease, a central nervous system (CNS) disease, ischemic brain injury, an ocular disease, a viral infection disease, and a malignancy.2023224057   08 Oct 202628. A method of treating a disease or condition mediated by receptor-interacting protein 1 (RIP1) signaling, comprising administering to a subject, a therapeutically effective amount of the compound according to any one of claims 1 to 25, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically 5 acceptable salt of the foregoing or the pharmaceutical composition according to claim 26.

29. A method of inhibiting receptor-interacting protein 1 (RIP1), comprising contacting the RIP1 protein or a fragment thereof with the compound according to any one of claims 1 to 25, the tautomer thereof, the stereoisomer of the compound or the tautomer thereof, or the pharmaceutically acceptable salt of the foregoing or the pharmaceutical 10 composition according to claim 26.